Document:

EX-10.19

 Exhibit 10.19 

FOIA CONFIDENTIAL TREATMENT REQUESTED 

RESEARCH COLLABORATION, OPTION AND LICENSE AGREEMENT 

BY AND BETWEEN 
 PFIZER
INC. 
 AND 

CYTOMX THERAPEUTICS, INC. 

MAY 30, 2013 

  
 ***Certain information contained
herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 TABLE OF CONTENTS 

 

					
	 	  	Page	 
		
	 1.      DEFINITIONS.
	  	 	1	  
		
	 2.      RESEARCH PROGRAM.
	  	 	18	  
		
	 2.1.          Selection of Research Project Targets.
	  	 	18	  
		
	 2.2.          Scope and Conduct of the Research Program.
	  	 	20	  
		
	 2.3.          Research Plans.
	  	 	20	  
		
	 2.4.          Governance of the Research Program.
	  	 	22	  
		
	 2.5.          Alliance Managers.
	  	 	23	  
		
	 2.6.          Conformance with Law.
	  	 	23	  
		
	 2.7.          CytomX Personnel Matters.
	  	 	24	  
		
	 2.8.          Debarment Certification.
	  	 	24	  
		
	 2.9.          Subcontractors.
	  	 	24	  
		
	 2.10.        Inspections
	  	 	24	  
		
	 2.11.        Records.
	  	 	25	  
		
	 2.12.        Transfer and Use of Pfizer Proprietary Materials.
	  	 	25	  
		
	 3.      PRODUCT DEVELOPMENT, MANUFACTURING, COMMERCIALIZATION AND REGULATORY MATTERS.
	  	 	26	  
		
	 3.1.          General.
	  	 	26	  
		
	 3.2.          Diligence.
	  	 	26	  
		
	 3.3.          Regulatory Approvals.
	  	 	28	  
		
	 3.4.          Control of Commercialization Activities.
	  	 	29	  
		
	 3.5.          Manufacturing.
	  	 	29	  
		
	 3.6.          Progress Reporting.
	  	 	29	  

  
 i 

***Certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has
been requested with respect to the omitted portions. 

					
		
	 3.7.          Regulatory Information.
	  	 	30	  
		
	 4.      LICENSES AND RELATED GRANTS OF RIGHTS.
	  	 	30	  
		
	 4.1.          Grants to Pfizer.
	  	 	30	  
		
	 4.2.          Grants to CytomX.
	  	 	33	  
		
	 4.3.          Reciprocal Non-Exclusive Research License for Disclosed Know-How and
Confidential Information.
	  	 	33	  
		
	 4.4.          Retained Rights.
	  	 	34	  
		
	 4.5.          Exclusivity.
	  	 	34	  
		
	 4.6.          Section 365(n) of Bankruptcy Code.
	  	 	35	  
		
	 4.7.          No Implied Rights.
	  	 	35	  
		
	 5.      PAYMENTS TO CYTOMX.
	  	 	35	  
		
	 5.1.          Upfront and Option Fee.
	  	 	35	  
		
	 5.2.          Option Exercise Fee.
	  	 	35	  
		
	 5.3.          Research Support Funding.
	  	 	35	  
		
	 5.4.          Milestones
	  	 	37	  
		
	 5.5.          Royalties.
	  	 	41	  
		
	 5.6.          Reports and Payments.
	  	 	43	  
		
	 5.7.          Maintenance of Records; Audits.
	  	 	44	  
		
	 6.      INTELLECTUAL PROPERTY.
	  	 	45	  
		
	 6.1.          Inventions.
	  	 	45	  
		
	 6.2.          Patent Rights.
	  	 	46	  
		
	 6.3.          Interference, Opposition, Revocation and Declaratory Judgment
Actions.
	  	 	53	  
		
	 7.      CONFIDENTIALITY
	  	 	53	  
		
	 7.1.          Confidentiality.
	  	 	53	  

  
 ii 

***Certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has
been requested with respect to the omitted portions. 

					
		
	 7.2.          Authorized Disclosure.
	  	 	54	  
		
	 7.3.          Public Announcements; Publications.
	  	 	56	  
		
	 7.4.          Obligations in Connection with Change of Control.
	  	 	58	  
		
	 8.      REPRESENTATIONS AND WARRANTIES.
	  	 	58	  
		
	 8.1.          Mutual Representations and Warranties.
	  	 	58	  
		
	 8.2.          Representations and Warranties of CytomX.
	  	 	59	  
		
	 8.3.          CytomX Covenants.
	  	 	61	  
		
	 8.4.          Representation by Legal Counsel.
	  	 	62	  
		
	 8.5.          Disclaimer.
	  	 	62	  
		
	 9.      GOVERNMENT APPROVALS; TERM AND TERMINATION.
	  	 	62	  
		
	 9.1.          Government Approvals.
	  	 	62	  
		
	 9.2.          Term.
	  	 	62	  
		
	 9.3.          Termination by Either Party for Cause.
	  	 	63	  
		
	 9.4.          Termination by Pfizer for Convenience.
	  	 	63	  
		
	 9.5.          Termination on Insolvency of CytomX.
	  	 	63	  
		
	 9.6.          Effects of Termination.
	  	 	63	  
		
	 9.7.          Disposition of Inventories of Products.
	  	 	67	  
		
	 9.8.          Survival of Certain Obligations.
	  	 	68	  
		
	 9.9.         Right to Termination of Research Project(s) or Research Program by Pfizer upon
Change of Control of  CytomX.
	  	 	68	  
		
	 9.10         Effects of CytomX Change of Control.
	  	 	69	  
		
	 10.    LIMITATION ON LIABILITY, INDEMNIFICATION AND INSURANCE.
	  	 	69	  
		
	 10.1.       No Consequential Damages.
	  	 	69	  
		
	 10.2.       Indemnification by Pfizer.
	  	 	69	  

  
 iii 

***Certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has
been requested with respect to the omitted portions. 

					
		
	 10.3.       Indemnification by CytomX.
	  	 	70	  
		
	 10.4.       Procedure.
	  	 	71	  
		
	 10.5.       Insurance.
	  	 	72	  
		
	 11.    MISCELLANEOUS.
	  	 	72	  
		
	 11.1.       Assignment.
	  	 	72	  
		
	 11.2.       Further Actions.
	  	 	73	  
		
	 11.3.       Force Majeure.
	  	 	73	  
		
	 11.4.       Notices.
	  	 	73	  
		
	 11.5.       Amendment.
	  	 	74	  
		
	 11.6.       Waiver.
	  	 	74	  
		
	 11.7.       Severability.
	  	 	74	  
		
	 11.8.       Descriptive Headings.
	  	 	75	  
		
	 11.9.       Dispute Resolution.
	  	 	75	  
		
	 11.10.     Governing Law.
	  	 	76	  
		
	 11.11.     Consent to Jurisdiction.
	  	 	76	  
		
	 11.12.     Entire Agreement.
	  	 	76	  
		
	 11.13.     Independent Contractors.
	  	 	76	  
		
	 11.14.     Counterparts.
	  	 	77	  
		
	 11.15.     No Third Party Rights or Obligations.
	  	 	77	  

  
 iv 

***Certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has
been requested with respect to the omitted portions. 

	
	EXHIBITS
	 Exhibit 2.3.1: EGFR Research Plan

	
	SCHEDULES
	
	 Schedule 1.51: EGFR

	 Schedule 1.54: EGFR Probody

	 Schedule 1.159: Tool Patent Rights

	 Schedule 6.2.1(d): Countries for Filing National Phase Applications (Part A and Part B)

	 Schedule 7.3.1: Press Release

	 Schedule 8.2.1: CytomX Third Party Agreements

	 Schedule 8.2.3: CytomX Patent Rights

	 Schedule 8.2.8: Government Funding Agreements

	 Schedule 8.2.9: Agreements Limiting IP Rights

	 Schedule 8.2.10: Disclosed Third Party Agreements

  
 v 

***Certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has
been requested with respect to the omitted portions. 

 RESEARCH COLLABORATION, OPTION AND LICENSE AGREEMENT 

This Research Collaboration, Option and License Agreement (the “Agreement”) is entered into as of May 30, 2013
(the “Effective Date”), by and among Pfizer, Inc., a corporation organized and existing under the laws of the State of Delaware and having a place of business at 235 East 42nd Street, New York, New York, 10017 United States
(“Pfizer”) and CytomX Therapeutics, Inc., a corporation organized and existing under the laws of Delaware and having a place of business at 650 Gateway Blvd., Suite 125, South San Francisco, California, 94080 United States
(“CytomX”). Pfizer and CytomX may each be referred to herein individually as a “Party” and collectively as the “Parties.” 

WHEREAS, Pfizer is engaged in the research, development and commercialization of pharmaceutical and health care products and has developed and
owns proprietary rights to certain technology enabling antibody-drug conjugation, including technology relating to Linkers and Payloads; 

WHEREAS, CytomX has developed and owns proprietary rights to certain technology relating to a proprietary platform to enable the development
of fully recombinant, protease-activated monoclonal antibodies, including Probodies (as defined below); and 
 WHEREAS, Pfizer and CytomX
desire to collaborate to discover and research novel Probodies and Probody drug conjugates active against certain designated targets and to provide for Pfizer to further research, develop, manufacture and commercialize Probody drug conjugates, as
provided for herein. 
 NOW THEREFORE, in consideration of the mutual promises and covenants set forth below and other good and valuable
consideration, the receipt and sufficiency of which is hereby acknowledged, the Parties hereby agree as follows: 
  

	1.	DEFINITIONS. 

 When used in this Agreement, the following capitalized terms shall have
the meanings set forth in this Article 1. Any terms defined elsewhere in this Agreement shall be given equal weight and importance as though set forth in Article 1. 

1.1. “Acquirer” is defined in Section 9.10.1(b). 

1.2. “ADC” means an Antibody conjugated to a Payload using a Linker, other than a PDC. 

1.3. “Additional Target” is defined in Section 2.1.6. 

1.4. “Additional Target Designation Date” is defined in Section 2.1.6. 

1.5. “Additional Target Fee” is defined in Section 2.1.6. 

  
 1 

***Certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has
been requested with respect to the omitted portions. 

 1.6. “Additional Third Party Licenses” is defined in Section 5.5.2(b).

 1.7. “Affiliate” means, with respect to any Person, any other Person that controls, is controlled by or is under common
control with such Person. A Person shall be regarded as in control of another entity if it owns or controls at least fifty percent (50%) of the equity securities of the subject entity entitled to vote in the election of directors (or, in the
case of an entity that is not a corporation, for the election of the corresponding managing authority), provided, however, that the term “Affiliate” shall not include subsidiaries or other entities in which a Party or its Affiliates owns a
majority of the ordinary voting power necessary to elect a majority of the board of directors or other managing authority, but is restricted from electing such majority by contract or otherwise, until such time as such restrictions are no longer in
effect. 
 1.8. “Agreement” is defined in the introduction to this Agreement. 

1.9. “Agreement PDC” means any PDC incorporating an Agreement Probody Targeting a Research Project Target. 

1.10. “Agreement Probody” means (a) an EGFR Probody, (b) any Probody that is identified, created or developed in the
course of the Research Program as Targeting a Research Project Target and (c) any modification or derivative of a Probody referenced under clause (a) or (b) of this Section 1.10 that is (i) developed by Pfizer,
(ii) Targets a Research Project Target and (iii) is claimed or covered by CytomX Technology or Developed IP. 
 1.11.
“Alliance Manager” is defined in Section 2.5. 
 1.12. “Annual Net Sales” means, with respect to any
Licensed Product in a Pfizer Year during the applicable Royalty Term for such Licensed Product, the aggregate Net Sales by Pfizer, its Affiliates and its Sublicensees from the sale of such Licensed Product in the Territory during such Pfizer Year.

 1.13. “Antibody” means a molecule which comprises or contains: (a) one or more immunoglobulin variable domains;
(b) fragments, variants, modifications or derivatives of such immunoglobulin variable domains irrespective of origin or source, including but not limited to antigen binding portions including Fab, Fab’, F(ab’)2, Fv, dAb and CDR
fragments, single chain antibodies (scFv), chimeric antibodies, monospecific antibodies, diabodies and polypeptides (including humanized versions thereof) that contain at least a portion of an immunoglobulin that is sufficient to confer specific
antigen binding to the polypeptide; or (c) the nucleic acid consisting of a sequence of nucleotides encoding (or complementary to a nucleic acid encoding) the foregoing molecules in (a) or (b). For clarity, as used in this Agreement, the
term “Antibody” shall not include Probodies or PDCs. 

  
 2 

***Certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has
been requested with respect to the omitted portions. 

 1.14. “Applicable Law” means the laws, statutes, rules, regulations, guidelines,
or other requirements that may be in effect from time to time and apply to a Party’s activities to be performed under this Agreement, including any such laws, statutes, rules, regulations, guidelines or other requirements of the FDA or the EMA.

 1.15. “Asia” means [***]. 

1.16. “Available” means [***]. 

1.17. “Bankruptcy Code” is defined in Section 4.6. 

1.18. “Binding Obligation” means, with respect to a Party (a) any oral or written agreement or arrangement that binds or
legally affects such Party’s operations or property, including any assignment, license agreement, loan agreement, guaranty, or financing agreement; (b) the provisions of such Party’s charter, bylaws or other organizational documents
or (c) any order, writ, injunction, decree or judgment of any court or Governmental Authority entered against such Party or by which any of such Party’s operations or property are bound. 

1.19. “Biosimilar Biologic Product” is defined in Section 5.5.2(a). 

1.20. “Biosimilar Notice” means a copy of any application submitted by a Third Party to the FDA under 42 U.S.C. § 262(k)
of the PHS Act (or, in the case of a country of the Territory outside the United States, any similar law) for Regulatory Approval of a biological product, which application identifies a Licensed Product as the reference product with respect to such
product, and other information that describes the process or processes used to manufacture the biological product. 
 1.21. “Business
Day” means a day other than a Saturday, a Sunday or a day that is a national holiday in the United States. 
 1.22.
“Calendar Quarter” means the respective periods of three (3) consecutive calendar months ending on March 31, June 30, September 30 or December 31, for so long as this Agreement is in effect. 

1.23. “Calendar Year” means each successive period of twelve (12) calendar months commencing on January 1 and ending
on December 31. 
 1.24. “CAN Status” means [***]. 

1.25. “Change of Control” means, with respect to a Party, (a) a merger, reorganization or consolidation of such Party
with a Third Party which results in the voting securities of such Party outstanding immediately prior thereto ceasing to represent at least fifty (50%) of the combined voting power of the surviving entity immediately after such merger,
reorganization or consolidation, (b) a Third Party becoming the beneficial owner of fifty (50%) or more of the combined voting power of the outstanding securities of such Party or (c) the sale or other transfer to a Third Party of all
or substantially all of such Party’s business or assets to which this Agreement relates. 

  
 3 

***Certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has
been requested with respect to the omitted portions. 

 1.26. “Combination Product” means a Licensed Product containing an Agreement PDC
and one or more other therapeutically active ingredients or products. For clarity, a Payload conjugated into an Agreement PDC contained in a Licensed Product shall not be considered an additional therapeutically active ingredient or product for the
purposes of determining whether such Licensed Product is a Combination Product under this Agreement. 
 1.27. “Commercial
License” is defined in Section 4.1.3. 
 1.28. “Commercialization” or “Commercialize” means
activities directed to marketing, promoting, distributing, importing, exporting, using for commercial purposes or selling or having sold a Licensed Product. Commercialization shall not include any activities related to Manufacturing or Development.

 1.29. “Commercially Reasonable Efforts” means, with respect to the efforts to be expended by a Party with respect to any
objective, those reasonable, good faith efforts to accomplish such objective as such Party would normally use to accomplish a similar objective under similar circumstances. With respect to any efforts relating to the Development, Regulatory Approval
or Commercialization of an Agreement PDC or Licensed Product by a Party, generally or with respect to any particular country in the Territory, a Party will be deemed to have exercised Commercially Reasonable Efforts if such Party has exercised those
efforts normally used by such Party, in the relevant country, with respect to a compound, product or product candidate, as applicable, owned or Controlled by such Party, or to which such Party has similar rights, which compound, product or product
candidate is of similar market potential in such country, and is at a similar stage in its development or product life cycle as the Agreement PDC or Licensed Product, taking into account all relevant factors in effect at the time such efforts are to
be expended. It is expressly understood that the use of Commercially Reasonable Efforts may result in ceasing the Development, Regulatory Approval or Commercialization of an Agreement PDC or Licensed Product. Further, to the extent that the
performance of a Party’s obligations hereunder is adversely affected by the other Party’s failure to perform its obligations hereunder, the impact of such performance failure will be taken into account in determining whether such Party has
used its Commercially Reasonable Efforts to perform any such affected obligations. 
 1.30. “Confidential Information” of a
Party means all Know-How or other information, including proprietary information and materials (whether or not patentable) regarding such Party’s technology, products, business or objectives, that is communicated in any way or form by the
Disclosing Party to the Receiving Party, either prior to or after the Effective Date of this Agreement (including any information disclosed pursuant to the Confidentiality Agreement), and whether or not such Know-How or other information is
identified as confidential at the time of disclosure. The terms and conditions of this 

  
 4 

***Certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has
been requested with respect to the omitted portions. 

 
Agreement shall be deemed to be the Confidential Information of each Party. CytomX Improvements shall be deemed to be the Confidential Information of CytomX. Pfizer Improvements shall be deemed
to be the Confidential Information of Pfizer. Confidential Information within the Developed IP conceived or generated in the course of performing Research Plan Activities with respect to a particular Research Plan Target shall be deemed to be the
Confidential Information of both Parties until the earlier of expiration of the Option Period for such Research Plan Target or such time as such Research Plan Target ceases to be a Research Project Target for purposes of this Agreement; thereafter,
Confidential Information within such Developed IP shall be deemed to be the Confidential Information of the Party owning such Developed IP or of both Parties in the case of Joint Developed IP, except that any such Confidential Information within the
PDC Developed IP, upon assignment thereof to Pfizer pursuant to Section 6.1.1(d), shall be deemed to be the Confidential Information solely of Pfizer. 

1.31. “Confidentiality Agreement” means that certain Confidentiality Agreement between the Parties dated July 27, 2012.

 1.32. “Control” or “Controlled” means, with respect to any (a) item of information, including
Know-How, or (b) intellectual property right, the possession (whether by ownership interest or license, other than pursuant to this Agreement) by a Party of the ability to grant to the other Party access to or a license under such item or
right, as provided herein, without violating the terms of any agreement or other arrangements with any Third Party. 
 1.33. “CytomX
Improvement” means [***]. 
 1.34. “CytomX Indemnified Party” is defined in Section 10.2. 

1.35. “CytomX Insolvency Event” means the occurrence of any of the following: (a) a case is commenced by or against
CytomX under applicable bankruptcy, insolvency or similar laws, and is not dismissed within ninety (90) days, (b) CytomX files for or is subject to the institution of bankruptcy, reorganization, liquidation, receivership or similar
proceedings, (c) CytomX assigns all or a substantial portion of its assets for the benefit of creditors, (d) a receiver or custodian is appointed for CytomX’s business, (e) a substantial portion of CytomX’s business is
subject to attachment or similar process, or (f) anything analogous to any of the events described in the foregoing clauses (a) through (e) occurs under the laws of any applicable jurisdiction. 

1.36. “CytomX Know-How” means any Know-How comprised in the CytomX Technology. 

1.37. “CytomX Letter” is defined in Section5.5.2(c)(ii). 

  
 5 

***Certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has
been requested with respect to the omitted portions. 

 1.38. “CytomX Patent Right” means any Patent Right comprised in the CytomX
Technology. The CytomX Patent Rights existing as of the Effective Date include those set forth on Schedule 8.2.3 attached hereto. 

1.39. “CytomX Proprietary Materials” means biological materials (including any Probodies, Masks or Substrates) and other
tangible research materials Controlled by CytomX and provided by CytomX to Pfizer under this Agreement. 
 1.40. “CytomX
Technology” means any Patent Right, Know-How or other intellectual property right that is Controlled by CytomX or any Affiliate of CytomX as of the Effective Date or, subject to the provisions of Sections 5.5.2(c) and 9.10, that comes into
the Control of CytomX or any Affiliate of CytomX at any time during the Term of this Agreement that claims, covers or is specifically directed to the composition of, or any method of using or method of making or any Tools for Developing, any
Probody, Mask or Substrate. 
 1.41. “CytomX Third Party Agreement” means: (i) any agreement between, on the one hand,
CytomX or its Affiliate and, on the other hand, a Third Party, existing as of the Effective Date under which CytomX obtains rights in or to any Licensed Intellectual Property; and (ii) any agreement between, on the one hand, CytomX or its
Affiliate and, on the other hand, a Third Party, entered into after the Effective Date under which CytomX or its Affiliate obtains rights in or to any Licensed Intellectual Property to the extent such Agreement is referenced under
Section 5.5.2(b) or is elected by Pfizer as a CytomX Third Party Agreement pursuant to Section 5.5.2(c). 
 1.42.
“CytomX Usable Developed IP” is defined in Section 7.2.1. 
 1.43. “Develop” or
“Development” means to discover, research or otherwise develop a product, including conducting any pre-clinical, non-clinical or clinical research and any drug development activity, including discovery, research, toxicology,
pharmacology and other similar efforts, test method development and stability testing, manufacturing process development, formulation development, delivery system development, quality assurance and quality control development, statistical analysis,
clinical studies (including pre- and post-approval studies), development of diagnostic assays in connection with clinical studies, and all activities directed to obtaining any Regulatory Approval, including any marketing, pricing or reimbursement
approval. 
 1.44. “Developed IP” means any Patent Right, Know-How or other intellectual property right, excluding CytomX
Improvements and Pfizer Improvements, that is conceived or generated in the course of performing Research Plan Activities during the applicable Research Term (a) solely by or on behalf of employees, agents or independent contractors of CytomX
or any of its Affiliates, (b) solely by or on behalf of employees, agents or independent contractors of Pfizer or any of its Affiliates or (c) jointly by or on behalf of (i) employees, agents or independent contractors of CytomX or
any of its Affiliates and (ii) employees, agents or independent contractors of Pfizer or any of its Affiliates. 

  
 6 

***Certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has
been requested with respect to the omitted portions. 

 1.45. “Development Milestone” is defined in Section 5.4.1. 

1.46. “Development Milestone Payment” is defined in Section 5.4.1. 

1.47. “Diligence Issue” is defined in Section 3.2.4. 

1.48. “Disclosed Third Party Agreement” is defined in Section 8.2.10. 

1.49. “Disclosing Party” is defined in Section 7.1. 

1.50. “Effective Date” is defined in the introduction to this Agreement. 

1.51. “EGFR” means the Target corresponding to epidermal growth factor receptor, as more specifically described on Schedule
1.51. 
 1.52. “EGFR Continuation Product” means all Agreement PDCs Targeting EGFR that are or have been under
Development or Commercialization by Pfizer under this Agreement at the time of or prior to termination of this Agreement. 
 1.53.
“EGFR PDC” means any Agreement PDC incorporating an EGFR Probody. 
 1.54. “EGFR Probody” means the Probody
described on Schedule 1.54 and any other Probody Targeting EGFR that is developed under the Research Plan for EGFR or otherwise provided to Pfizer hereunder and which shall be added to the Schedule 1.54. 

1.55. “EMA” means the European Medicines Agency, or any successor agency thereto. 

1.56. “FD&C Act” means the United States Federal Food, Drug, and Cosmetic Act (21 U.S.C. § 301 et seq.), as amended,
and the rules and regulations promulgated thereunder. 
 1.57. “FDA” means the United States Food and Drug Administration or
any successor agency thereto. 
 1.58. “Field” means human and veterinary therapeutic, diagnostic, prophylactic and
prognostic purposes. 
 1.59. “First Commercial Sale” means, with respect to any Licensed Product and any country of the
world, the first sale of such Licensed Product under this Agreement by Pfizer, its Affiliates or its Sublicensees to a Third Party in such country, after such Licensed Product has been granted Regulatory Marketing Approval by the competent
Regulatory Authorities in such country. When used without reference to a specified indication, First Commercial Sale means the First Commercial Sale for any indication. 

  
 7 

***Certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has
been requested with respect to the omitted portions. 

 1.60. “FTE” means a full time scientific equivalent person (with B.S., M.S. or
Ph.D. level or equivalent degrees, including laboratory technicians with exams recognized according to European standards) year, consisting of a minimum of a total of [***] per year of scientific work directly related to and in support of the
Research Program by an employee or natural person engaged as an independent contractor of CytomX or any of its Affiliates. 
 1.61.
“FTE Rate” means [***]. 
 1.62. “GAAP” means United States generally accepted accounting principles,
consistently applied. 
 1.63. “Generic Competition” is defined in Section 5.5.2(a). 

1.64. “Governmental Authority” means any court, agency, department, authority or other instrumentality of any national, state,
county, city or other political subdivision. 
 1.65. “HSR Act” means the Hart-Scott-Rodino Antitrust Improvements Act of
1976, as amended. 
 1.66. “IND” means an Investigational New Drug Application, as defined in the FD&C Act, that is
required to be filed with the FDA before beginning clinical testing of a Licensed Product in human subjects, or an equivalent foreign filing. 

1.67. “Indemnified Party” is defined in Section 10.4.1. 

1.68. “Indemnifying Party” is defined in Section 10.4.1. 

1.69. “Infringement” is defined in Section 6.2.2(a). 

1.70. “Joint Developed IP” is defined in Section 6.1.1(c). 

1.71. “Joint Patent Right” is defined in Section 6.2.1(e). 

1.72. “Joint Research Committee” or “JRC” is defined in Section 2.4.1. 

1.73. “Know-How” means any proprietary invention, discovery, data, information, process, method, technique, material,
technology, result or other know-how, whether or not patentable. 
 1.74. “Liability” is defined in Section 10.2.

 1.75. “Licensed Intellectual Property” means any and all intellectual property (including Patent Rights and Know-How)
Controlled by CytomX, including the CytomX Technology, the CytomX Improvements and CytomX’s interest in the Developed IP, that is actually used by CytomX in developing Licensed Products under the applicable

  
 8 

***Certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has
been requested with respect to the omitted portions. 

 
Research Plan or that is otherwise necessary or useful for Pfizer to make, have made, use, have used, sell, have sold, offer for sale, have offered for sale, import, have imported and otherwise
exploit and Commercialize Licensed Products. Notwithstanding the foregoing, Licensed Intellectual Property shall not include: (a) any Tools, or (b) any other intellectual property generated after the end of the applicable Research Term
that is not Necessary for the Development or Commercialization of the Licensed Products. 
 1.76. “Licensed Product” means
any product containing an Agreement PDC, which would infringe a Valid Claim of any Licensed Intellectual Property in the absence of the Commercial License or that is claimed or covered by, or was made using or otherwise incorporates, any Licensed
Intellectual Property or Developed IP. 
 1.77. “Linker” means a moiety or means used to conjugate a Payload to an Antibody
or Probody. 
 1.78. “Litigation Conditions” is defined in Section 10.4.2. 

1.79. “Major EU Market Country” means any of [***]. 

1.80. “Major Market Country” means any [***]. 

1.81. “Manufacturing” or “Manufacture” means activities directed to making, producing, manufacturing,
processing, filling, finishing, packaging, labeling, quality assurance testing and release, shipping or storage of a product. 
 1.82.
“Marginal Royalty Rates” is defined in Section 5.5. 
 1.83. “Mask” means a peptide linked to an
Antibody that is capable of inhibiting the specific binding of the Antibody to its Target. 
 1.84. “Milestone Payment”
means any Development Milestone Payment or Sales Milestone Payment. 
 1.85. “Necessary” is defined in Section
5.5.2(b). 
 1.86. “Net Sales” means, with respect to a Licensed Product that is not a Combination Product, gross
receipts from sales by Pfizer and its Affiliates and Sublicensees of such Licensed Product to Third Parties in the Territory, less in each case (i) bad debts, (ii) sales returns and allowances actually paid, granted or accrued, including
trade, quantity and cash discounts and any other adjustments, including those granted on account of price adjustments, billing errors, rejected goods, damaged or defective goods, recalls, returns, rebates, chargeback rebates, reimbursements or
similar payments granted or given to wholesalers or other distributors, buying groups, health care insurance carriers, chain pharmacies, mass merchandisers, staff model HMO’s, pharmacy benefit managers or other institutions in respect of the
purchase price, (iii) adjustments actually paid, granted or accrued arising from consumer discount programs or other similar programs, 

  
 9 

***Certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has
been requested with respect to the omitted portions. 

 
(iv) customs or excise duties, sales tax, consumption tax, value added tax, and other taxes (except income taxes) or duties relating to sales, (v) any payment made by Pfizer, its Affiliates
or Sublicensees in respect of sales to the United States government, any state government or any foreign government, or to any other Governmental Authority, or with respect to any government-subsidized program or managed care organization, and
(vi) freight and freight insurance (to the extent that Pfizer bears the cost of freight and freight insurance for the Licensed Product), in each case in accordance with GAAP, as consistently applied by Pfizer with respect to sales of the
Licensed Product (the deductions described above are referred to collectively herein as “Permitted Deductions”); and 
 1.86.1. in
the event a Licensed Product is sold as a Combination Product in any country, the Net Sales of the Combination Product, for the purposes of determining royalty payments, shall be determined by multiplying the Net Sales (as defined above in this
Section) of the Combination Product by the fraction, A/(A+B) where A is the weighted (by sales volume) average sale price in such country of the Licensed Product when sold separately in finished form, and B is the aggregate weighted (by sales
volume) average sale price in such country of the other therapeutically active ingredients included in such Combination Product when sold separately in finished form. In the event that such average sale price cannot be determined for both the
Licensed Product and the other product(s) included in the Combination Product, Net Sales for purposes of determining royalty payments shall be agreed by the Parties based on the relative value contributed by each component, such agreement not to be
unreasonably withheld or delayed. 
 1.86.2. Sales between Pfizer and its Affiliates or Sublicensees shall be excluded from the computation
of Net Sales and no payments will be payable on such sales except where such Affiliates or Sublicensees are end users, but Net Sales shall include the subsequent final sales to Third Parties by such Affiliates or Sublicensees. Net Sales shall be
determined from books and records maintained in accordance with GAAP, as consistently applied by Pfizer with respect to sales of the Licensed Product. 

1.86.3. The Parties acknowledge that Pfizer does not currently intend to Commercialize any Licensed Product solely for in vivo
diagnostic purposes and that the Parties anticipate that any sales of any Licensed Product for such diagnostic purposes will occur only in connection with or in support of sales of a Licensed Product for therapeutic purposes. Notwithstanding the
foregoing, in the event Pfizer, its Affiliates or Sublicensees Commercialize any Licensed Product for in vivo diagnostic purposes, sales of such Licensed Product for such diagnostic purposes shall be included in the calculation of Net Sales
provided that Pfizer and CytomX will negotiate in good faith a reasonable royalty applicable to Net Sales of any such Licensed Product for such diagnostic purposes during the applicable Royalty Term, which royalty shall be no greater than the
Marginal Royalty Rates 

  
 10 

***Certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has
been requested with respect to the omitted portions. 

 
otherwise set forth for Licensed Products under this Agreement, and will negotiate any changes to the definition of the terms “Agreement PDC” or “Payload” necessary to cover
the proposed Licensed Product for such diagnostic purposes if such Licensed Product does not contain a Payload. 
 1.87.
“Non-Disclosing Party” is defined in Section 7.3.2. 
 1.88. “Notice of Dispute” is defined in
Section 11.9.1. 
 1.89. “Option” is defined in Section 4.1.1. 

1.90. “Option Exercise Date” is defined in Section 4.1.2. 

1.91. “Option Exercise Fee” is defined in Section 5.2. 

1.92. “Option Period” means, on a Research Project Target-by-Research Project Target basis, the period commencing on the
Effective Date and expiring upon the earlier of (a) sixty (60) days following Pfizer’s first designation of CAN Status for the first Agreement PDC Targeting such Research Project Target or (b) with respect to EGFR, the third
(3rd) year anniversary of the Effective Date or, with respect to the Second Target or the Replacement Target, as the case may be, the fifth (5th) anniversary of the Effective
Date, or (c) with respect to an Additional Target, the third (3rd) anniversary of the Additional Target Designation Date with respect to such Additional Target. 

1.93. “Party” and “Parties” is defined in the introduction to this Agreement. 

1.94. “Patent Rights” means any and all (a) patents, (b) pending patent applications, including all provisional
applications, substitutions, continuations, continuations-in-part, divisions and renewals, and all patents granted thereon, (c) all patents-of-addition, reissues, reexaminations and extensions or restorations by existing or future extension or
restoration mechanisms, including patent term extensions, supplementary protection certificates or the equivalent thereof, (d) inventor’s certificates, (e) any other form of government-issued right substantially similar to any of the
foregoing and (f) all United States and foreign counterparts of any of the foregoing. The Patent Rights owned by either Party include any Patent Right assigned to such Party pursuant to the provisions of this Agreement. 

1.95. “Payload” means a therapeutically active ingredient other than an Antibody. 

1.96. “PDC” means a Probody conjugated to a Payload using a Linker. 

1.97. “PDC Developed IP” means, with respect to a Research Project Target, Developed IP that is directed to the manufacture,
composition or use of PDCs Targeting such Research Project Target. 
 1.98. “Permitted Uses” is defined in Section
7.2.1. 

  
 11 

***Certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has
been requested with respect to the omitted portions. 

 1.99. “Person” means an individual, sole proprietorship, partnership, limited
partnership, limited liability partnership, corporation, limited liability company, business trust, joint stock company, trust, incorporated association, joint venture or similar entity or organization, including a government or political
subdivision or department or agency of a government. 
 1.100. “Pfizer” is defined in the introduction to this Agreement.

 1.101. “Pfizer Diligence Obligation” is defined in Section 3.2.3. 

1.102. “Pfizer Improvements” means any [***]. 

1.103. “Pfizer Indemnified Party” is defined in Section 10.3. 

1.104. “Pfizer Know-How” means any Know-How comprised in the Pfizer Technology. 

1.105. “Pfizer Linker” means a Linker of which the composition, or any method of using or method of making, is Controlled by
Pfizer or any Affiliate of Pfizer as of the Effective Date or that comes into the Control of Pfizer or any Affiliate of Pfizer at any time during the Term of this Agreement or is used in any Agreement PDC. 

1.106. “Pfizer Patent Right” means any Patent Right comprised in the Pfizer Technology. 

1.107. “Pfizer Payload” means a Payload of which the composition, or any method of using or method of making, is Controlled by
Pfizer or any Affiliate of Pfizer as of the Effective Date or that comes into the Control of Pfizer or any Affiliate of Pfizer at any time during the Term of this Agreement or is used in any Agreement PDC. 

1.108. “Pfizer Proprietary Materials” means any chemical, biological (including any Antibodies) and other tangible research
materials Controlled by Pfizer and provided by Pfizer to CytomX under this Agreement. 
 1.109. “Pfizer Quarter” means each
of the four thirteen week periods (a) with respect to the United States, commencing on January 1 of any Pfizer Year and (b) with respect to any country in the Territory other than the United States, commencing on December 1 of
any Pfizer Year. 
 1.110. “Pfizer Site-Specific Conjugation Technology” means any Know-How or Confidential Information
Controlled by Pfizer that is specifically directed to site-specific conjugation technology. 
 1.111. “Pfizer Technology”
means [***]. 

  
 12 

***Certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has
been requested with respect to the omitted portions. 

 1.112. “Pfizer Year” means the 12 month fiscal periods observed by Pfizer
(a) commencing on January 1 with respect to the United States and (b) commencing on December 1 with respect to any country in the Territory other than the United States 

1.113. “Phase I Clinical Study” means a study of a Licensed Product in human subjects or patients with the endpoint of
determining initial tolerance, safety, metabolism or pharmacokinetic information and clinical pharmacology of such product as and to the extent defined for the United States in 21 C.F.R. § 312.21(a), or its successor regulation, or the
equivalent regulation in any other country. 
 1.114. “Phase II Clinical Study” means a study of a Licensed Product in human
patients to determine the safe and effective dose range in a proposed therapeutic indication as and to the extent defined for the United States in 21 C.F.R. § 312.21(b), or its successor regulation, or the equivalent regulation in any other
country. 
 1.115. “Phase III Clinical Study” means a study of a Licensed Product in human patients with a defined dose or a
set of defined doses of a Licensed Product designed to (a) ascertain efficacy and safety of such Licensed Product for its intended use; (b) define warnings, precautions and adverse reactions that are associated with the Licensed Product in
the dosage range to be prescribed; and (c) support preparing and submitting applications for Regulatory Marketing Approval to the competent Regulatory Authorities in a country of the world, as and to the extent defined for the United States in
21 C.F.R.§ 312.21(c), or its successor regulation, or the equivalent regulation in any other country. Phase III Clinical Study shall also include any other human clinical trial serving as a pivotal study from which the data are actually
submitted to the applicable Regulatory Authority in connection with a Regulatory Marketing Approval Application, whether or not such trial is called a “Phase III” study. 

1.116. “PHS Act” means the United States Public Health Service Act, as amended, and the rules and regulations promulgated
thereunder. 
 1.117. “Probody” means an Antibody linked to a Substrate and a Mask that is claimed or covered by CytomX
Technology, where such Antibody is not conjugated to a Payload using a Linker. 
 1.118. “Proposed Target Notice” means a
written notice provided by Pfizer to CytomX that includes a confidential written description of the proposed Target, including the Genbank accession number and the amino acid sequence for the proposed Target. 

1.119. “Proprietary Material” means any CytomX Proprietary Material or Pfizer Proprietary Material. 

1.120. “Receiving Party” is defined in Section 7.1. 

1.121. “Regulatory Approval” means any technical, medical, scientific or other license, registration, authorization or
approval of any Regulatory Authority (including any 

  
 13 

***Certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has
been requested with respect to the omitted portions. 

 
approval of a New Drug Application or Biologic License Application) necessary for the Development, Manufacture or Commercialization of a pharmaceutical product in any regulatory jurisdiction.

 1.122. “Regulatory Approval Application” means any application submitted to an appropriate Regulatory Authority seeking
any Regulatory Approval. 
 1.123. “Regulatory Authority” means, with respect to any national, supra-national, regional,
state or local regulatory jurisdiction, any agency, department, bureau, commission, council or other governmental entity involved in the granting of a Regulatory Approval for such jurisdiction. 

1.124. “Regulatory Marketing Approval” means, with respect to any pharmaceutical product and any Indication, Regulatory
Approval (including any supplement thereto) to sell such pharmaceutical product for such Indication, including, in any jurisdiction other than the United States, to the extent required for any sale in such country, all pricing and reimbursement
approvals to be obtained from the Regulatory Authority granting such Regulatory Approval or any affiliated Regulatory Authority. 
 1.125.
“Regulatory Marketing Approval Application” means any Regulatory Approval Application submitted to an appropriate Regulatory Authority seeking any Regulatory Marketing Approval. 

1.126. “Replacement Target” is defined in Section 2.1.5. 

1.127. “Representatives” is defined in Section 7.2.1. 

1.128. “Research Plan” is defined in Section 2.3.1. 

1.129. “Research Plan Activities” is defined in Section 2.3.2. 

1.130. “Research Plan Change” is defined in Section 2.3.3. 

1.131. “Research Program” is defined in Section 2.2. 

1.132. “Research Project” is defined in Section 2.3.1. 

1.133. “Research Project Target” means each of EGFR and the Second Target, provided that if the Second Target is replaced by a
Replacement Target pursuant to Section 2.1.4, then such Replacement Target shall thereafter be a Research Project Target and the Second Target shall cease to be a Research Project Target for purposes of this Agreement, and further provided
that upon election of an available Additional Target pursuant to Section 2.1.8, then such Additional Target shall be a Research Project Target as of the Additional Target Designation Date. 

  
 14 

***Certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has
been requested with respect to the omitted portions. 

 1.134. “Research Term” means, on a Research Project Target-by-Research Project
Target basis, three (3) years from the applicable Target Designation Date, provided that Pfizer, upon written notice to CytomX at least three (3) months prior to the end of the then-current Research Term, shall have the right to extend the
Research Term for each Research Project Target on a quarterly basis for up to an additional four (4) Calendar Quarters, but in no case beyond the date on which Pfizer files an IND with the applicable Regulatory Authority for a Licensed Product
Targeting such Research Project Target. 
 1.135. “Royalty Term” means, on a Licensed Product-by-Licensed Product and
country-by-country basis, the period of time from the First Commercial Sale of such Licensed Product in such country until the later of (i) the expiration of the last Valid Claim that would, but for the license to or ownership by Pfizer
hereunder, be infringed by the import or sale of such Licensed Product in such country or (ii) the tenth (10th) anniversary of the date of the First Commercial Sale of such Licensed
Product in such country, but in the case of (ii), in no event later than the twentieth (20th) anniversary of the earlier of the date of the First Commercial Sale of such Licensed Product in
the United States or the date of the First Commercial Sale of such Licensed Product in any Major EU Market Country. 
 1.136. “Sales
Milestone” is defined in Section 5.4.2. 
 1.137. “Sales Milestone Payment” is defined in Section
5.4.2. 
 1.138. “Sales Threshold” is defined in Section 5.4.2. 

1.139. “SEC” means the United States Securities and Exchange Commission. 

1.140. “Second Target” is defined in Section 2.1.3. 

1.141. “Second Target Designation Date” is defined in Section 2.1.3. 

1.142. “Second Target Window” is defined in Section 2.1.2. 

1.143. “Second Tumor Type” means the second Tumor Type for the applicable Licensed Product in the applicable country. 

1.144. “Subcontractors” is defined in Section 2.9. 

1.145. “Sublicensee” means any Person to whom Pfizer grants or has granted, directly or indirectly, a sublicense or license of
rights licensed or assigned by CytomX to Pfizer under this Agreement, in accordance with the provisions of this Agreement. 
 1.146.
“Substrate” means a moiety that is linked to the Antibody and to the Mask of a Probody and is capable of being cleaved, reduced or photolysed. 

  
 15 

***Certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has
been requested with respect to the omitted portions. 

 1.147. “Target” means (a) a specific biological molecule that is identified
by a GenBank accession number or similar information, or by its amino acid or nucleic acid sequence, (b) any naturally occurring mutant or allelic variant of a molecule disclosed in clause (a), including transcriptional and post-transcriptional
isoforms (e.g., alternative splice variants), and post-translational modification variants (e.g., protein processing, maturation and glycosylation variants); and (c) truncated forms (including fragments thereof) which have a biological function
substantially identical to that of any biological molecules disclosed in clause (a) or (b). 
 1.148. “Target Designation
Date” means, (a) with respect to EGFR, the Effective Date, (b) with respect to the Second Target, the Second Target Designation Date, (c) with respect to a Replacement Target, such date as provided in
Section 2.1.5 and (d) with respect to an Additional Target, the applicable Additional Target Designation Date. 
 1.149.
“Target Expansion Window” is defined in Section 2.1.7. 
 1.150. “Target Replacement Fee” is defined
in Section 2.1.5. 
 1.151. “Targeting” means, when used to describe the relationship between a molecule and a
Target, that the molecule (a) selectively binds to the Target (or a portion thereof) and (b) is designed or being developed to exert its primary biological effect through binding to such Target (or such portion thereof). 

1.152. “Term” is defined in Section 9.2. 

1.153. “Terminated Licensed Product” is defined in Section 9.6.1(c). 

1.154. “Terminated Target” is defined in Section 9.6.1. 

1.155. “Territory” means the entire world. 

1.156. “Third Party” means any Person other than Pfizer, CytomX or their respective Affiliates. 

1.157. “Third Party Claim” is defined in Section 10.4.1. 

1.158. “Third Tumor Type” means the third Tumor Type for the applicable Licensed Product in the applicable country. 

1.159. “Tools” means [***]. 

1.160. “Trademark” means any trademark, trade dress, design, logo, slogan, house mark or name used in connection with the
Commercialization of any Licensed Product by Pfizer or its Affiliates or Sublicensees hereunder, including any registration or application for registration of any of the foregoing. 

  
 16 

***Certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has
been requested with respect to the omitted portions. 

 1.161. “Tumor Type” means any oncological disease or condition. For clarity, a
distinct form of cancer (e.g., breast cancer) shall be considered a separate Tumor Type from other distinct forms of cancer (e.g., ovarian cancer), provided that, distinct patient populations within a disease or condition shall not be considered
separate Tumor Types. For the avoidance of doubt, the treatment of the same Tumor Type in a different patient population, or as a different line of therapy, shall not be deemed to be a separate Tumor Type for purposes of this Agreement. 

1.162. “UCSB” means The Regents of the University of California Acting Through Its Santa Barbara Campus. 

1.163. “UCSB Agreement” means that certain Amended and Restated License Agreement between UCSB and CytomX for UC Case
No. 2003-460, et al., effective as of August 19, 2010, as the same may be amended from time to time. 
 1.164.
“Useful” is defined in Section 5.5.2(b). 
 1.165. “Valid Claim” means, with respect to a particular
country, (a) a claim of an issued and unexpired patent right included within the [***] that (i) has not been held permanently revoked, unenforceable or invalid by a decision of a court or other governmental authority of competent
jurisdiction, which decision is unappealed or unappealable within the time allowed for appeal, and (ii) has not been cancelled, withdrawn, abandoned, disclaimed or admitted to be invalid or unenforceable through reissue, disclaimer or
otherwise; or (b) a bona fide claim of a pending patent application included within the [***] that has not been (i) cancelled, withdrawn or abandoned without being refiled in another application in the applicable jurisdiction or
(ii) finally rejected by an administrative agency action from which no appeal can be taken or that has not been appealed within the time allowed for appeal, provided that any claim in any patent application pending for more than [***] years
from the earliest date on which such patent application claims priority shall not be considered a Valid Claim for purposes of the Agreement from and after such [***] year date unless and until a patent containing such claim issues from such patent
application and solely if such patent issues while another Valid Claim covers the relevant Licensed Product in the relevant country. 

1.166. Construction. Except where the context expressly requires otherwise, (a) the use of any gender herein shall be deemed to
encompass references to either or both genders, and the use of the singular shall be deemed to include the plural (and vice versa), (b) the words “include”, “includes” and “including” shall be deemed to be followed
by the phrase “without limitation,” (c) the word “will” shall be construed to have the same meaning and effect as the word “shall,” (d) any definition of or reference to any agreement, instrument or other
document herein shall be construed as referring to such agreement, instrument or other document as from time to time amended, supplemented or otherwise modified (subject to any restrictions on such amendments, supplements or modifications set forth
herein), (e) any reference herein to any Person shall be construed to include the Person’s successors and assigns, (f) the words “herein”, “hereof” and 

  
 17 

***Certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has
been requested with respect to the omitted portions. 

 
“hereunder”, and words of similar import, shall be construed to refer to this Agreement in its entirety and not to any particular provision hereof, (g) all references herein to
sections or exhibits shall be construed to refer to sections or exhibits of this Agreement, and references to this Agreement include all exhibits hereto, (h) the word “notice” means notice in writing (whether or not specifically
stated) and shall include notices, consents, approvals and other written communications contemplated under this Agreement, (i) provisions that require that a Party, the Parties or any committee hereunder “agree,” “consent”
or “approve” or the like shall require that such agreement, consent or approval be specific and in writing, whether by written agreement, letter, approved minutes or otherwise (but excluding e-mail and instant messaging),
(j) references to any specific law, rule or regulation, or article, section or other division thereof, shall be deemed to include the then-current amendments thereto or any replacement or successor law, rule or regulation thereof, (k) any
definition of or reference to any agreement, instrument or other document herein shall be construed as referring to such agreement, instrument or other document as from time to time amended, supplemented or otherwise modified (subject to any
restrictions on such amendments, supplements or modifications set forth herein), and (l) the term “or” shall be interpreted in the inclusive sense commonly associated with the term “and/or.” 

 

	2.	RESEARCH PROGRAM. 

 2.1. Selection of Research Project Targets. 

2.1.1. Research Project Targets. Pfizer hereby designates EGFR as the Research Project Target for the first Research Project. 

2.1.2. Designation of a Second Research Project Target. Pfizer shall have a one-time right to nominate a second Research Project Target,
exercisable upon written notice to CytomX, at any time prior to [***] (“Second Target Window”) of the Effective Date, subject to availability of such Target as specified in Section 2.1.3. 

2.1.3. Availability of Second Target. During the Second Target Window, if Pfizer desires to nominate a second Target, Pfizer shall
provide CytomX with a Proposed Target Notice (each such proposed Target, a “Second Target”). Within [***] following CytomX’s receipt of such Proposed Target Notice, CytomX shall notify Pfizer in writing whether the exclusive
Commercial License described in Section 4.1.3 of this Agreement is Available with respect to such Second Target as of CytomX’s receipt of such Proposed Target Notice, including, if such Target is not Available, a written explanation of
the reason therefor in accordance with Section 1.16, including a certification pursuant to Section 1.16(c), as applicable. To the extent such exclusive Commercial License is Available, then such Second Target shall
automatically be considered a Research Project Target on the date CytomX so notifies Pfizer (such date, the “Second Target Designation Date” for such Second Target), and the Parties shall adopt a Research Plan for such Second Target
in accordance with Section 2.3.1. 

  
 18 

***Certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has
been requested with respect to the omitted portions. 

 2.1.4. Target Replacement Right. If the Second Target Designation Date is on or before
[***] of the Effective Date, Pfizer shall have a one-time right to replace the Second Target, if such Second Target has become a Research Project Target, with a Replacement Target, exercisable upon written notice to CytomX, at any time prior
to [***] (“Replacement Window”) of the Effective Date, subject to availability of such Target and payment of the Target Replacement Fee, if applicable, as specified in Section 2.1.5. For clarity, Pfizer shall have no right to
replace the Second Target with a Replacement Target if the Second Target Designation Date is after [***] of the Effective Date. 
 2.1.5.
Availability of Replacement Target. During the Replacement Window, if Pfizer desires to replace the Second Target with another Target, Pfizer shall provide CytomX with a Proposed Target Notice for the Target with which it desires to
replace the Second Target (each such proposed Target, a “Replacement Target”). Within [***] following CytomX’s receipt of such Proposed Target Notice, CytomX shall notify Pfizer in writing whether the exclusive Commercial
License described in Section 4.1.3 of this Agreement is Available with respect to such Replacement Target as of CytomX’s receipt of such Proposed Target Notice, including, if such Target is not Available, a written explanation of the
reason therefor in accordance with Section 1.16, including a certification pursuant to Section 1.16(c), as applicable. To the extent such exclusive Commercial License is Available, then such Replacement Target shall
automatically be considered a Research Project Target on the date CytomX so notifies Pfizer (such date, the “Target Designation Date” for such Replacement Target), subject to payment of a replacement fee in the amount of
[***] (the “Target Replacement Fee”) if such Target Designation Date is more than [***] after the Effective Date, due within [***] after such Target Designation Date, the Second Target shall thereupon cease to be a Research Project
Target for all purposes under this Agreement and the Parties shall adopt a Research Plan for such Replacement Target in accordance with Section 2.3.1. 

2.1.6. Exclusivity of Research Project Targets. During the Option Period for each Research Project Target, neither CytomX nor any of its
Affiliates shall (a) grant, or seek to grant, any right under any CytomX Technology or Developed IP to any Third Party with respect to such Research Project Target or (b) use any CytomX Technology or Developed IP to Develop (itself or
through or with a Third Party) (x) Probodies Targeting such Research Project Target other than EGFR or (y) PDCs Targeting any Research Project Target. 

2.1.7. Additional Targets. Pfizer shall have the right to add up to two (2) additional Targets (in addition to the Second Target
and any Replacement Target designated pursuant to Sections 2.1.3 and 2.1.5, respectively), exercisable upon 

  
 19 

***Certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has
been requested with respect to the omitted portions. 

 
written notice to CytomX, at any time prior to the [***] (“Target Expansion Window”) of the Effective Date, subject to availability of such Target and payment of the Additional
Target Fee, if applicable, as specified in Section 2.1.8. 
 2.1.8. Availability of Additional Target. During the Target
Expansion Window, if Pfizer desires to add an additional Target, Pfizer shall provide CytomX with a Proposed Target Notice (each such proposed Target, an “Additional Target”). Within [***] following CytomX’s receipt of such
Proposed Target Notice, CytomX shall notify Pfizer in writing whether the exclusive Commercial License described in Section 4.1.3 of this Agreement is Available with respect to such Additional Target as of CytomX’s receipt of such
Proposed Target Notice, including, if such Target is not Available, a written explanation of the reason therefor in accordance with Section 1.16, including a certification pursuant to Section 1.16(c), as applicable. To the
extent such exclusive Commercial License is Available, then such Additional Target shall automatically be considered a Research Project Target on the date CytomX so notifies Pfizer (such date, the “Additional Target Designation
Date” for such Additional Target), subject to payment of an additional target fee in the amount of one million five hundred thousand dollars ($1,500,000.00) per Additional Target (the “Additional Target Fee”), due within
[***] after such Target Designation Date, and the Parties shall adopt a Research Plan for such Additional Target in accordance with Section 2.3.1, which plan shall specify any additional FTE support to be provided by Pfizer to CytomX in
support of the Research Plan, which support upon agreement of the Parties may be in excess of the [***] FTE limit set forth in Section 5.3.1. 

2.2. Scope and Conduct of the Research Program. Under the terms and conditions set forth herein, CytomX and Pfizer shall collaborate to
conduct discovery and pre-clinical Development activities to generate and validate Agreement Probodies and generate Agreement PDCs to the Research Project Targets (the “Research Program”). The Research Program shall be conducted in
accordance with the Research Plan for each Research Project (as more fully provided in Section 2.3 below), and each Party shall use its Commercially Reasonable Efforts to perform all activities assigned to it and fulfill all of its
obligations under each Research Plan. In addition, each Party shall conduct its activities under the Research Plan(s) in accordance with Applicable Law. 

2.3. Research Plans. 

2.3.1. Adoption of Research Plans. The Parties shall adopt a research plan (each a “Research Plan”) for each Research
Project Target; a “Research Project” shall mean the work to be performed pursuant to such a Research Plan. The Research Plan for EGFR is attached as Exhibit 2.3.1. The Research Plan for any other Research Project Target shall
be prepared by the JRC and adopted within [***] of the Target Designation Date for such Research Project Target by the JRC, including in the case of a Second Target, Replacement Target or Additional Target, as applicable. Each Research Plan shall
reference this Agreement and 

  
 20 

***Certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has
been requested with respect to the omitted portions. 

 
shall be subject to all of the provisions of this Agreement, in addition to the specific details set forth in such Research Plan. To the extent any provisions of a Research Plan conflict or are
inconsistent with the provisions of this Agreement, the provisions of this Agreement shall control. Unless otherwise expressly stated in a Research Plan, the provisions of each Research Plan shall be independent of and shall not affect the
provisions of any other Research Plan. If the Parties are unable to agree on a Research Plan within the specified time period, the JRC may specify the Research Plan, and all disputes regarding the preparation or modification of any Research Plan
(including the approval of any Research Plan Change) shall be resolved by the JRC; provided, however, that unless the Parties agree in writing, in no case will a Research Plan impose any financial obligations on a Party to this Agreement that, in
aggregate, exceed the financial obligations set forth in this Agreement. 
 2.3.2. Responsibilities. Each Research Plan shall set
forth the services and the obligations and responsibilities assigned to each Party under the corresponding Research Project (collectively the “Research Plan Activities”), and shall include the following minimum terms: 

(a) For each Research Project Target other than EGFR, Pfizer shall provide Antibodies Targeting the applicable Research Project Target, which
CytomX will use to generate Probodies that Target such Research Project Target. For each Research Project, CytomX will support the construction, expression and purification of all Agreement Probodies. 

(b) CytomX will investigate and validate each Agreement Probody in accordance with the applicable Research Plan. 

(c) Pfizer will conjugate the Agreement Probodies to Linkers and Payloads using the Pfizer Technology to generate Agreement PDCs. 

(d) Pfizer will perform in vivo modeling and IND-enabling studies with respect to Agreement PDCs. 

2.3.3. Changes in Research Plans. A Research Plan may be amended by a written amendment (a “Research Plan Change”) to
such Research Plan. Proposed Research Plan Changes shall be prepared in writing by the JRC and shall be subject to review and approval by the JRC. Each Research Plan Change shall set forth the agreed changes to the applicable task, protocol,
specifications, responsibility, budget, timeline or other matter; provided that in no case will a Research Plan Change reduce the number of FTEs assigned to such Research Plan except in accordance with Section 5.3.1. As used in this
Agreement, a Research Plan will be deemed to include any Research Plan Changes with respect thereto. Each Research Plan Change shall reference this Agreement and the Research Plan it relates to and shall be subject to the provisions of this
Agreement. To the extent 

  
 21 

***Certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has
been requested with respect to the omitted portions. 

 
any provisions of a Research Plan Change conflict or are inconsistent with the provisions of this Agreement, the provisions of this Agreement shall control. All Research Plan Changes shall be
incorporated herein by reference and form a part hereof. 
 2.4. Governance of the Research Program. 

2.4.1. Formation of the Joint Research Committee. CytomX and Pfizer shall establish a “Joint Research Committee” (or
“JRC”) to oversee and coordinate the activities of the Parties under this Agreement in regard to the Research Program. The JRC shall also serve as a forum to facilitate communications between the Parties regarding the Research
Program. The JRC shall be comprised of three (3) representatives from each Party as appointed by such Party, with such representatives possessing appropriate expertise and seniority to carry out the Research Projects. The JRC may change its
size from time to time by mutual consent of its members. A Party may replace one or more of its representatives from time to time upon written notice to the other Party. The initial members of the JRC will be: [***]. The JRC shall exist until
expiration of the last to expire Option Period, unless the Parties otherwise agree in writing. 
 2.4.2. Co-Chairpersons and Secretary of
the Joint Research Committee. Each Party shall designate a co-chairperson of the JRC, and a secretary of the JRC shall be designated in accordance with Section 2.5 below. A Party may change the designation of its co-chairperson from time
to time upon written notice to the other Party. The co-chairpersons shall be responsible for scheduling meetings of the JRC, preparing agendas for meetings and sending to all JRC members notices of all regular meetings and agendas for such meetings
at least five (5) Business Days before such meetings. The co-chairpersons shall solicit input from both Parties regarding matters to be included on the agenda, and any matter either Party desires to have included on the agenda shall be included
for discussion. Nothing herein shall be construed to prohibit the JRC from discussing or acting on matters not included on the applicable agenda. The secretary shall record the minutes of the meeting, circulate copies of meeting minutes to the
Parties and each JRC member promptly following the meeting for review, comment and approval by the JRC members and finalize approved meeting minutes. The co-chairpersons shall be members of the JRC but the secretary need not be a member of the JRC.
The initial co-chairpersons shall be: [***]. 
 2.4.3. Meetings. The JRC shall meet at least once each Calendar Quarter until it has
been terminated in accordance with Section 2.4.1 at dates and times mutually agreed by the JRC, unless otherwise mutually agreed by the Parties. The initial meeting of the JRC shall be held within thirty (30) days after the Effective
Date. Either Party may call a special meeting of the JRC on fifteen (15) days written notice to the other Party’s members of the JRC (or upon such shorter notice as exigent circumstances may require). Such written notice shall include an
agenda 

  
 22 

***Certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has
been requested with respect to the omitted portions. 

 
for the special meeting. In-person meetings, including special meetings, of the JRC shall alternate between the offices of the Parties, unless otherwise agreed upon by the members of the JRC.
Meetings of the JRC may be held telephonically or by video conference; provided, however, that at least two (2) meetings per year shall be held in-person. Meetings of the JRC shall be effective only if at least one (1) representative of
each Party is in attendance or participating in the meeting. Members of the JRC shall have the right to participate in and vote at meetings held by telephone or video conference. In addition, the JRC may act on any matter or issue without a
meeting if it is documented in a written consent signed by each member of the JRC. 
 2.4.4. Responsibilities of the Joint Research
Committee. The JRC shall be responsible for (a) planning and supervising research and development under this Agreement, including establishing, reviewing and recommending modifications and updates to the Research Plans; (b) receiving
and reviewing all data and other information obtained by either Party in connection with the Research Program and monitoring and reporting to the Parties on activities conducted pursuant to the Research Plans; (c) documenting and approving
initiation and completion of each Research Project; (d) evaluating FTE requirements for the performance of the Research Plans; and (e) such other functions as expressly specified hereunder or as agreed by the Parties. 

2.4.5. Decisions by Consensus. All decisions of the JRC shall be made by unanimous agreement of both Parties’ representatives, with
each Party having a single vote, irrespective of the number of JRC representatives in attendance at a meeting. If the JRC cannot or does not reach unanimous agreement on a matter within the purview of the JRC, then Pfizer shall have the deciding
vote on such matter; provided, however, that if a Party so requests, the designated officers of the Parties shall meet to attempt to resolve such matter in accordance with Section 11.9.4, except that, notwithstanding anything in
Section 11.9, if such officers are unable to resolve such matter in ten (10) Business Days, then the matter shall be returned to the JRC and Pfizer’s vote shall be deemed final. 

2.5. Alliance Managers. In addition to the foregoing governance provisions, each of the Parties shall appoint a single individual to
serve as that Party’s alliance manager (“Alliance Manager”). The role of each Alliance Manager will be to participate and otherwise facilitate the relationship between the Parties as established by this Agreement. A Party may
replace its Alliance Manager from time to time upon written notice to the other Party. 
 2.6. Conformance with Law. Each Party shall
perform and discharge its obligations under this Agreement and the Research Program in conformance with (a) professional standards and practices, (b) this Agreement and the Research Plan(s) and (c) all Applicable Laws. Without
limiting the generality of the foregoing, each Party shall retain all records relating to its performance of this Agreement and the Research Plan(s) for the time periods required by Applicable Laws. 

  
 23 

***Certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has
been requested with respect to the omitted portions. 

 2.7. CytomX Personnel Matters. CytomX acknowledges and agrees that it is solely
responsible for the compensation of the personnel assigned to the Research Plan Activities, and shall be responsible for withholding all national, state, local or other applicable taxes and similar items for such personnel. CytomX also shall be
responsible for all other employer related obligations, including providing appropriate insurance coverage and employee benefits, and making all other deductions required by law affecting the gross wages of each employee. CytomX personnel assigned
to the Research Plan Activities are not nor shall they be deemed to be employees of Pfizer. 
 2.8. Debarment Certification. Neither
Party nor any Person employed or retained to perform services by either Party has been debarred under Section 306(a) or (b) of the FD&C Act or any comparable provision of foreign law and no debarred Person shall in the future be
employed or retained to perform services by either Party in connection with any work to be performed for or on behalf of the other Party. If, at any time after execution of this Agreement, either Party becomes aware that such Party or any Person
employed or retained to perform services by such Party in connection with any work performed for or on behalf of such Party is, or is in the process of being, debarred, such Party shall so notify the other Party immediately. 

2.9. Subcontractors. Except for natural persons engaged as independent contractors providing services as an FTE to CytomX, neither
CytomX nor its Affiliate may engage any contractor, subcontractor or other vendor (a “Subcontractor”) to perform any Research Plan Activities or Research Program activities without Pfizer’s prior written consent. CytomX shall
be responsible for the management of all permitted Subcontractors. The engagement by CytomX or its Affiliate of any Subcontractor in compliance with this Section 2.9 shall not relieve CytomX of its obligations under this Agreement or any
applicable Research Plan. Any agreement between CytomX or its Affiliate and a permitted Subcontractor pertaining to the Research Plan Activities shall be consistent with the provisions of this Agreement. Furthermore, as provided in
Section 8.3.3, unless otherwise agreed by Pfizer in writing, prior to or at the time of engagement of any Subcontractor to perform any obligations hereunder, CytomX or its Affiliate shall cause such Subcontractor to agree in writing to
be bound by terms providing for Pfizer rights no less favorable to Pfizer than the rights granted to Pfizer in this Agreement. 
 2.10.
Inspections. Pfizer authorized representative(s), and Regulatory Authorities to the extent required by law and applicable to the scope of the Research Plan Activities performed, may, during regular business hours and, to the extent legally
possible, at times arranged in advance with CytomX, audit, inspect and copy all data, records and written work products, and audit and inspect all CytomX facilities used in the performance of the Research Plan Activities, to the extent relating to
the Research Plan Activities and CytomX’s performance under this Agreement and the applicable Research Plan(s) (including all data, records, written work products and facilities of Subcontractors). 

  
 24 

***Certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has
been requested with respect to the omitted portions. 

 2.11. Records. Each Party shall prepare, maintain and retain complete and accurate written
records, accounts, notes, reports and data of the Research Plan Activities and its performance under this Agreement and the Research Plan(s), in a form and of quality reasonably acceptable to both Parties. All such information, to the extent it
specifically pertains to Agreement PDCs, shall be treated as Confidential Information of Pfizer for the purpose of this Agreement, for clarity, not including CytomX Improvements. 

2.12. Transfer and Use of Proprietary Materials. 

2.12.1. Transfer. From time to time, pursuant to a Research Plan, or otherwise, Pfizer may provide CytomX with Pfizer Proprietary
Materials and CytomX may provide Pfizer with CytomX Proprietary Materials. Each Party’s Proprietary Materials are provided by such Party on an “as-is” basis without representation or warranty of any type, express or implied, including
any representation or warranty of merchantability, non-infringement, title or fitness for a particular purpose, each of which is hereby disclaimed by such providing Party. 

2.12.2. Use of Proprietary Materials. Each Party shall use the other Party’s Proprietary Materials solely in connection with
conducting the specific activities under this Agreement for which such other Party’s Proprietary Materials are provided to the receiving Party, including, if applicable, the provisions of any specific Research Plan under which such Proprietary
Materials are provided, and for no other purpose. Without limiting the generality of the foregoing, except as expressly set forth in this Agreement or in any applicable Research Plan, neither Party shall make or attempt to make analogues, progeny or
derivatives of, or modifications to, the Pfizer Proprietary Materials or CytomX Proprietary Materials, as the case may be, using the other Party’s Confidential Information or the tangible materials provided by the other Party, and each Party
shall not use the other Party’s Proprietary Materials for the benefit of any Third Party or of its own internal research programs outside of the Research Program; provided that after exercising the Option with respect to a Research Project
Target pursuant to Section 4.1.2, Pfizer may use CytomX Proprietary Materials related to such Research Project Target to the extent assigned or licensed to Pfizer. CytomX shall not administer any of the Pfizer Proprietary Materials to any
human. Each Party shall comply with all Applicable Laws regarding the handling and use of the other Party’s Proprietary Materials. Each Party agrees to retain possession over the other Party’s Proprietary Materials and not to provide the
other Party’s Proprietary Materials to any Third Party without the providing Party’s prior written consent, except as required to perform the Research Program. 

2.12.3. Unauthorized Use of Materials. In the event that either Party uses the other Party’s Proprietary Materials for any purpose
other than the purposes authorized herein, the results of such unauthorized research, and any discoveries or inventions that arise from such unauthorized research, whether patentable or not, shall belong solely and exclusively to the Party providing
its Proprietary 

  
 25 

***Certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has
been requested with respect to the omitted portions. 

 
Materials. If required in order to perfect or enforce a Party’s ownership of such results, discoveries or inventions, each hereby assigns and agrees to assign to the other Party all of its
right, title and interest in and to all such results, discoveries or inventions made through unauthorized research with the other Party’s Proprietary Materials. Each Party agrees to cooperate with the other Party, and to execute and deliver any
and all documents that the providing Party reasonably deems necessary, to perfect and enforce its rights hereunder. 
 2.12.4. Title to
Proprietary Materials. All right, title and interest in the Pfizer Proprietary Materials shall remain the sole property of Pfizer notwithstanding the transfer to and use by CytomX of the same. Except as provided in Section 6.1.1(d),
all right, title and interest in the CytomX Proprietary Materials shall remain the sole property of CytomX notwithstanding the transfer to and use by Pfizer of the same. 

2.12.5. Return of Proprietary Materials. Upon completion of the activities for which the Pfizer Proprietary Materials have been
provided, or upon expiration or termination of this Agreement or the applicable Research Plan, if earlier, CytomX shall, at Pfizer’s option, either destroy or return to Pfizer all unused Pfizer Proprietary Materials, provided that if any
materials provided by Pfizer to CytomX include both CytomX Proprietary Materials and Pfizer Proprietary Materials, then such materials shall be destroyed. Upon completion of the activities for which the CytomX Proprietary Materials have been
provided, or upon expiration or termination of this Agreement or the applicable Research Plan, if earlier, Pfizer shall, at CytomX’s option, either destroy or return to CytomX all unused CytomX Proprietary Materials, provided that if any
materials provided by CytomX to Pfizer include both CytomX Proprietary Materials and Pfizer Proprietary Materials, then such materials shall be destroyed. For clarity, however, the foregoing obligation shall not apply to Agreement Probodies
Targeting a Research Project Target for which Pfizer exercises its Option. 
  

	3.	PRODUCT DEVELOPMENT, MANUFACTURING, COMMERCIALIZATION AND REGULATORY MATTERS. 

 3.1.
General. Except as expressly set forth in Article 2, and subject to Pfizer exercising the Option with respect to the applicable Research Project Target pursuant to Section 4.1.2, Pfizer shall have sole authority over and control
of the Development, Manufacture and Commercialization of Licensed Products Targeting such Research Project Target, and shall bear all costs associated with such Development, Manufacture and Commercialization. 

3.2. Diligence. 
 3.2.1.
Development Diligence. Pfizer will use Commercially Reasonable Efforts to Develop (including to seek Regulatory Approval for) at least one (1) Licensed 

  
 26 

***Certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has
been requested with respect to the omitted portions. 

 
Product in one (1) Major Market Country for each Research Project Target for which Pfizer exercises its Option. Except as provided in Section 2.2 and this
Section 3.2.1, Pfizer will have no other diligence obligations with respect to the Development or Regulatory Approval of Licensed Products under this Agreement. For avoidance of doubt, any actions taken by Pfizer’s Affiliates or
Sublicensees under this Agreement shall be treated as actions taken by Pfizer in regard to satisfaction of the requirements of this Section 3.2.1. 

3.2.2. Commercial Diligence. Subject to Pfizer exercising an Option pursuant to Section 4.1.2, on a Research Project
Target-by-Research Project Target basis, Pfizer will use Commercially Reasonable Efforts to Commercialize one (1) Licensed Product in one (1) Major Market Country in the Field for one (1) Tumor Type where Pfizer has received
Regulatory Approval for such Licensed Product in such country. Pfizer will have no other diligence obligations with respect to the Commercialization of Licensed Products under this Agreement. For avoidance of doubt, any actions taken by
Pfizer’s Affiliates or Sublicensees under this Agreement shall be treated as actions taken by Pfizer in regard to satisfaction of the requirements of this Section 3.2.2. 

3.2.3. Exceptions to Diligence Obligations. Notwithstanding any provision of this Agreement to the contrary, Pfizer will be relieved
from and will have no obligation to undertake any efforts with respect to any diligence obligation under Section 3.2.1 or Section 3.2.2 with respect to a given Agreement PDC or Licensed Product (each, a “Pfizer Diligence
Obligation”) in the event that: 
 (a) Pfizer or CytomX receives or generates any safety, tolerability or other data reasonably
indicating or signaling, as measured by Pfizer’s safety and efficacy evaluation criteria and methodology, that an Agreement PDC or a Licensed Product has or would have an unacceptable risk-benefit profile or is otherwise not reasonably suitable
for initiation or continuation of clinical trials in humans; 
 (b) Pfizer or CytomX receive any notice, information or correspondence from
any applicable Regulatory Authority, or any applicable Regulatory Authority takes any action, that reasonably indicates that a Licensed Product is unlikely to receive Regulatory Approval; or 

(c) CytomX materially breaches any of its Development or other obligations under a Research Plan or this Agreement related to such Licensed
Product upon which performance of the applicable Pfizer Diligence Obligation is dependent. 

  
 27 

***Certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has
been requested with respect to the omitted portions. 

 3.2.4. Assertion of Pfizer Diligence Obligation Claims. If CytomX is, becomes or
reasonably should be aware of facts that might form a reasonable basis to allege that Pfizer has failed to meet any Pfizer Diligence Obligation, then CytomX will promptly notify Pfizer in writing of such potential alleged performance failure (each
such potential alleged performance failure, a “Diligence Issue”). Promptly upon Pfizer’s receipt of any notice of a Diligence Issue pursuant to this Section 3.2.4, the Pfizer Alliance Manager will contact the CytomX
Alliance Manager to discuss the specific nature of such Diligence Issue and seek to identify an appropriate corrective course of action. If, no later than [***] after Pfizer’s receipt of such a notice, (a) the Parties have not reached
consensus regarding whether Pfizer has failed to satisfy the Pfizer Diligence Obligations and (b) the Parties’ respective Alliance Managers have not agreed upon an appropriate corrective course of action for such Diligence Issue, then such
Diligence Issue will be escalated and resolved pursuant to the dispute resolution provisions set forth in Section 11.9. If CytomX fails to notify Pfizer of a Diligence Issue pursuant to this Section 3.2.4 within [***] after the
date on which CytomX receives the minutes of the JRC meeting or the written report provided under Section 3.6.2, as applicable, on which the alleged Diligence Issue is based, then Pfizer will be deemed to have satisfied its Diligence
Obligations with respect to such Diligence Issue. 
 3.2.5. Remedies for Breach of Pfizer Diligence Obligations. If Pfizer materially
breaches any Pfizer Diligence Obligation and fails to remedy such breach within [***] of Pfizer’s receipt of notice of such breach from CytomX, then CytomX may, in its sole discretion, elect to either (a) terminate this Agreement pursuant
to the provisions of Section 9.3 on a Licensed Product-by-Licensed Product and country-by-country basis, but only to the extent that a Licensed Product in a given country in the Territory is directly and adversely impacted by such uncured
material breach or (b) convert any exclusive licenses granted to Pfizer under this Agreement with respect to a Licensed Product in a given country in the Territory into non-exclusive licenses, but only to the extent that such Licensed Product
in such country is directly and adversely impacted by such uncured material breach. CytomX acknowledges and agrees that the elections set forth in this Section 3.2.5 (i) have been negotiated by the Parties to fully address any harm that
CytomX may incur as a result of Pfizer’s material breach of any Pfizer Diligence Obligation and (ii) constitute CytomX’s sole and exclusive remedies with respect to any breach by Pfizer of the Pfizer Diligence Obligations. 

3.3. Regulatory Approvals. Subject to Pfizer exercising the Option with respect to the applicable Research Project Target pursuant to
Section 4.1.2, Pfizer or its designated Affiliate(s) shall file, in its own name, all Regulatory Approval applications for Licensed Products Targeting such Research Project Target where Pfizer, in its sole discretion, determines it is
commercially advantageous to do so. Pfizer, or its designated Affiliate(s), shall have the sole responsibility for, and sole authority with respect to, communications with any Regulatory Authority regarding any Regulatory Approval Application or any
Regulatory Approval for a Licensed Product once granted. Except to the extent necessary to fulfill its obligations under Section 3.2.1, neither Pfizer nor any of its Affiliates shall have any obligation to seek Regulatory Approval for any
Licensed Product. 

  
 28 

***Certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has
been requested with respect to the omitted portions. 

 3.4. Control of Commercialization Activities. Subject to Pfizer exercising the Option with
respect to the applicable Research Project Target pursuant to Section 4.1.2: 
 3.4.1. General. Pfizer shall have sole and
exclusive control over all matters relating to the Commercialization of Licensed Products Targeting such Research Project Target; and 

3.4.2. Trademarks. Pfizer shall select and own all Trademarks used in connection with the Commercialization of any such Licensed
Products, including all goodwill associated therewith. Neither CytomX nor its Affiliates shall use or seek to register, anywhere in the world, any trademarks which are confusingly similar to any Trademarks used by or on behalf of Pfizer, its
Affiliates or Sublicensees in connection with any Licensed Product. Nothing in this Section 3.4.2 shall be construed to prevent CytomX from granting Pfizer any license or right in and to any trademark, trade dress, design, logo, slogan, house
mark or name Controlled by CytomX. 
  

	 	3.5.	Manufacturing. Subject to Pfizer exercising the Option with respect to the applicable Research Project Target pursuant to Section 4.1.2, Pfizer shall have the exclusive right to Manufacture Licensed
Products Targeting such Research Project Target itself or through one or more Affiliates or Third Parties selected by Pfizer for both clinical purposes and for Commercialization of such Licensed Product. Pfizer shall have no diligence obligations
with respect to the Manufacture of Licensed Products except to the extent necessary to fulfill the Pfizer Diligence Obligations. For the avoidance of doubt, CytomX shall retain the right to manufacture any EGFR Probody other than for incorporation
in a PDC. 

 3.6. Progress Reporting. 

3.6.1. During the Research Term and thereafter, until the last-to-expire Option Period for each applicable Research Project Target, Pfizer
shall keep the JRC reasonably informed of its progress in researching and Developing Agreement PDCs Targeting such Research Project Target. 

3.6.2. After Pfizer’s exercise of the Option with respect to an applicable Research Project Target, Pfizer shall provide CytomX with [***]
written report with respect to EGFR, and [***] written report with respect to any other Research Project Target, and update on Pfizer’s activities to Develop or Commercialize Licensed Products Targeting such Research Project Target, and, upon
CytomX’s request, [***] per Calendar Year, the Parties agree to meet, such meeting to be held at a mutually agreed upon time, location and meeting method, within [***] 

  
 29 

***Certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has
been requested with respect to the omitted portions. 

 
after CytomX’s request, to discuss such report and updates. Any information or written report provided by Pfizer to CytomX pursuant to this Section 3.6 shall be deemed to be
Pfizer’s Confidential Information subject to the provisions of Article 7. 
 3.7. Regulatory Information. To the extent
either Party receives a communication or request for information from a Regulatory Authority that pertains to an EGFR Probody and the receiving Party reasonably believes that (a) such communication has or could have an impact on an EGFR Probody
that the other Party currently has in Development or (b) information or data being developed by such other Party could be necessary or useful to the receiving Party in responding to such communication or request for information, then such receiving
Party shall notify the other Party of such communication or request, which may include, at the receiving Party’s discretion, a copy of such communication or request redacted, if necessary, to omit information not pertaining to such EGFR
Probody, and such other Party shall promptly respond and provide reasonable assistance to the receiving Party in responding to such communication or request for information. For the avoidance of doubt, any such communication or request provided or
disclosed in any form to such other Party shall be, subject to the provisions of Article 7, treated as Confidential Information of the providing Party. 
  

	4.	LICENSES AND RELATED GRANTS OF RIGHTS. 

 4.1. Grants to Pfizer. 

4.1.1. Research License and Option Grants. Subject to the terms and conditions of this Agreement and during the Research Term with
respect to each Research Project Target, CytomX hereby grants to Pfizer and its Affiliates (a) a non-exclusive, worldwide, sublicensable, royalty-free license under the Licensed Intellectual Property to perform the activities assigned to Pfizer
under the applicable Research Plan, and (b) during the applicable Option Period, an exclusive option (each, an “Option”) to obtain the Commercial License with respect to Licensed Products Targeting such Research Project Target
as set forth in Section 4.1.3. 
 4.1.2. Exercise of Option. On a Research Project Target-by-Research Project Target basis, the
Options granted to Pfizer under Section 4.1 may be exercised by Pfizer at any time during the applicable Option Period by providing CytomX with written notice of its election to so exercise the Option(s), together with payment of the
applicable Option Exercise Fee (the date of any such Option exercise, the “Option Exercise Date”). If Pfizer does not exercise the Option with respect to any Research Project Target in the applicable Option Period, then the Target
shall no longer be considered a Research Project Target, and any Probody Targeting such Research Project Target shall no longer be considered an Agreement Probody, without limiting CytomX’s obligations under Article 7. Upon the exercise
of an Option as provided in this Section 4.1.2, if Pfizer believes that a 

  
 30 

***Certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has
been requested with respect to the omitted portions. 

 
filing under the HSR Act is necessary, Pfizer shall promptly inform CytomX and each Party shall make an appropriate filing of a Notification and Report Form pursuant to the HSR Act with respect
to the exercise of such Option as promptly as practicable and shall supply as promptly as practicable any additional information and documentary material that may be requested pursuant to the HSR Act and use Commercially Reasonable Efforts to take,
or cause to be taken, all other actions necessary to cause the expiration or termination of the applicable waiting periods under the HSR Act (including any extensions thereof) as soon as practicable, including keeping the other Party informed in all
material respects and on a reasonably timely basis of any material communication received by such Party from, or given by such Party to, the Federal Trade Commission, the Antitrust Division of the Department of Justice or any other Governmental
Authority in connection therewith. 
 4.1.3. Commercial License. Subject to the terms and conditions of this Agreement, on a Research
Project Target-by-Research Project Target basis and effective on the Option Exercise Date for such Research Project Target, CytomX hereby grants to Pfizer and its Affiliates an exclusive (even as to CytomX, except to the extent necessary for CytomX
to perform its obligations under the Research Program) license under the Licensed Intellectual Property, to make, have made, use, have used, sell, have sold, offer for sale, have offered for sale, import, have imported and otherwise exploit and
Commercialize Licensed Products in the Field in the Territory, with the right to sublicense as provided in Section 4.1.6 (the “Commercial License”). 

4.1.4. License to CytomX Improvements. Subject to the terms and conditions of this Agreement, CytomX hereby grants to Pfizer and its
Affiliates a non-exclusive, worldwide, sublicensable, royalty-free, perpetual and irrevocable license under any CytomX Improvements that were solely or jointly invented by the employees, agents or independent contractors of Pfizer or its Affiliates
to (a) make, have made, use, have used, sell, have sold, offer for sale, have offered for sale, import, have imported and otherwise exploit and Commercialize any products and processes other than Probodies alone or as incorporated in a PDC and
(b) make, have made, use and have used any Probodies alone or incorporated in a PDC for research purposes. 
 4.1.5. Licenses to
Certain Developed IP. 
 (a) Subject to the terms and conditions of this Agreement and without limiting any other license granted to
Pfizer under this Agreement, CytomX hereby grants to Pfizer and its Affiliates a non-exclusive, worldwide, sublicensable, royalty-free, perpetual and irrevocable license under any Developed IP solely owned by CytomX to (i) make, have made, use,
have used, sell, have sold, offer for sale, have offered for sale, import, have imported and otherwise exploit and Commercialize any products and 

  
 31 

***Certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has
been requested with respect to the omitted portions. 

 
processes other than Probodies alone or as incorporated in a PDC and (ii) make, have made, use and have used any Probodies alone or as incorporated in a PDC for research purposes. 

(b) Subject to the terms and conditions of this Agreement and without limiting any other license granted to Pfizer under this Agreement, in
the event Pfizer does not exercise the Option for a Research Project Target, to the extent CytomX solely owns any Developed IP that consists of (i) conjugation chemistry or conjugation methods that are unique to Pfizer Linkers or Pfizer
Payloads or (ii) a conjugated ADC using Pfizer Linkers or Pfizer Payloads made using the chemistry or methods referenced under clause (a), CytomX shall grant and hereby does grant to Pfizer and its Affiliates a non-exclusive, worldwide,
sublicensable, royalty-free, perpetual and irrevocable license under such Developed IP to make, have made, use, have used, sell, have sold, offer for sale, have offered for sale, import, have imported and otherwise exploit and Commercialize ADCs
containing Pfizer Linkers or Pfizer Payloads. 
 4.1.6. Right to Sublicense. Pfizer shall have the right to grant sublicenses to its
Affiliates and Third Parties of any and all licenses granted to Pfizer under this Agreement by CytomX, provided that (a) Pfizer shall be jointly and severally responsible with its Sublicensees to CytomX for failure by its Sublicensees to comply
with the terms and conditions of this Agreement and (b) Pfizer shall remain responsible for the payment to CytomX of all Milestone Payments and royalties payable with respect to the activities and Net Sales of any Sublicensee. 

4.1.7. Direct License to Affiliates. Pfizer may at any time request and authorize CytomX to grant licenses directly to Affiliates of
Pfizer by giving written notice designating to which Affiliate a direct license is to be granted. Upon receipt of any such notice, CytomX shall enter into and sign a separate direct license agreement with such designated Affiliate of Pfizer. All
such direct license agreements shall be within the scope of the licenses granted in Section 4 and shall be consistent with the terms and conditions of this Agreement, except for such modifications as may be required by the laws and
regulations in the country in which the direct license will be exercised. The Parties further agree to make any amendments to this Agreement that are necessary to conform the combined terms of such direct license agreements and this Agreement to the
terms of this Agreement as set forth on the Effective Date. In countries where the validity of such direct license agreements requires prior governmental approval or registration, such direct license agreements shall not become binding between the
parties thereto until such approval or registration is granted, which approval or registration shall be obtained by Pfizer. All costs of making such direct license agreement(s), including CytomX’s reasonable attorneys’ fees, under this
Section 4.1.7 shall be borne by Pfizer. 

  
 32 

***Certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has
been requested with respect to the omitted portions. 

 4.1.8. Right of Reference. CytomX hereby grants to Pfizer a “Right of
Reference,” as that term is defined in 21 C.F.R. § 314.3(b), to any data Controlled by CytomX or its Affiliates (a) to the extent that it specifically pertains to a Probody contained in the Agreement PDCs, the Licensed Products or
preclinical studies with respect to the Licensed Products and (b) that Pfizer reasonably believes may be necessary or useful to the Development, Manufacturing or Commercialization of any Agreement PDC or any Licensed Product pursuant to this
Agreement, and CytomX will provide a signed statement to the foregoing effect, if so requested by Pfizer in accordance with 21 C.F.R. § 314.50(g)(3). 

4.1.9. Technology Transfer Assistance. CytomX shall provide reasonable assistance, at no additional cost to Pfizer beyond reimbursement
of FTE costs for CytomX personnel providing such assistance as provided in Section 5.3.1, to effect the timely and orderly transfer to Pfizer of the Know-How included in the Licensed Intellectual Property necessary for Pfizer’s use
in performing its responsibilities under the Research Plans, and, if Pfizer exercises an Option granted to it under Section 4.1.1, for the Development, Manufacturing and Commercialization of Licensed Products pursuant to the Commercial
License. 
 4.2. Grants to CytomX. 

4.2.1. Research License. Subject to the terms and conditions of this Agreement and during the Research Term with respect to each
Research Project Target, Pfizer hereby grants to CytomX a non-exclusive, worldwide, royalty-free license, with no right to grant sublicenses, under the Pfizer Technology to perform the activities assigned to CytomX under the applicable Research
Plan. 
 4.2.2. License to Certain Developed IP. [***] 

4.3. Reciprocal Non-Exclusive Research License for Disclosed Know-How and Confidential Information. Without limiting any other license
granted to either Party under this Agreement and subject to the terms of Section 7: 
 4.3.1. CytomX hereby grants to Pfizer and its
Affiliates a non-exclusive, irrevocable, perpetual, royalty-free, fully paid-up, worldwide license to use any and all Know-How included in the Licensed Intellectual Property and CytomX Confidential Information disclosed to Pfizer during the Term of
this Agreement solely for internal research purposes, other than research on Substrates, it being understood and agreed that Pfizer will have no right under this Section 4.3.1 to use any such CytomX Know-How or CytomX Confidential
Information in connection with the sale or manufacture for sale of any pharmaceutical product or process. 

  
 33 

***Certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has
been requested with respect to the omitted portions. 

 4.3.2. Pfizer hereby grants to CytomX and its Affiliates a non-exclusive, irrevocable, perpetual,
royalty-free, fully paid-up, worldwide license to use any and all Pfizer Know-How and Pfizer Confidential Information (other than any information regarding the identity of or Pfizer’s reasons for selecting any Research Project Target,
Replacement Target or Additional Target, which shall only be disclosed by CytomX to its Representatives as necessary to comply with the terms of this Agreement) disclosed to CytomX during the Term of this Agreement solely for internal research
purposes, other than Pfizer Site-Specific Conjugation Technology, it being understood and agreed that CytomX will have no right under this Section 4.3.2 to use any Pfizer Know-How or Pfizer Confidential Information in connection with the
sale or manufacture for sale of any pharmaceutical product or process. 
 4.3.3. Notwithstanding the foregoing, neither Pfizer nor CytomX
shall have any right under this Section 4.3 to (a) make or use any physical material supplied by the other Party for use in the Research Program other than for use in the Research Program or (b) practice under any Patent Right
Controlled by the other Party. 
 4.4. Retained Rights. For the avoidance of doubt, except as expressly provided in regard to the
licenses contained in this Article 4 or in the provisions of Section 6.1.1, neither Party will have any rights in the other Party’s Antibodies, in the case of Pfizer, or Probodies, in the case of CytomX, and each Party will retain
ownership of all of its Pfizer Technology or CytomX Technology, as applicable, covering any Antibody or Probody, as applicable, that such Party contributes to the Research Program. 

4.5. Exclusivity. 
 4.5.1.
Exclusivity Covenant. During the Term of this Agreement, except to the extent required for CytomX to fulfill its obligations under the Agreement, CytomX and its Affiliates will not engage in, and will not license or otherwise grant any right
to, or enter into any collaborative arrangement with, any Third Party to engage in, any activity where a goal of such activity is to Develop or Commercialize any Probody or PDC Targeting any Research Project Target for which Pfizer has exercised its
Option for use in the Field, except that Pfizer acknowledges and agrees that CytomX and its Affiliates may continue Development of and Commercialize (and to license and enter into collaborative arrangements regarding) an EGFR Probody as a Probody
but not as a PDC. 
 4.5.2. Other Pfizer Programs. CytomX understands and acknowledges that Pfizer may have present or future
initiatives or opportunities, including initiatives or opportunities with its Affiliates or Third Parties, involving similar products, programs, technologies or processes that are similar to or that may compete with a product, program, technology or
process covered by this Agreement. CytomX acknowledges and agrees that nothing in this Agreement will be construed as a representation, warranty, covenant or inference that Pfizer will not itself Develop, Manufacture or Commercialize or enter into
business relationships with one or more of its Affiliates or Third Parties to Develop, Manufacture or Commercialize 

  
 34 

***Certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has
been requested with respect to the omitted portions. 

 
products, programs, technologies or processes that are similar to or that may compete with any product, program, technology or process covered by this Agreement. 

4.6. Section 365(n) of Bankruptcy Code. All rights and licenses now or hereinafter granted by CytomX to Pfizer under or pursuant to
any section of this Agreement, including Sections 4.1.1, 4.1.3, 4.1.4, 4.1.5 and 4.3.1, are rights to “intellectual property” (as defined in Section 101(35A) of Title 11 of the United States Code, as
amended (such Title 11, the “Bankruptcy Code”)). The Parties hereto acknowledge and agree that the payments provided for under Sections 5.1, 5.2, 5.3 and 5.4, and all other payments by Pfizer to CytomX
under this Agreement, other than royalty payments pursuant to Section 5.5, do not constitute royalties within the meaning of Section 365(n) of the Bankruptcy Code or relate to licenses of intellectual property under this Agreement. 

4.7. No Implied Rights. Except as expressly provided in this Agreement, neither Party shall be deemed, by estoppel, implication or
otherwise, to have granted the other Party any license or other right with respect to any intellectual property of such Party. 
  

	5.	PAYMENTS TO CYTOMX. 

 5.1. Upfront and Option Fee. Within [***] after the
Effective Date, Pfizer shall pay to CytomX the non-creditable, non-refundable amount of Six Million Dollars ($6,000,000). 
 5.2. Option
Exercise Fee. Upon exercise of the Option for a Research Project Target pursuant to Section 4.1.2, Pfizer shall pay to CytomX the “Option Exercise Fee” for such Research Project Target, as set forth in the table below. 

 

					
	 Research Project Target
	  	Option Exercise Fee	 
	 EGFR
	  	$	[	***] 
	 Second Target or Replacement Target
	  	$	[	***] 
	 Each Additional Target
	  	$	[	***] 

 5.3. Research Support Funding. 

5.3.1. FTE Reimbursement. During the applicable Research Term, Pfizer shall reimburse CytomX for the costs of CytomX FTEs incurred in
performing its Research Plan Activities at the FTE Rate. Pfizer shall be obligated to reimburse CytomX for [***] FTEs in aggregate per Calendar Year. Subject to the foregoing, the JRC shall determine the specific number of FTEs that shall perform
Research Plan Activities for CytomX from time to time. By [***] of the applicable Research Term, the JRC shall estimate the number of projected CytomX FTE’s to be utilized in the subsequent [***] period of such Research Term, provided that the
JRC shall evaluate and revise, as applicable, such estimate at each Calendar 

  
 35 

***Certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has
been requested with respect to the omitted portions. 

 
Quarterly meeting for the following Calendar Quarter, provided, further, that the JRC shall not reduce the number of FTEs set forth in such estimate unless Pfizer has provided CytomX with
[***]’ advanced written notice of its intention to reduce such number from the most recent annual estimate. Notwithstanding the foregoing, Pfizer shall only be obligated to reimburse CytomX for the number of FTEs actually incurred and reported
pursuant to Section 5.3.3 in the performance of its Research Plan Activities. 
 5.3.2. Other Expenses. Except as expressly set
forth in Section 5.3.1, CytomX shall be solely responsible for all costs and expenses it incurs in performing its obligations under the Research Program, except as specifically set forth in the applicable Research Plan; provided, however,
that CytomX shall not be required to assign any FTEs to the performance of the Research Plan Activities in excess of the number of FTEs that Pfizer is obligated to reimburse. 

5.3.3. Reports and Reimbursement Payments. Within [***] after the end of each Calendar Quarter of the applicable Research Term, CytomX
shall provide Pfizer with a quarterly report containing a detailed account of activities performed together with an invoice for amounts payable under Section 5.3.1, with respect to such Calendar Quarter. Each report must be accompanied by a
certificate executed by a duly appointed officer of CytomX confirming the actual total number of FTEs supplied by CytomX during such Calendar Quarter, and the percent effort of the FTEs in performing Research Plan Activities engaged during such
Calendar Quarter. Payment shall be due within [***] after Pfizer receives such an invoice from CytomX. 
 5.3.4. Audit Rights. During
the applicable Research Term and for a period of [***] thereafter, CytomX shall keep and maintain accurate and complete records showing the time devoted and general activities performed (on a monthly basis) by each FTE in performing CytomX’s
obligations under the Research Program. Upon [***] prior written notice from Pfizer, CytomX shall permit an independent certified public accounting firm of nationally recognized standing selected by Pfizer and reasonably acceptable to CytomX to
examine, at Pfizer’s sole expense, the relevant books and records of CytomX as may be reasonably necessary to verify the accuracy of the invoices submitted to Pfizer under Section 5.3.3 for the number of FTEs applied to the performance
of CytomX’s obligations under the Research Program. An examination by Pfizer under this Section 5.3.4 shall occur not more than [***] and shall be limited to the pertinent books and records for any Calendar Year ending not more than
[***] before the date of the request. Such examination shall be conducted during CytomX’s normal business hours at CytomX’s facility(ies) where such books and records are normally kept. CytomX may require the accounting firm to sign a
reasonable and customary non-disclosure agreement. The accounting firm shall provide both CytomX and Pfizer a written report disclosing whether the invoices submitted by CytomX are correct or incorrect and the specific details concerning any
discrepancies. If the audit 

  
 36 

***Certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has
been requested with respect to the omitted portions. 

 
establishes that the number of FTEs actually utilized by CytomX was less than the number funded by Pfizer during the period covered by the audit, CytomX shall, at Pfizer’s sole discretion,
either (a) refund the excess payments to Pfizer within [***] of its receipt of the auditor’s report so concluding or (b) immediately offset all such excess payments against any outstanding or future amounts payable by Pfizer to CytomX
under this Agreement until Pfizer has received full credit for all such overpayments. Additionally, if the amount to be refunded exceeds more than [***] of the amount that was properly payable, CytomX shall reimburse Pfizer for the reasonable
out-of-pocket cost of the audit. If CytomX reasonably and in good faith disputes the result of any audit under this Section 5.3, the payments of disputed amounts due under this Section 5.3 shall be tolled until resolution of
such dispute pursuant to Section 11.9. 
 5.4. Milestones 

5.4.1. Development Milestones. Within [***] following the first occurrence of each event (each, a “Development
Milestone”) described below for each Research Project Target, Pfizer shall provide written notice to CytomX identifying the Research Project Target and the Development Milestone achieved, and Pfizer shall pay to CytomX the amount set forth
below within [***] of receipt of CytomX’s invoice with respect to such Development Milestone (each such amount, a “Development Milestone Payment”) to be payable only once with respect to each Research Project Target regardless
of how many Agreement PDCs or Licensed Products Targeting such Research Project Target achieve such Development Milestone. Notwithstanding anything to the contrary in this Agreement, Development Milestone Payments shall only be owed pursuant to this
Section 5.4.1 for those Agreement PDCs and Licensed Products of which the manufacture or sale is covered by a Valid Claim. For the avoidance of doubt, if any Development Milestone Payment is paid for an Agreement PDC or Licensed Product
Targeting the Second Target, such Development Milestone Payment will not be owed by Pfizer if an Agreement PDC or Licensed Product Targeting a Replacement Target (but not an Additional Target) later achieves the same Development Milestone. 

  
 37 

***Certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has
been requested with respect to the omitted portions. 

									
	 Development Milestone
	  	Development
Milestone Payment
for Licensed
Products Targeting
EGFR	 	 	Development
Milestone
Payment for
Licensed
Products
Targeting the
Second Target
or a
Replacement
Target 
or an
Additional
Target	 
			
	 (A) Dosing of first subject in a Phase I Clinical Study with an Agreement PDC Targeting such applicable Research Project
Target
	  	 	[	***] 	 	 	[	***] 
			
	 (B) Dosing of first subject in a Phase II Clinical Study with an Agreement PDC Targeting such applicable Research Project
Target
	  	 	[	***] 	 	 	[	***] 
			
	 (C) Dosing of first subject in a Phase III Clinical Study with an Agreement PDC Targeting such applicable Research Project
Target
	  	 	[	***] 	 	 	[	***] 
			
	 (D) First Commercial Sale of a Licensed Product containing an Agreement PDC Targeting such applicable Research Project Target in
[***]
	  	 	[	***] 	 	 	[	***] 
			
	 (E) First Commercial Sale of a Licensed Product containing an Agreement PDC Targeting such applicable Research Project Target in
[***]
	  	 	[	***] 	 	 	[	***] 
			
	 (F) First Commercial Sale of a Licensed Product containing an Agreement PDC Targeting such applicable Research Project Target in
[***]
	  	 	[	***] 	 	 	[	***] 
			
	 (G) First Commercial Sale of a Licensed Product in a Second Tumor Type containing an Agreement PDC Targeting such applicable Research
Project Target in [***]
	  	 	[	***] 	 	 	[	***] 

  
 38 

***Certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has
been requested with respect to the omitted portions. 

									
			
	 (H) First Commercial Sale of a Licensed Product in a Second Tumor Type containing an Agreement PDC Targeting such applicable Research
Project Target in [***]
	  	 	[	***] 	 	 	[	***] 
			
	 (I) First Commercial Sale of a Licensed Product in a Second Tumor Type containing an Agreement PDC Targeting such applicable Research
Project Target in [***]
	  	 	[	***] 	 	 	[	***] 
			
	 (J) First Commercial Sale of a Licensed Product in a Third Tumor Type containing an Agreement PDC Targeting such applicable Research
Project Target in [***]
	  	 	[	***] 	 	 	[	***] 
			
	 (K) First Commercial Sale of a Licensed Product in a Third Tumor Type containing an Agreement PDC Targeting such applicable Research
Project Target in [***]
	  	 	[	***] 	 	 	[	***] 
			
	 (L) First Commercial Sale of a Licensed Product in a Third Tumor Type containing an Agreement PDC Targeting such applicable Research
Project Target in [***]
	  	 	[	***] 	 	 	[	***] 

 For clarity, if a Subsequent Milestone is achieved and any Previous Milestone for such Research Project Target
has not yet been achieved for any reason, notwithstanding anything herein to the contrary such Previous Milestone(s) shall be deemed to have been achieved and the corresponding Development Milestone Payment set forth in the table above shall be
payable simultaneously with the Development Milestone Payment for the achievement of the Subsequent Milestone. For purposes of the foregoing, each Development Milestone B through F shall be deemed a “Subsequent Milestone” for each
Development Milestone A through C prior in alphabetical order in the above table (each, a “Previous Milestone”); provided that Development Milestones D, E, and F shall each be deemed Subsequent Milestones only of Development
Milestones A through C. For example, if Development Milestone C were achieved before Development Milestone B, then the Development Milestone Payment for Development Milestone B would be due and payable on such achievement of Development Milestone C.

  
 39 

***Certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has
been requested with respect to the omitted portions. 

 5.4.2. Sales Milestones. Pfizer shall pay to CytomX the following one-time payments (each,
a “Sales Milestone Payment”) when aggregate Annual Net Sales of a Licensed Product in the Territory in a Pfizer Year first reach the respective threshold (a “Sales Threshold”) indicated below (each, a “Sales
Milestone”); provided that such Sales Threshold with respect to a Licensed Product must be reached within the first seven (7) full Pfizer Years following the First Commercial Sale of such Licensed Product in the United States. 

 

													
	 Total Annual Net
Sales
	  	Sales Milestone
Payment for
Licensed
Products
Targeting EGFR	 	 	Sales Milestone
Payment for
Licensed
Products
Targeting the
Second Target or
a 
Replacement
Target	 	 	Sales Milestone
Payment for
Licensed
Products
Targeting an
Additional
Target	 
				
	 Total Annual Net Sales exceeding $500,000,000
	  	 	[	***] 	 	 	[	***] 	 	 	[	***] 
				
	 Total Annual Net Sales exceeding $1,000,000,000
	  	 	[	***] 	 	 	[	***] 	 	 	[	***] 
				
	 Total Annual Net Sales exceeding $2,000,000,000
	  	 	[	***] 	 	 	[	***] 	 	 	[	***] 
				
	 Total Annual Net Sales exceeding $3,000,000,000
	  	 	[	***] 	 	 	[	***] 	 	 	[	***] 

 If more than one unmet Sales Threshold is achieved with respect to the same Pfizer Year, payment will be made
with respect to the higher or highest Sales Threshold achieved in such Pfizer Year and all other previously unmet Sales Thresholds achieved with respect to such Pfizer Year will remain eligible to be met in future Pfizer Years. Any Sales Milestone
Payment with respect to any Pfizer Year shall be payable within [***] of the end of such Pfizer Year in the United States. Each Sales Milestone Payment is payable a maximum of one time only, regardless of the number of Licensed Products that achieve
a particular Sales Threshold. 

  
 40 

***Certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has
been requested with respect to the omitted portions. 

 5.5. Royalties. With respect to each Research Project Target and subject to the provisions
of Section 5.5.2, Pfizer shall pay CytomX royalties in the amount of the applicable rates (“Marginal Royalty Rates”) set forth below of Annual Net Sales of any Licensed Product Targeting such Research Project Target during
the Royalty Term: 
  

									
	 Annual Net Sales
	  	Marginal Royalty
Rate for Licensed
Products Targeting
EGFR
(% of the Annual Net
Sales)	 	 	Marginal Royalty
Rate for Licensed
Products
Targeting the
Second Target or
a Replacement
Target or
an
Additional Target
(% of the Annual
Net Sales)	 
	 Annual Net Sales of such Licensed Product during a given Pfizer Year up to and including $750,000,000
	  	 	[	***]% 	 	 	[	***]% 
	 Annual Net Sales of such Licensed Product during a given Pfizer Year above $750,000,000, up to and including $1,500,000,000
	  	 	[	***]% 	 	 	[	***]% 
	 Annual Net Sales of such Licensed Product during a given Pfizer Year above $1,500,000,000, up to and including $2,250,000,000
	  	 	[	***]% 	 	 	[	***]% 
	 Annual Net Sales of such Licensed Product during a given Pfizer Year above $2,250,000,000
	  	 	[	***]% 	 	 	[	***]% 

 5.5.1. Marginal Royalty Rate Application. Each Marginal Royalty Rate set forth in the table above shall
apply only to that portion of the Annual Net Sales of a given Licensed Product in the Territory during a given Pfizer Year that falls within the indicated range. 

5.5.2. Royalty Adjustments. The following adjustments shall be made, on a Licensed Product-by-Licensed Product and country-by-country
basis, to the royalties payable pursuant to this Section 5.5: 
 (a) Generic Competition. Royalties payable following
establishment of Generic Competition with respect to the sale by a Third Party of a product that is a Biosimilar Biologic Product to such Licensed Product in such country shall be payable at [***] of the otherwise applicable rate prior to
application of this Section 5.5.2(a). “Generic Competition” means, with respect to a given Calendar Year with respect to a Licensed 

  
 41 

***Certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has
been requested with respect to the omitted portions. 

 
Product in any country, that during such Calendar Year, (x) one (1) or more Third Parties have received Regulatory Marketing Approval to sell in such country a Biosimilar Biologic
Product, (y) such Biosimilar Biologic Product(s) shall be commercially available in such country and (z) such Biosimilar Biologic Product(s) shall have, in the aggregate, a [***] market share of the aggregate of such Licensed Product and
Biosimilar Biologic Product(s) (based on data provided by IMS International, or if such data is not available, such other reliable data source as reasonably designated by Pfizer) as measured by the number of prescriptions. In the event IMS
International data (or such other designated data source) is not sufficient to determine the percentage market share for each country in the European Union, the percent market share for the European Union countries for which data is not available
will be deemed to be the average percent market share for those European Union countries in which the data is available. A product shall be a “Biosimilar Biologic Product” with respect to a Licensed Product if such product
(1) has been licensed as a biosimilar or interchangeable product by FDA pursuant to Section 351(k) of the Public Health Service Act (42 U.S.C. 262(k)), as may be amended, or any subsequent or superseding law, statute or regulation,
(2) has been licensed as a similar biological medicinal product by EMA pursuant to Directive 2001/83/EC, as may be amended, or any subsequent or superseding law, statute or regulation, or (3) has otherwise achieved analogous Regulatory
Marketing Approval from another applicable Regulatory Authority. In no event will the royalty payable to CytomX for such Licensed Product be reduced below three percent (3%) by operation of this Section 5.5.2(a). 

(b) Third Party Patents. If, after the Effective Date, it is Necessary or Useful for Pfizer to license one or more Patent Rights from
one or more Third Parties in order to Develop, Manufacture, Commercialize or use any Licensed Product, whether directly or through any Pfizer Affiliate or Sublicensee, then Pfizer may, in its sole discretion, negotiate and obtain a license under
such Patent Right(s) (each such Third Party license referred to herein as an “Additional Third Party License”). Any royalty otherwise payable to CytomX under this Agreement with respect to Net Sales of any Licensed Product by
Pfizer, its Affiliates or Sublicensees shall be reduced by [***] of the royalties payable to Third Parties pursuant to any Additional Third Party Licenses with respect to such Licensed Product, such reduction to continue until all such royalties
have been expended, provided that in no event (other than in the case of CytomX’s breach of any representation, warranty or covenant hereunder) shall the total royalty payable to CytomX for such Licensed Product be less than [***] of the
royalty amounts otherwise payable for such Licensed Product and in no event will the royalty payable to CytomX for such Licensed Product be reduced below three percent (3%). For purposes of this 

  
 42 

***Certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has
been requested with respect to the omitted portions. 

 
Section 5.5.2(b), [***]. For the avoidance of doubt, the Parties agree and acknowledge that this Section 5.5.2(b) shall not apply with respect to royalties payable by Pfizer to any
Third Party under any agreement in existence as of the Effective Date. 
 (c) CytomX Third Party Agreements.  

(i) [***] 
 (ii) [***] 

(iii) [***] 
 5.5.3.
Fully Paid-Up, Royalty Free License. After expiration of the Royalty Term for any Licensed Product in a country in the Territory, no further royalties shall be payable in respect of sales of such Licensed Product in such country and
thereafter the Commercial License with respect to such Licensed Product in such country shall be a fully paid-up, perpetual, exclusive, irrevocable, royalty-free license. 

5.6. Reports and Payments. 

5.6.1. Cumulative Royalties. The obligation to pay royalties under Section 5.5 shall be imposed only once with respect to
a single unit of a Licensed Product regardless of how many Valid Claims in Patent Rights included within the Licensed Intellectual Property would, but for this Agreement, be infringed by the use or sale of such Licensed Product in the country in
which such Licensed Product is used or sold. 
 5.6.2. Royalty Statements and Payments. Within [***] after the end of
each Pfizer Quarter, Pfizer shall deliver to CytomX a report setting forth for such Pfizer Quarter the following information, on a Licensed Product-by-Licensed Product basis: (a) the Net Sales of each Licensed Product, (b) the basis for
any adjustments to the royalty payable for the sale of each Licensed Product and (c) the royalty due hereunder for the sale of each Licensed Product. No such reports shall be due for any Licensed Product before the First Commercial Sale of such
Licensed Product in the Territory. The total royalty due for the sale of Licensed Products during such Pfizer Quarter shall be remitted at the time such report is delivered to CytomX. 

5.6.3. Taxes and Withholding. It is understood and agreed between the Parties that any payments made this Agreement are inclusive
of any value added or similar tax imposed upon such payments. In addition, in the event any of the payments made by Pfizer pursuant to this Agreement become subject to withholding taxes under the Applicable Law of any jurisdiction, Pfizer shall
deduct and withhold the amount of such taxes for the account of CytomX, to the  

  
 43 

***Certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has
been requested with respect to the omitted portions. 

 
extent required by Applicable Law, such amounts payable to CytomX shall be reduced by the amount of taxes deducted and withheld, and Pfizer shall pay the amounts of such taxes to the proper
Governmental Authority in a timely manner and promptly transmit to CytomX an official tax certificate or other evidence of such tax obligations together with proof of payment from the relevant Governmental Authority of all amounts deducted and
withheld sufficient to enable CytomX to claim such payment of taxes. Any such withholding taxes required under Applicable Law to be paid or withheld shall be an expense of, and borne solely by, CytomX. Pfizer will provide CytomX with reasonable
assistance to enable CytomX to recover such taxes as permitted by Applicable Law. 
 5.6.4. Currency. All amounts payable and
calculations hereunder shall be in United States dollars, and all payments due under this Agreement shall be made by wire transfer in immediately available funds to an account designated by the Party owed such payment, or by other mutually
acceptable means. As applicable, Net Sales and any royalty deductions shall be converted into United States dollars in accordance with Pfizer’s customary and usual conversion procedures, consistently applied. 

5.6.5. Additional Provisions Relating to Payments. CytomX acknowledges and agrees that nothing in this Agreement (including any
schedules and exhibits hereto) shall be construed as representing an estimate or projection of either (a) the number of Licensed Products that shall or may be successfully Developed or Commercialized or (b) anticipated sales or the actual
value of any Licensed Product. PFIZER MAKES NO REPRESENTATION OR WARRANTY, EITHER EXPRESS OR IMPLIED, THAT IT SHALL BE ABLE TO SUCCESSFULLY DEVELOP OR COMMERCIALIZE ANY PRODUCT OR, IF COMMERCIALIZED, THAT IT WILL ACHIEVE ANY PARTICULAR SALES LEVEL
OF SUCH PRODUCT(S), PROVIDED THAT THE FOREGOING SHALL NOT LIMIT PFIZER’S OBLIGATIONS UNDER THIS AGREEMENT. 
 5.7. Maintenance of
Records; Audits. 
 5.7.1. Record Keeping. Pfizer shall keep, and cause its Affiliates and Sublicensees to keep, accurate
books of account and records in connection with the sale of Licensed Products, in sufficient detail to permit accurate determination of all figures necessary for verification of royalties to be paid hereunder. Pfizer shall maintain, and cause its
Affiliates and Sublicensees to maintain, such records for a period of at least [***] after the end of the Calendar Year in which they were generated. 

5.7.2. Audits. Upon [***] prior written notice from CytomX, Pfizer shall permit an independent certified public accounting firm
of internationally recognized standing selected by CytomX and reasonably acceptable to Pfizer to examine, at  

  
 44 

***Certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has
been requested with respect to the omitted portions. 

 
CytomX’s sole expense, the relevant books and records of Pfizer during the period covered by such examination, as may be reasonably necessary to verify the accuracy of the reports submitted
by Pfizer in accordance with Section 5.6 and the payment of royalties hereunder. An examination by CytomX under this Section 5.7.2 shall occur not more than once in any Calendar Year and shall be limited to the pertinent books and
records for any Calendar Year ending not more than [***] before the date of the request. The accounting firm shall be provided access to such books and records at Pfizer’s or its Affiliates’ facilities where such books and records are kept
and such examination shall be conducted during Pfizer’s normal business hours. Pfizer may require the accounting firm to sign a reasonable and customary non-disclosure agreement before providing the accounting firm access to Pfizer’s
facilities or records. Upon completion of the audit, the accounting firm shall provide both Pfizer and CytomX a written report disclosing whether the reports submitted by Pfizer are correct or incorrect, whether the royalties paid are correct or
incorrect and, in each case, the specific details concerning any discrepancies. No other information shall be provided to CytomX. 

5.7.3. Underpayments/Overpayments. If such accounting firm concludes that additional royalties were due to CytomX, Pfizer shall
pay to CytomX the additional royalties within [***] of the date Pfizer receives such accountant’s written report so concluding. If such underpayment exceeds [***] of the royalties that were to be paid to CytomX, Pfizer also shall reimburse
CytomX for all reasonable charges of such accountants for conducting the audit. If such accounting firm concludes that Pfizer overpaid royalties to CytomX, CytomX shall repay such amount to Pfizer in full within [***] of the receipt of such
accountant’s report, or, at Pfizer’s option, Pfizer shall be entitled to offset all such overpayments against any outstanding or future amounts payable to CytomX hereunder until Pfizer has received full credit for such overpayments.

 5.7.4. Confidentiality. All financial information of Pfizer which is subject to review under this Section 5.7.4.
shall be deemed to be Pfizer’s Confidential Information subject to the provisions of Article 7 hereof, and CytomX shall not disclose such Confidential Information to any Third Party or use such Confidential Information for any purpose
other than verifying payments to be made by Pfizer to CytomX hereunder. 
  

	6.	INTELLECTUAL PROPERTY. 

 6.1. Inventions. 

6.1.1. Ownership. All determinations of inventorship under this Agreement shall be made in accordance with the laws of the United
States.  
 (a) Pfizer Improvements. Pfizer shall own all Pfizer Improvements. 

  
 45 

***Certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has
been requested with respect to the omitted portions. 

 (b) CytomX Improvements. CytomX shall own all CytomX Improvements.  

(c) Developed IP. Except as provided in Section 6.1.1(d), [***]. 

(d) Assignment of PDC Developed IP. On a Research Project Target-by-Research Project Target basis, contingent upon and effective
as of the Option Exercise Date for such Research Project Target, including payment of the applicable Option Exercise Fee, [***] all PDC Developed IP [***] thereafter any such PDC Developed IP [***]. 

(e) Implementation. Each Party shall assign, and does hereby assign, to the other Party such Patent Rights, Know-How or other
intellectual property rights as necessary to achieve ownership as provided in this Section 6.1.1. Each assigning Party shall execute and deliver all documents and instruments reasonably requested by the other Party to evidence or record such
assignment or to file for, perfect or enforce the assigned rights. Each assigning Party shall make its relevant employees, agents and independent contractors (and their assignments and signatures on such documents and instruments) reasonably
available to the other Party for assistance in accordance with this Section 6.1.1 at no charge. 
 6.1.2.
Disclosure. Each Party shall, no less than [***] before filing any initial Patent Right disclosing such intellectual property, disclose to the other Party any Developed IP, CytomX Improvement and Pfizer Improvement, or any other Patent Right
that contains the other Party’s Confidential Information, including all invention disclosures or other similar documents submitted to such Party by its, or its Affiliates’, employees, agents or independent contractors describing such
Developed IP, CytomX Improvement or Pfizer Improvement, and the proposed inventorship of any new Patent Rights intended to be filed. The other Party shall promptly raise any issue regarding inventorship of any such Patent Rights, and the Parties
agree to use their best efforts to determine in good faith the correct inventorship of any Patent Rights.  
 6.2. Patent
Rights. 
 6.2.1. Filing, Prosecution and Maintenance of Patent Rights.  

(a) Patent Filing Rights Prior to Option Exercise. [***]  

(b) Cooperation. Without limiting any other rights and obligations of the Parties under this Agreement, the Parties shall
cooperate with respect to the timing, scope and filing of patent applications and patent claims relating to any CytomX Improvements, Pfizer Improvements and Developed IP to preserve and enhance the patent protection for Agreement PDCs, including the
manufacture and use thereof. [***] 

  
 46 

***Certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has
been requested with respect to the omitted portions. 

 (c) Pfizer Patent Rights. Pfizer, at its own expense, shall have the sole right,
but not the obligation, to prepare, file, prosecute and maintain, throughout the world, any Patent Rights that it solely owns, including Pfizer Patent Rights and Patent Rights in the Pfizer Improvements and [***]. Pfizer shall keep CytomX informed
regarding any Patent Right comprised in any such [***] and shall consider in good faith any recommendations made by CytomX in regard to the filing, prosecution or maintenance of any such Patent Right. To the extent Pfizer decides not to file, and
except in a case in which the decision not to file, prosecute or maintain any such Patent Right is made by Pfizer in the ordinary course of filing continuation applications or as part of an overall strategy to optimize the scope or other aspects of
the intellectual property protecting the relevant Agreement PDCs, Pfizer shall provide CytomX with [***] prior written notice to such effect (i.e., at least [***] prior to the date on which any such filing or other action is due), in which event
CytomX may elect to file or continue prosecution or maintenance of such Patent Right, at CytomX’s expense, and Pfizer, upon CytomX’s written request received within such thirty (30) day period, shall execute such documents and perform
such acts, at CytomX’s expense, as may be reasonably necessary to permit CytomX to file, prosecute and maintain such Patent Right. Any such Patent Right that is prosecuted or maintained by CytomX pursuant to this Section 6.2.1(c)(i) will
continue to be owned by Pfizer, and (ii) subject to the Parties’ other rights and obligations under this Agreement, may be licensed by Pfizer to one or more Third Parties. [***]. 

(d) CytomX Patent Rights. CytomX, at its own expense, shall have the sole right, but not the obligation, to prepare, file, prosecute
and maintain, throughout the world, any Patent Rights included in Licensed Intellectual Property that it solely owns, including CytomX Patent Rights and Patent Rights comprised in the CytomX Improvements. CytomX shall not disclose any Pfizer
Confidential Information in any Patent Rights that it files, or in connection with the prosecution of any such Patent Rights, without Pfizer’s prior written consent. CytomX shall notify Pfizer promptly, and no later than [***] after request by
Pfizer of any Patent Right after the Effective Date that covers the Development, Manufacture, Commercialization or use of any Licensed Product. In the absence of such prompt notification, any such Patent Rights shall be excluded from the Valid Claim
definition. CytomX shall keep Pfizer informed regarding each Patent Right included in the Licensed Intellectual Property that CytomX or any Third Party licensor is prosecuting and shall consider in good faith any recommendations made by Pfizer in
regard to the filing, prosecution or maintenance of any such Patent Right. To the extent 

  
 47 

***Certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has
been requested with respect to the omitted portions. 

 
CytomX decides not to prosecute or maintain any Patent Right of CytomX that CytomX reasonably believes covers or may cover the Development, Manufacture, Commercialization or use of any Licensed
Product (other than any such Patent Right owned or co-owned by a Third Party licensor or the filing of any such new initial Patent Right) and except in the case in which the decision not to file, prosecute or maintain such Patent Right is made by
CytomX in the ordinary course of filing continuation applications or as part of an overall strategy to optimize the scope or other aspects of the Licensed Intellectual Property, CytomX shall provide Pfizer written notice to such effect at least
[***] prior to the date on which any filing or other action is due, in which event Pfizer may elect to continue prosecution or maintenance of such Patent Right, at Pfizer’s sole expense, and CytomX, upon Pfizer’s written request, shall
execute such documents and perform such acts, at Pfizer’s expense, as may be reasonably necessary to permit Pfizer to file, prosecute and maintain, at its own discretion, such Patent Right. Notwithstanding anything to the contrary, [***].
CytomX will continue to own any Patent Rights that are filed, prosecuted or maintained by Pfizer pursuant to this Section 6.2.1(d) provided that (x) such Patent Rights in such countries will be excluded from the Valid Claim
definition; and (y) in addition to the exclusive licenses granted to Pfizer under Section 4, CytomX will and does hereby grant to Pfizer (subject to any existing Third Party rights) a non-exclusive, sublicensable, perpetual,
irrevocable, royalty-free, fully paid-up, worldwide license to practice and exploit such Patent Rights in such countries for any and all purposes, provided that [***]. Except in the ordinary course of filing continuation applications or as part of
an overall strategy to optimize the scope or other aspects of the intellectual property protecting the relevant Agreement PDCs, CytomX shall not decline to pay for or participate in the filing, prosecution or maintenance of any Patent Right under
any CytomX Third Party Agreement, to the extent CytomX is obligated to pay for such or has the right to participate in such filing, prosecution or maintenance, that is included in the Licensed Intellectual Property and that, in Pfizer’s
reasonable discretion, covers a Licensed Product Developed or Commercialized by Pfizer or its Affiliates, and the loss of which would result in loss of right to or would materially diminish the overall protection of such Licensed Product, without
Pfizer’s prior written consent, not to be unreasonably withheld or delayed. 
 (e) Joint Patent Rights. In the event the
Parties conceive or generate any Joint Developed IP, other than [***], the Parties shall promptly meet to discuss and determine, based on mutual consent, whether to seek patent protection thereon. Neither Party will file any Patent Right covering or
claiming any such Joint Developed IP (a “Joint Patent Right”) without the consent of the other Party, provided that following the Option Exercise Date for a Research Project Target, including payment of the applicable 

  
 48 

***Certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has
been requested with respect to the omitted portions. 

 
Option Exercise Fee, Pfizer shall have the first right to file on and control prosecution of any Patent Right covering or claiming any Joint Developed IP used in the development, manufacture,
composition or use of any PDC Targeting such Research Project Target, that does not claim or cover any invention that is generally applicable to Probodies or PDCs other than a PDC Targeting such Research Project Target. If Pfizer controls
prosecution of any such Joint Developed IP, Pfizer shall keep CytomX informed regarding each Patent Right that Pfizer is prosecuting and shall consider in good faith any recommendations made by CytomX in regard to the filing, prosecution or
maintenance of any such Patent Right. For avoidance of doubt, “prosecution” as used in this Section 6.2.1 includes oppositions, nullity or revocation actions, post-grant reviews and other patent office proceedings involving the
referenced Patent Rights. 
 (f) Liability. To the extent that a Party is obtaining, prosecuting or maintaining a Patent Right
included in the Licensed Intellectual Property or Developed IP (including PDC Developed IP) or otherwise exercising its rights under this Section 6.2.1, such Party, and its Affiliates, employees, agents or representatives, shall not be
liable to the other Party in respect of any act, omission, default or neglect on the part of any such Party, or its Affiliates, employees, agents or representatives, in connection with such activities undertaken in good faith. 

(g) Extensions. The decision to file for a patent term extension and particulars thereof (including which patent(s) to extend)
will be made with the goal of obtaining the optimal patent term and scope of protection for Licensed Products. Pfizer shall have the right after it has submitted for Regulatory Approval of a Licensed Product, but not the obligation, to request
permission from CytomX to seek, in CytomX’s name if so required, patent term extensions, supplemental protection certificates and the like available under applicable law, including 35 U.S.C. § 156 and applicable foreign counterparts,
(each, an “extension”) for any patent included in the Licensed Intellectual Property (a “Licensed Patent”) that covers such Licensed Product. CytomX agrees to grant Pfizer such permission on request, unless at the time of
such request CytomX has determined to seek such extension under such Licensed Patent for a product for which CytomX has sole development and commercialization rights or for which CytomX is obligated to a Third Party to seek such extension for the
Third Party’s or a collaboration product (each an “Other Product”), in each case where the Other Product has advanced to at least Phase III clinical testing and the Other Product is covered by a Valid Claim of the Licensed
Patent. If Pfizer does not seek to extend any Licensed Patent in relation to a Licensed Product but CytomX is interested in doing so, then CytomX shall notify Pfizer of such interest and CytomX may only seek to do so if in Pfizer’s
reasonable legal determination such  

  
 49 

***Certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has
been requested with respect to the omitted portions. 

 
Licensed Patent may be extended under applicable law in relation to a Licensed Product without limiting Pfizer’s right to extend any other patent in relation to the Licensed Product or to
extend the same Licensed Patent with respect to another Licensed Product. 
 (h) Joint Research Agreement. This Agreement
shall be understood to be a joint research agreement under 35 U.S.C. § 103(c)(3) entered into for the purpose of researching, identifying and Developing Agreement PDCs and Licensed Products. 

(i) Recording. If Pfizer deems it necessary or desirable to register or record this Agreement or evidence of this Agreement with
any patent office or other appropriate government authorities in one or more jurisdictions in the Territory, then Pfizer shall submit to CytomX any proposed evidence of such recording and the Parties will comply with the terms of Section
7.2.3 in respect of such filing. CytomX shall execute and deliver to Pfizer any documents necessary or desirable, in Pfizer’s reasonable judgment, to complete such registration or recordation in accordance with the terms of Section
7.2.3. 
 6.2.2. Enforcement of Patent Rights.  

(a) Notice. If either Pfizer or CytomX becomes aware of any infringement anywhere in the world of any issued Patent Right within
the Licensed Intellectual Property or Developed IP by any Third Party PDC that Targets a Research Project Target (an “Infringement”) or by any Third Party Probody that Targets a Research Project Target, such Party shall promptly
notify the other Party in writing to that effect.  
 (b) Infringement of Certain Patent Rights. 

(i) Subject to Pfizer exercising the Option with respect to the applicable Research Project Target pursuant to Section 4.1.2, and
subject to the terms and conditions of any applicable CytomX Third Party Agreements, in the event of any Infringement of a Patent Right included in the Licensed Intellectual Property or Developed IP, Pfizer shall have the first right, and in the
case of [***], but not the obligation, to take action to obtain a discontinuance of Infringement or bring suit against a Third Party infringer of such Patent Right within [***] from the date of notice and to join CytomX as a party plaintiff. 

(ii) Pfizer shall bear all the expenses of any suit brought by it claiming infringement of any such Patent Right. CytomX shall cooperate with
Pfizer in any such suit and shall have the right to 

  
 50 

***Certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has
been requested with respect to the omitted portions. 

 
consult with Pfizer and to participate in and be represented by independent counsel in such litigation at its own expense. Pfizer shall incur no liability to CytomX as a consequence of such
litigation or any unfavorable decision resulting therefrom, including any decision holding any such Patent Right invalid or unenforceable, and Pfizer shall not, without CytomX’s prior written consent, enter into any settlement or consent decree
that requires any payment by or admits or imparts any other liability to CytomX or admits the invalidity or unenforceability or limits the scope of any such Patent Right. 

(iii) If Pfizer has not obtained a discontinuance of such Infringement by, or filed suit against, any such Third Party infringer within the
[***] period set forth in subsection (i) above, then CytomX shall have the right, but not the obligation, to bring suit against such Third Party infringer, at CytomX’s sole expense, under any Licensed Intellectual Property or under any
Developed IP owned by CytomX. Pfizer shall reasonably cooperate with CytomX in any such litigation, at CytomX’s expense, provided that Pfizer shall not be required to join such litigation as a party and Pfizer may, at its sole discretion, elect
to be represented by independent counsel in such litigation at its own expense. CytomX shall incur no liability to Pfizer as a consequence of such litigation or any unfavorable decision resulting therefrom, including any decision holding any such
CytomX Patent Right or Joint Patent Right invalid or unenforceable; and CytomX shall not, without Pfizer’s prior written consent, enter into any settlement or consent decree that requires any payment by or admits or imparts any other liability
to Pfizer or admits the invalidity or unenforceability or limits the scope of any such Patent Right. 
 (iv) The enforcing Party shall keep
the other Party reasonably informed of all material developments in connection with any such suit. Subject to the terms and conditions of any applicable CytomX Third Party Agreements, any recoveries obtained by either Party as a result of any
proceeding against such a Third Party infringer shall be allocated as follows: 
 (A) Such recovery shall first be used to reimburse each
Party for all out-of-pocket litigation costs in connection with such litigation paid by that Party; and 
 (B) [***]; or 

(C) [***]. 

  
 51 

***Certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has
been requested with respect to the omitted portions. 

 (c) Other Infringement. For any infringement of any Licensed Intellectual Property other
than an Infringement, CytomX retains the sole right (as between the Parties), but not the obligation, to enforce the Licensed Intellectual Property. 

(d) Other Infringement of Joint Patent Rights. With respect to any notice of a Third Party infringer of any Joint Patent Right other
than in the case of a Joint Patent Right subject to Section 6.2.2(b), the Parties shall meet as soon as reasonably practicable to discuss such infringement and determine an appropriate course of action and the Parties’ respective rights
and responsibilities with respect to any enforcement thereof. 
 6.2.3. Biosimilar Notices. 

(a) Upon Pfizer’s request any time after completion of the first Phase II Clinical Study for any Licensed Product, CytomX shall use
reasonable efforts to assist and cooperate with Pfizer in establishing a strategy for responding to requests for information from Regulatory Authorities and Third Party requestors and preparing submissions responsive to any Biosimilar Notices
received by Pfizer; provided that Pfizer shall make the final decisions with respect to such strategy and any such responses. 
 (b)
Biosimilar Notices. Pfizer shall comply with the applicable provisions of 42 U.S.C. § 262(l) (or any amendment or successor statute thereto), any similar statutory or regulatory requirement enacted in the future regarding biologic
products in the United States, or any similar statutory or regulatory requirement in any non-U.S. country or other regulatory jurisdiction, in each case, with respect to any Biosimilar Notice received by Pfizer from any Third Party regarding any
Licensed Product that is being Commercialized in the applicable jurisdiction, and the exchange of information between any Third Party and Pfizer pursuant to such requirements; provided that, prior to any submission of information by Pfizer to a
Third Party, CytomX shall have the right to review the patent information included in such proposed submission, solely with respect to Patent Rights Controlled by CytomX, and to make suggestions as to any changes to such patent information that
CytomX reasonably believes to be necessary; provided further that Pfizer shall determine the final content of any such submission. In the case of a Licensed Product approved in the United States under the PHS Act (or, in the case of a country in the
Territory other than the United States, any similar law), to the extent permitted by Applicable Law, Pfizer, as the sponsor of the application for the Licensed Product, will be the “reference product sponsor” under the PHS Act. Pfizer
shall give written notice to CytomX of receipt of a Biosimilar Notice received by Pfizer with respect to a Licensed Product, and Pfizer shall consult with CytomX with respect to 

  
 52 

***Certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has
been requested with respect to the omitted portions. 

 
the selection of the Patent Rights to be submitted pursuant to 42 U.S.C. § 262(l) (or any similar law in any country of the Territory outside the United States); provided that Pfizer
shall have final say on such selection of Patent Rights. CytomX agrees to be bound by the confidentiality provisions of 42 U.S.C. § 262(l)(1)(B)(iii). In order to establish standing in connection with any action brought by Pfizer under this
Section 6.2.3, CytomX, upon Pfizer’s request, shall reasonably cooperate with Pfizer in any such action, including timely commencing or joining in any action brought by Pfizer under this Section 6.2.3 solely to the
extent any Patent Rights Controlled by CytomX are involved in any such action, and the Parties rights and responsibilities regarding any action shall be determined in accordance with Section 6.2.2(b). 

6.3. Interference, Opposition, Revocation and Declaratory Judgment Actions. If the Parties mutually determine that, based upon the
review of a Third Party’s patent or patent application or other intellectual property rights, it may be desirable in connection with any Agreement PDC or Licensed Product to provoke or institute an interference, opposition, revocation,
post-grant review or other patent office proceedings or declaratory judgment action with respect thereto, then the Parties shall consult with one another and shall reasonably cooperate in connection with such an action. Unless otherwise mutually
determined by the Parties and except for any interferences involving any Licensed Intellectual Property or other Patent Rights Controlled by CytomX which shall be governed by Section 6.2, Pfizer shall control such action and shall select
counsel for such action. The rights and obligations of the Parties under Section 6.4 are expressly subject to this Section 6.3. Notwithstanding anything to the contrary, CytomX shall retain all rights to control any actions
initiated by CytomX prior to the Effective Date, provided that CytomX shall keep Pfizer reasonably informed of, and shall consider in good faith, any recommendations made by Pfizer in connection with such actions. 

6.4. Infringement of Third Party Patent Rights. If the Development, Manufacture or Commercialization of any Licensed Product is alleged
by a Third Party to infringe a Third Party’s patent or other intellectual property rights, the Party becoming aware of such allegation shall promptly notify the other Party. The Party that is alleged to infringe the Third Party’s patent or
intellectual property rights shall have the right to take such action as it deems appropriate in response to such allegation, and shall be solely responsible for all damages, costs and expenses in connection therewith, subject to Article 10. 

 

	7.	CONFIDENTIALITY 

 7.1. Confidentiality. Except to the extent expressly authorized
by this Agreement, the Parties agree that, during the Term and for [***] thereafter, each Party (the “Receiving Party”) receiving any Confidential Information of the other Party (the “Disclosing Party”) hereunder
shall: (a) keep the Disclosing Party’s Confidential Information 

  
 53 

***Certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has
been requested with respect to the omitted portions. 

 
confidential; (b) not disclose, or permit the disclosure of, the Disclosing Party’s Confidential Information; and (c) not use, or permit to be used, the Disclosing Party’s
Confidential Information for any purpose, in each case, except for the performance of its obligations or exercise of its rights under this Agreement, provided, however, that a Receiving Party may use or disclose Confidential Information of the
Disclosing Party to the extent that such Confidential Information (i) was already known by the Receiving Party (other than under an obligation of confidentiality to the Disclosing Party) at the time of disclosure by the Disclosing Party;
(ii) was generally available to the public or otherwise part of the public domain at the time of its disclosure to the Receiving Party; (iii) became generally available to the public or otherwise part of the public domain after its
disclosure to the Receiving Party, other than through any act or omission of the Receiving Party in breach of its obligations under this Agreement; (iv) was disclosed to the Receiving Party, other than under an obligation of confidentiality, by
a Third Party who had no obligation to the Disclosing Party not to disclose such information to the Receiving Party; or (v) was independently discovered or developed by or on behalf of the Receiving Party without the use of any Confidential
Information of the Disclosing Party. 
 7.2. Authorized Disclosure. 

7.2.1. Disclosure to Party Representatives. Notwithstanding the foregoing provisions of Section 7.1, the Receiving Party may
disclose Confidential Information belonging to the Disclosing Party to the Receiving Party’s, its Affiliates’ and its Sublicensees’ officers, directors, employees, consultants, contractors, or agents (collectively,
“Representatives”) who (a) have a need to know such Confidential Information in connection with the performance of the Receiving Party’s obligations or the exercise of the Receiving Party’s rights under this Agreement
and (b) have agreed in writing to non-disclosure and non-use provisions with respect to such Confidential Information that are at least as restrictive as those set forth in this Article 7. For clarity, notwithstanding the foregoing,
CytomX may use and disclose Confidential Information within the Developed IP that is (i) owned by CytomX, or (ii) licensed to CytomX pursuant to Section 4.2.2 within the scope of such license (the “CytomX Usable
Developed IP”), to any entities that have a need to know such Confidential Information in connection with the Development, Manufacture or Commercialization of Probodies and PDCs that do not otherwise incorporate Pfizer Technology or Pfizer
Improvements, or with respect to information licensed under Section 4.2.2, within the scope of such license (the “Permitted Uses”), and have entered into an agreement as described in (b) above, subject in each case
to the exclusive rights expressly granted to Pfizer under Sections 2.1.6 and 4.5 above and, with respect to Developed IP disclosed as provided in (ii) above, the restrictions in Section 4.2.2. 

  
 54 

***Certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has
been requested with respect to the omitted portions. 

 7.2.2. Disclosure to Third Parties. 

(a) Notwithstanding the foregoing provisions of Section 7.1, the Parties may disclose Confidential Information belonging to the other
Party: 
 (i) to Governmental Authorities (A) in the case of Pfizer, subject to Pfizer exercising the Option with respect to the
applicable Research Project Target pursuant to Section 4.1.2, to the extent reasonably necessary to obtain or maintain INDs or Regulatory Approvals for any Licensed Product Targeting such Research Project Target within the Territory,
(B) in the case of CytomX, with respect to CytomX Usable Developed IP, to the extent reasonably necessary to obtain or maintain INDs or Regulatory Approvals for any Probodies and PDCs within the Permitted Uses, and (C) in the case of
either Party, in order to respond to inquiries, requests, investigations, orders or subpoenas of Governmental Authorities relating to this Agreement; 

(ii) (A) in the case of Pfizer, subject to Pfizer exercising the Option with respect to the applicable Research Project Target pursuant to
Section 4.1.2, to outside consultants, contractors, advisory boards, managed care organizations, and non-clinical and clinical investigators, in each case to the extent reasonably necessary to Develop, Manufacture or Commercialize any
Licensed Product Targeting such Research Project Target and under reasonable obligations of confidentiality, and (B) in the case of CytomX, with respect to CytomX Usable Developed IP, to outside consultants, contractors, advisory boards,
managed care organizations, and non-clinical and clinical investigators, in each case to the extent reasonably necessary to Develop, Manufacture or Commercialize any Probodies and PDCs within the Permitted Uses and under reasonable obligations of
confidentiality; 
 (iii) subject to Section 6.2.1(c), to the extent reasonably necessary, in connection with filing or
prosecuting Patent Rights or Trademark rights as permitted by this Agreement; 
 (iv) to the extent reasonably necessary, in connection with
prosecuting or defending litigation as permitted by this Agreement; 
 (v) (A) regarding the existence of this Agreement, this Agreement
itself or the material and financial terms of this Agreement, to its accountants, lawyers, and other advisers, and to actual or potential investors, lenders, acquirers, investment bankers, or agents of the foregoing in connection with a financing,
merger, or acquisition, and (B) to any other third parties in connection with the events in (A) with the consent of the disclosing Party, such 

  
 55 

***Certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has
been requested with respect to the omitted portions. 

 
consent not to be unreasonably withheld, in each case (A)-(B) under confidentiality obligations no less restrictive than those set forth in this Agreement; 

(vi) subject to Section 7.3.2, in connection with or included in scientific presentations and publications relating to Licensed
Products, including abstracts, posters, journal articles and the like, and posting results of and other information about clinical trials to clinicaltrials.gov or PhRMA websites; and 

(vii) to the extent necessary in order to enforce its rights under this Agreement. 

All disclosures by CytomX under this Section 7.2.2(a) are subject in each case: to the exclusive rights expressly granted to
Pfizer under Sections 2.1.6 and 4.5 above and, with respect to Developed IP licensed to CytomX under Section 4.2.2, to the restrictions in Section 4.2.2. 

(b) In the event a Party deems it reasonably necessary to disclose Confidential Information belonging to the other Party pursuant to
Section 7.2.2(a)(i)(C), the Disclosing Party shall to the extent possible give reasonable advance written notice of such disclosure to the other Party and take all reasonable measures to ensure confidential treatment of such information. 

7.2.3. SEC Filings and Other Disclosures. Notwithstanding any provision of this Agreement to the contrary, either Party may disclose the
terms of this Agreement to the extent required, in the reasonable opinion of such Party’s legal counsel, to comply with applicable Law, including the rules and regulations promulgated by the United States Securities and Exchange Commission or
any equivalent governmental agency in any country in the Territory. Notwithstanding the foregoing, before disclosing this Agreement or any of the terms hereof pursuant to this Section 7.2.3, the Parties will consult with one another on the
terms of this Agreement to be redacted in making any such disclosure. Further, if a Party discloses this Agreement or any of the terms hereof in accordance with this Section 7.2.3, such Party shall, at its own expense, use Commercially
Reasonable Efforts to seek such confidential treatment of confidential portions of this Agreement and such other terms, as may be reasonably requested by the other Party. 

7.3. Public Announcements; Publications. 

7.3.1. Announcements. Except as may be expressly permitted under Section 7.2.3, neither Party will make any public
announcement regarding this 

  
 56 

***Certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has
been requested with respect to the omitted portions. 

 
Agreement without the prior written approval of the other Party. For the sake of clarity, nothing in this Agreement shall prevent (a) either Party from making any public disclosure relating
to this Agreement if the contents of such public disclosure have previously been made public other than through a breach of this Agreement by the issuing Party or its Affiliates; or (b) Pfizer, subject to its exercising the Option with respect
to the applicable Research Project Target pursuant to Section 4.1.2, from making any scientific publication or public announcement with respect to any Licensed Product Targeting such Research Project Target under this Agreement; provided,
however, that, except as permitted under Section 7.2, Pfizer shall not disclose any of CytomX’s Confidential Information in any such publication or announcement without obtaining CytomX’s prior written consent to do so. The Parties
agree that CytomX may release the announcement attached hereto as Schedule 7.3.1 regarding the signing of this Agreement following the Effective Date. The Parties agree that CytomX may issue future announcements concerning Pfizer’s
achievement of any significant milestones, including the selection of a clinical candidate, under this Agreement, provided that the content of any such announcement has been mutually agreed upon by the Parties.

7.3.2. Publications. During the Term, each Party shall submit to the other Party (the “Non-Disclosing Party”) for
review and approval any proposed academic, scientific and medical publication or public presentation which contains the Non-Disclosing Party’s Confidential Information. In addition, each Party shall submit to the other Party for review and
approval any proposed publication or public presentation relating to data generated under the Research Program, provided that Pfizer shall not be required to submit any proposed publication or public presentation to CytomX for review and approval
pursuant to this sentence to the extent such publication or presentation relates to any Research Project Target for which Pfizer has exercised its Option pursuant to this Agreement and to the extent consistent with Pfizer’s normal and customary
publication practices. In both instances, such review and approval will be conducted for the purposes of preserving the value of the Licensed Intellectual Property and [***] and determining whether any portion of the proposed publication or
presentation containing the Non-Disclosing Party’s Confidential Information should be modified or deleted. Written copies of such proposed publication or presentation required to be submitted hereunder shall be submitted to the Non-Disclosing
Party no later than thirty (30) days before submission for publication or presentation (the “Review Period”). The Non-Disclosing Party shall provide its comments with respect to such publications and presentations within twenty
(20) days after its receipt of such written copy, and the other Party shall delete any Confidential Information of the Non-Disclosing Party upon request. The Review Period may be extended for an additional sixty (60) days in the event the
Non-Disclosing Party can, within fifteen (15) days of receipt of the written copy, demonstrate reasonable need for such extension, including for the preparation and filing of patent applications. CytomX and Pfizer will each comply with standard
academic practice regarding authorship of scientific publications and recognition of contribution of other parties in any publication governed by this Section 7.3.2. 

  
 57 

***Certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has
been requested with respect to the omitted portions. 

 7.4. Obligations in Connection with Change of Control. If CytomX is subject to a Change of
Control, CytomX will, and it will cause its Affiliates and Representatives to, ensure that no Confidential Information of Pfizer, other than with respect to the status of Development or Commercialization of a Licensed Product, is released to
(a) any Affiliate of CytomX that becomes an Affiliate as a result of the Change of Control or (b) any Representatives of CytomX (or of the relevant surviving entity of such Change of Control) who become Representatives as a result of the
Change of Control, unless such Representatives have signed individual confidentiality agreements which include equivalent obligations to those set out in this Article 7. If any Change of Control of CytomX occurs, CytomX shall promptly notify
Pfizer, share with Pfizer the policies and procedures it plans to implement in order to protect the confidentiality of Pfizer’s Confidential Information prior to such implementation and make any adjustments to such policies and procedures that
are reasonably requested by Pfizer. Notwithstanding the foregoing, this Section 7.4 shall not be deemed to limit CytomX’s right to disclose Developed IP that CytomX would otherwise have a right to use and disclose to a Third Party
(i.e., if such Third Party did not acquire CytomX). 
  

	8.	REPRESENTATIONS AND WARRANTIES. 

 8.1. Mutual Representations and Warranties. Each
of CytomX and Pfizer hereby represents and warrants to the other Party that: 
 8.1.1. it is duly organized, validly existing and in good
standing under the laws of the jurisdiction of its organization; 
 8.1.2. the execution, delivery and performance of this Agreement by such
Party has been duly authorized by all requisite action under the provisions of its charter, bylaws and other organizational documents, and does not require any action or approval by any of its shareholders or other holders of its voting securities
or voting interests; 
 8.1.3. it has the power and authority to execute and deliver this Agreement and to perform its obligations hereunder;

 8.1.4. this Agreement has been duly executed and is a legal, valid and Binding Obligation on each Party, enforceable against such Party in
accordance with its terms; and 
 8.1.5. the execution, delivery and performance by such Party of this Agreement and its compliance with the
terms and provisions hereof does not and will not conflict with or result in a breach of or default under any Binding Obligation existing as of the Effective Date. 

  
 58 

***Certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has
been requested with respect to the omitted portions. 

 8.2. Representations and Warranties of CytomX. CytomX hereby represents and warrants to
Pfizer that as of the Effective Date: 
 8.2.1. CytomX is the sole and exclusive owner of, or otherwise Controls pursuant to a CytomX Third
Party Agreement listed on Schedule 8.2.1, the CytomX Technology existing as of the Effective Date, all of which is free and clear of any claims, liens, charges or encumbrances; 

8.2.2. it has and will have the full right, power and authority to grant all of the right, title and interest in the licenses and other rights
granted or to be granted to Pfizer or Pfizer’s Affiliates under this Agreement; 
 8.2.3. as of the Effective Date (a) Schedule
8.2.3 sets forth a true and complete list of all CytomX Patent Rights, (b) to CytomX’s knowledge after reasonable inquiry, each such Patent Right outside of the United States owned by CytomX is in full force and effect and
(c) each such Patent Right in the United States owned by CytomX is in full force and effect and (d) to CytomX’s knowledge, each such Patent Right Controlled by CytomX pursuant to the UCSB Agreement is in full force and effect; 

8.2.4. to its knowledge: (i) the CytomX Patent Rights existing as of the Effective Date, are, or, upon issuance, will be, valid and
enforceable patents and (ii) as of the Effective Date, no Third Party (a) is infringing any CytomX Patent Right or (b) has challenged or threatened to challenge the extent, validity or enforceability of any CytomX Patent Right
(including, by way of example, through the institution or threat of institution of interference, nullity or similar invalidity proceedings before the United States Patent and Trademark Office or any analogous foreign Governmental Authority); 

8.2.5. to its knowledge, it and its counsel, and to its knowledge, UCSB and its counsel with respect to the Patent Rights subject to the UCSB
Agreement, have complied with all Applicable Laws, including any disclosure requirements, in connection with the filing, prosecution and maintenance of the CytomX Patent Rights existing as of the Effective Date; 

8.2.6. CytomX has independently developed all CytomX Know-How existing as of the Effective Date or otherwise has a valid right to use, and to
permit Pfizer, Pfizer’s Affiliates and Pfizer’s Sublicensees to use, such CytomX Know-How for all permitted purposes under this Agreement; 

8.2.7. it (or UCSB, with respect to the Patent Rights subject to the UCSB Agreement) has obtained from all inventors of CytomX Technology
existing as of the Effective Date, valid and enforceable agreements assigning to CytomX (or to UCSB, with respect to the Patent Rights subject to the UCSB Agreement) each such inventor’s entire right, title and interest in and to all such
CytomX Technology; 

  
 59 

***Certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has
been requested with respect to the omitted portions. 

 8.2.8. except as expressly disclosed in Schedule 8.2.8, no CytomX Technology existing as
of the Effective Date is subject to any funding agreement with any Governmental Authority; 
 8.2.9. except as expressly disclosed in
Schedule 8.2.9, neither CytomX nor any of its Affiliates are subject to any agreement or obligation that limits any ownership or license right granted to Pfizer or its Affiliates under this Agreement, including any right granted to Pfizer or
its Affiliates to access, practice, grant any licenses or sublicenses under, or provide Pfizer’s Sublicensees with access to any intellectual property right or material (including any Patent Right, Know-How or other data or information), in
each case, that would, but for such agreement or obligation, be included in the rights licensed or assigned to Pfizer or its Affiliates pursuant to this Agreement; 

8.2.10. (a) there are no agreements between CytomX and any Third Party existing as of the Effective Date under which CytomX obtains rights in
or to any Licensed Intellectual Property, other than the CytomX Third Party Agreements expressly disclosed in Schedule 8.2.10 (each, a “Disclosed Third Party Agreement”), true and complete copies of which have been provided
to Pfizer, (b) except as provided in the Disclosed Third Party Agreements, no Third Party has any right, title or interest in or to, or any license under, any CytomX Technology, (c) no rights granted by or to CytomX or its Affiliates under
any Disclosed Third Party Agreement conflict with any right or license granted to Pfizer or its Affiliates hereunder and (d) CytomX and its Affiliates are in compliance in all respects with all Disclosed Third Party Agreements, including all
due diligence obligations of CytomX under the Disclosed Third Party Agreements; 
 8.2.11. to its knowledge, the use, practice or application
by CytomX or Pfizer (or their respective Affiliates or Sublicensees) of any CytomX Technology does not and will not infringe any valid claim of an issued and unexpired patent of any Third Party (excluding, for clarity, any potential infringement
that might arise solely as a result of the combination of any CytomX Technology with any other technology or intellectual property); and 

8.2.12. there is no (a) claim, demand, suit, proceeding, arbitration, inquiry, investigation or other legal action of any nature, civil,
criminal, regulatory or otherwise, pending or, to the knowledge of CytomX, threatened against CytomX or any of its Affiliates or (b) judgment or settlement against or owed by CytomX or any of its Affiliates, in each case in connection with the
CytomX Technology or relating to the transactions contemplated by this Agreement. 

  
 60 

***Certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has
been requested with respect to the omitted portions. 

 8.2.13. The CytomX Letter and the Patent Rights licensed under the UCSB Agreement together set
forth all Third Party Patent Rights of which CytomX is aware that are or may be relevant to the Licensed Intellectual Property, including the composition of, or any method of using or method of making or any Tools for Developing, any Probody, Mask,
Substrate or PDC. 
 8.3. CytomX Covenants. In addition to the covenants made by CytomX elsewhere in this Agreement, CytomX
hereby covenants to Pfizer that, from the Effective Date until expiration or termination of this Agreement: 
 8.3.1. except in
CytomX’s ordinary course of prosecution or in the course of enforcement of Patent Rights in accordance with the provisions of Article 6, or with Pfizer’s prior written consent, it will not (a) take any action that conflicts
with the rights under the Licensed Intellectual Property or Developed IP granted or assigned to Pfizer or Pfizer’s Affiliates under this Agreement or (b) fail to take any action that is reasonably necessary to avoid a conflict with the
rights under the Licensed Intellectual Property or Developed IP granted or assigned to Pfizer or Pfizer’s Affiliates under this Agreement; 

8.3.2. it will (a) not enter into any CytomX Third Party Agreement that conflicts with or limits (i) the rights granted to Pfizer or
Pfizer’s Affiliates hereunder or (ii) CytomX’s ability to fully perform its obligations hereunder; (b) not amend, terminate or otherwise modify any CytomX Third Party Agreement (including any Disclosed Third Party Agreement) or
consent or waive rights with respect thereto in any manner that adversely affects (i) the rights granted to Pfizer or Pfizer’s Affiliates hereunder or (ii) CytomX’s ability to fully perform its obligations hereunder;
(c) promptly furnish Pfizer with copies of all (i) amendments to the Disclosed Third Party Agreements and (ii) CytomX Third Party Agreements and related amendments executed following the Effective Date; (d) fulfill, and cause its
Affiliates to fulfill, all of their respective obligations under all CytomX Third Party Agreements (including Disclosed Third Party Agreements) so as not to be in breach of such agreements; (e) furnish Pfizer with copies of all notices received
by CytomX or its Affiliates relating to any actual or alleged breach by CytomX or its Affiliates under any CytomX Third Party Agreement (including any Disclosed Third Party Agreement), and all other notices received by CytomX or its Affiliates in
connection with any CytomX Third Party Agreement (including any Disclosed CytomX Third Party Agreement) that pertain to the rights granted to Pfizer or Pfizer’s Affiliates hereunder, within five (5) Business Days after receipt thereof; and
(f) in the event that CytomX does not resolve any such actual or alleged breach, notify Pfizer within a sufficient period of time before the expiration of the cure period for such actual or alleged breach under such CytomX Third Party Agreement
such that Pfizer is able to cure or otherwise resolve such actual or alleged breach or default, and if Pfizer makes any payments to any Third Party in connection with the cure or other resolution of such breach or default, then Pfizer may credit the
amount of such payments against any royalties or other amounts payable to CytomX pursuant to this Agreement. 

  
 61 

***Certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has
been requested with respect to the omitted portions. 

 8.3.3. it will not enter into any agreement or arrangement which limits the ownership rights of
Pfizer or its Affiliates with respect to any Developed IP, or limits the ability of Pfizer or its Affiliates to grant a license, sublicense or access, or provide or provide access or other rights in, to or under, any intellectual property right or
material (including any Patent Right, Know-How or other data or information), in each case, that is within the Licensed Intellectual Property, subject to the terms of CytomX Third Party Agreements accepted by Pfizer in accordance with
Section 5.5.2(c) above; and 
 8.3.4. it will maintain agreements with all Persons acting by or on behalf of CytomX or its
Affiliates under this Agreement which require such Persons to assign to CytomX their entire right, title and interest in and to all Patent Rights, Know-How or other intellectual property rights that are conceived or generated in the course of
performing Research Plan Activities. 
 8.4. Representation by Legal Counsel. Each Party hereto represents that it has been
represented by legal counsel in connection with this Agreement and acknowledges that it has participated in the drafting hereof. In interpreting and applying the terms and provisions of this Agreement, the Parties agree that no presumption shall
exist or be implied against the Party which drafted such terms and provisions. 
 8.5. Disclaimer. THE FOREGOING
REPRESENTATIONS AND WARRANTIES OF EACH PARTY ARE IN LIEU OF ANY OTHER REPRESENTATIONS AND WARRANTIES, EXPRESS OR IMPLIED, INCLUDING ANY IMPLIED WARRANTIES OF MERCHANTABILITY OR ANY IMPLIED WARRANTIES OF FITNESS FOR A PARTICULAR PURPOSE, ALL OF WHICH
ARE HEREBY SPECIFICALLY EXCLUDED AND DISCLAIMED. 
  

	9.	GOVERNMENT APPROVALS; TERM AND TERMINATION. 

 9.1. Government Approvals.
Each of CytomX and Pfizer shall cooperate with the other Party and use Commercially Reasonable Efforts to make all registrations, filings and applications, to give all notices and to obtain as soon as practicable all governmental or other consents,
transfers, approvals, orders, qualifications authorizations, permits and waivers, if any, and to do all other things necessary or desirable for the consummation of the transactions as contemplated hereby.  

9.2. Term. The term of this Agreement (the “Term”) shall commence on the Effective Date and shall extend, unless this
Agreement is terminated earlier in accordance with this Article 9, on a Licensed Product-by-Licensed Product and country-by-country basis, until such time as the Royalty Term with respect to the sale of such Licensed Product in such country
expires. Notwithstanding the foregoing, this Agreement shall terminate upon the expiration of the last-to-expire Option Exercise Period if Pfizer has not elected to exercise any Option under Section 4.1.2 prior to such time. 

  
 62 

***Certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has
been requested with respect to the omitted portions. 

 9.3. Termination by Either Party for Cause. Except as otherwise provided in
Section 3.2.5, either Party may terminate this Agreement, in its entirety or, at the terminating Party’s option, on a Research Project Target-by-Research Project Target basis, at any time during the Term of this Agreement by giving
written notice to the other Party if the other Party commits a material breach of its obligations under this Agreement and such breach remains uncured for ninety (90) days, measured from the date written notice of such breach is given to the
breaching Party. Notwithstanding the foregoing, a Party shall have the right to terminate this Agreement pursuant to this Section 9.3 (a) in part with respect to an individual Research Project Target only if the other Party’s
material breach giving rise to such termination right relates to such Research Project Target or (b) in its entirety only if such material breach fundamentally frustrates the objectives of or transactions contemplated by this Agreement taken as
a whole or affects substantially all of the Research Program. 
 9.4. Termination by Pfizer for Convenience. At any time
after the one (1) year anniversary of the Effective Date, Pfizer shall have the right to terminate this Agreement for any or no reason, either in its entirety or on a Research Project Target-by-Research Project Target basis, by providing sixty
(60) days advance written notice of such termination to CytomX. 
 9.5. Termination on Insolvency of CytomX. This
Agreement may be terminated upon written notice by Pfizer at any time in the event of a CytomX Insolvency Event. 
 9.6.
Effects of Termination.  
 9.6.1. Effect of Termination by Pfizer for Cause. If Pfizer terminates this Agreement
with respect to any or all Research Project Targets pursuant to Section 9.3 (each, a “Terminated Target”): 

(a) all work under the applicable Research Plan with respect to each Terminated Target shall cease, and CytomX shall have no further
obligation to: (i) perform any of its obligations under the applicable Research Plan with respect to such Terminated Target, (ii) to provide any additional assistance under Section 4.1.9 related to such Terminated Target, or
(iii) to disclose or provide any rights with respect to the Terminated Target under any Third Party agreements entered into after the date of termination pursuant to Section 5.5.2(c)(iii); 

(b) if the Terminated Target is the Second Target, then Pfizer’s Target replacement right under Section 2.1.4 shall terminate
as of the date of such termination notice; 

  
 63 

***Certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has
been requested with respect to the omitted portions. 

 (c) all options and licenses granted to Pfizer with respect to such Terminated Target and
any Licensed Product Targeting such Terminated Target (each, a “Terminated Licensed Product”), including under Section 4.1, shall continue and become irrevocable and perpetual and the Parties rights and obligations under
Section 8.3 shall continue;  
 (d) Pfizer shall have no further obligations to CytomX under this Agreement with respect
to any such Terminated Target or Terminated Licensed Product, other than (i) those obligations that expressly survive termination in accordance with Section 9.8, or (ii) as provided in this Section 9.6.1; 

(e) Pfizer shall have an obligation to pay (i) except if such termination arises as a result of CytomX’s breach of Sections
2.1.6, 4.5, 7 and 8.2.3 through 8.2.13, [***] of any Option Fee that becomes due with respect to such Terminated Target pursuant to Section 5.2; (ii) except if such termination arises as a result of
CytomX’s breach of Sections 2.1.6, 4.5, 7 and 8.2.3 through 8.2.13, [***] of Milestone Payments with respect to Terminated Licensed Products and (iii) royalties with respect to Net Sales of Terminated
Licensed Products in accordance with the terms and conditions of this Agreement, in an amount equal to [***] of the amount that would otherwise have been payable under this Agreement, [***]. 

(f) Pfizer shall have the right to offset, against any payment owing to CytomX under subparagraph (b) above, any damages found or agreed by
the Parties to be owed by CytomX to Pfizer; 
 (g) CytomX shall remain entitled to receive payments that accrued before the effective date
of such termination; 
 (h) nothing in this Section 9.6.1 shall limit any other remedy Pfizer may have for CytomX’s breach of
this Agreement; 
 (i) the rights and obligations of the Parties with respect to all Research Project Targets other than any such Terminated
Target shall remain in full force and effect; and 
 (j) for the avoidance of doubt, all licenses granted by Pfizer to CytomX under
Section 4.2.1 shall terminate as of the effective date of such termination with respect to any such Terminated Target, and, if this Agreement is terminated in its entirety, all rights granted by Pfizer under Section 4.2.1
shall terminate as of the effective date of such termination. For clarity, the licenses granted by Pfizer to CytomX under Sections 4.2.2 and 4.3.2 shall survive any such termination. 

  
 64 

***Certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has
been requested with respect to the omitted portions. 

 9.6.2. Effect of Termination by Pfizer on Insolvency of CytomX. If Pfizer
terminates this Agreement pursuant to Section 9.5: 
 (a) CytomX shall have no further obligation to perform any of its
obligations under this Agreement (including CytomX’s obligations under the Research Program and CytomX’s obligations related to CytomX Third Party Agreements) other than those obligations that expressly survive termination of this
Agreement in accordance with Sections 9.6.2(b) and 9.8 and without limiting Pfizer’s right to cure or otherwise resolve any breach or alleged breach under any CytomX Third Party Agreement pursuant to Section 8.3.2;

 (b) All options and licenses granted to Pfizer, including under Section 4.1.3 (but only with respect to a particular Research
Project Target if Pfizer exercised its Option and paid the applicable Option Fee), shall continue and become, subject only to the royalty obligation set forth below in this Section 9.6.2(b), irrevocable and perpetual, the Parties’ rights
and obligations under Section 8.3 shall continue, and Pfizer shall have no further obligations to CytomX under this Agreement other than (i) those obligations that expressly survive termination in accordance with Section 9.8
and (ii) an obligation to pay royalties with respect to Net Sales of Licensed Products under Section 5.5 in accordance with the terms and conditions of this Agreement; 

(c) CytomX shall remain entitled to receive payments that accrued before the effective date of such termination; 

(d) Pfizer shall have the right to offset, against any payment owing to CytomX under subparagraph (b) above, any damages found or agreed by
the Parties to be owed by CytomX to Pfizer; and 
 (e) nothing in this Section 9.6.2 shall limit any other remedy Pfizer may have for
CytomX’s breach of this Agreement. 
 9.6.3. Effect of Termination by CytomX for Cause or by Pfizer for Convenience.

 (a) If CytomX terminates this Agreement with respect to any Research Project Target pursuant to Section 9.3, or if Pfizer
terminates this Agreement with respect to any Research Project Target pursuant to Section 9.4, then all licenses and options granted by CytomX to Pfizer under Sections 4.1.1 and 4.1.3 with

  
 65 

***Certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has
been requested with respect to the omitted portions. 

 
respect to any such Research Project Target and any Licensed Product Targeting such Research Project Target shall terminate. Upon any such termination, the following provisions shall apply: 

(i) CytomX shall have no further obligation to perform any of its obligations under the Research Program, or provide any additional assistance
under Section 4.1.9, with respect to such Research Project Target; 
 (ii) any Research Project Target with respect to which
this Agreement has been terminated shall no longer be considered a Research Project Target for all purposes of this Agreement, including Sections 2.1.6, 3.5, 4.5.1, and 6.2.2, without limiting any obligations under
Section 7; 
 (iii) CytomX shall remain entitled to receive payments that accrued before the effective date of such
termination; and 
 (iv) If the termination is with respect to the Second Target and Pfizer has not exercised its Target replacement right
under Section 2.1.4 prior to the date of the termination notice, then such Target replacement right shall terminate as of the date of such termination notice. 

(b) If CytomX terminates this Agreement in its entirety pursuant to Section 9.3, or if Pfizer terminates this Agreement in its
entirety pursuant to Section 9.4: (i) all licenses and options granted by CytomX to Pfizer under this Agreement, excluding those granted under Sections 4.1.4, 4.1.5 and 4.3.1, shall terminate, (ii) the licenses
granted by Pfizer to CytomX under Sections 4.2.2 and 4.3.2 shall survive such termination, and (iii) CytomX shall have no further obligations to Pfizer, and Pfizer no further rights, under this Agreement other than those rights
and obligations that expressly survive termination in accordance with Section 9.8.  
 (c) If Pfizer, pursuant to Section
9.4, terminates this Agreement in its entirety or solely with respect to EGFR after the initiation of dosing of the first subject in a Phase I Clinical Study with respect to a Licensed Product Targeting EGFR, then the Parties, upon CytomX’s
written request made within [***] after the effective date of termination, shall for a period of [***] negotiate in good faith the terms and conditions of a license to CytomX, under relevant Pfizer Technology and Developed IP Controlled by Pfizer
(including any PDC Developed IP), to Develop and Commercialize the EGFR Continuation Product, such terms and conditions to be mutually agreeable, reasonable and customary. 

  
 66 

***Certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has
been requested with respect to the omitted portions. 

 (d) If Pfizer, pursuant to Section 9.4, terminates this Agreement with respect to any
Research Project Target (either by terminating this Agreement in its entirety or solely with respect to such Research Project Target) after Pfizer exercises its Option with respect to such Research Project Target and prior to initiation of dosing of
the first subject in a Phase I Clinical Study of a Licensed Product Targeting such Research Project Target, then the Parties, upon CytomX’s written request made within [***] after the effective date of termination, shall for a period of [***]
negotiate in good faith the terms and conditions of a license to CytomX, under relevant Developed IP Controlled by Pfizer, to Develop and Commercialize PDCs Targeting such Research Project Target; provided that, for clarity, such license shall not
include any rights under any Pfizer Technology or Pfizer Improvement. 
 (e) For the avoidance of doubt, if CytomX terminates this Agreement
with respect to any Research Project Target pursuant to Section 9.3, or if Pfizer terminates this Agreement with respect to any Research Project Target pursuant to Section 9.4, in each case including all Research Project Targets
in the event that this Agreement is terminated in its entirety, any such Research Project Target will no longer be considered to be a Research Project Target for the purpose of this Agreement. 

9.6.4. Satisfaction of Obligations During Notice Period. During the period from providing a notice of termination through the
termination of the Agreement, the Parties shall continue to perform their obligations under this Agreement.  
 9.6.5.
Pending Dispute Resolution. If a Party gives notice of termination under Section 9.3 and the other Party disputes whether such notice was proper, then the issue of whether this Agreement has been terminated shall be resolved in
accordance with Section 11.9 and this Agreement shall remain in effect pending the resolution of such dispute. If as a result of such dispute resolution process it is determined that the notice of termination was proper, then such termination
shall be effective immediately. If as a result of such dispute resolution process it is determined that the notice of termination was improper, then no termination shall have occurred and this Agreement shall remain in effect. 

9.7. Disposition of Inventories of Products. Following termination of this Agreement with respect to one or more Research Project
Targets, Pfizer, its Affiliates and its Sublicensees shall have the right to continue to sell their existing inventories of Licensed Product(s) Targeting such Research Project Targets that have received Regulatory Marketing Approval prior to such
termination for a period not to exceed [***] after the effective date of such termination or expiration and Pfizer shall pay any royalties payable in connection with such sales in accordance with Section 5.5.  

  
 67 

***Certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has
been requested with respect to the omitted portions. 

 9.8. Survival of Certain Obligations. Expiration or termination of this Agreement
shall not relieve the Parties of any obligation that accrued before such expiration or termination. The following provisions shall survive expiration or termination of this Agreement: Sections 2.11, 2.12.3, 2.12.4,
2.12.5, 4.1.4, 4.1.5, 4.1.7 (solely with respect to any licenses that survive such expiration or termination), 4.2.2, 4.3, 4.4, 4.6, 5.3.4 (for the period set forth therein), 5.6
(for any payment obligations accrued prior to such termination or expiration), 5.7.1 (for the period set forth therein), 5.7.2 (for the period set forth therein), 5.7.3, 5.7.4, 6.1, 6.2.1(a),
6.2.1(e), and Articles 1, 7, 10 (provided that obligations under Section 10.5 shall only survive for [***] after termination or expiration), and 11. For avoidance of doubt, any other Section that
explicitly states it survives expiration or termination of this Agreement shall so survive. 
 9.9. Right to Termination of
Research Project(s) or Research Program by Pfizer upon Change of Control of CytomX. If a Change of Control of CytomX is consummated during any Research Term, Pfizer shall have the right to terminate any Research Project or the Research Program
in its entirety (in each case, without terminating the associated Option(s)), upon written notice to CytomX within [***] after consummation of such Change of Control of CytomX, such termination effective [***] after Pfizer’s notice. Such
termination of any Research Project or the Research Program (a) shall not constitute termination of this Agreement, (b) shall not affect the Parties’ rights and obligations under this Agreement other than those relating to such
Research Project or the Research Program and (c) shall not relieve either Party of any obligation that arose prior to such termination. Following any such termination of any Research Project or the Research Program, as applicable, Pfizer shall
have no further funding obligation under Article 2 or Section 5.3 with respect to such Research Project or the Research Program, as applicable, other than that which may have accrued prior to such termination. In addition, if, at any
time following a Change of Control of CytomX consummated during any Research Term, CytomX or its successor fails to perform its obligations under the Research Program in any material respect, then, effective upon written notice to CytomX or its
successor, Pfizer shall have the right to terminate any Research Project or the Research Program in its entirety pursuant to this Section 9.9, and CytomX, upon Pfizer’s request, shall promptly transfer to a Third Party designated by
Pfizer, at no additional cost to Pfizer, such CytomX Know-How and CytomX Improvements, including related materials, as is necessary for such Third Party to complete all activities allocated to CytomX under such Research Project or the Research
Program, as applicable (which Third Party shall agree in writing to be bound by terms providing for Pfizer rights no less favorable to Pfizer than the rights granted to Pfizer in this Agreement). For the avoidance of doubt, in the event that Pfizer
terminates a Research Project or the Research Program in accordance with this Section 9.9, such termination will not be deemed to be a termination for cause under Section 9.3 or a termination for convenience under Section 9.4,
and the only effects of such termination are as set forth in this Section 9.9. Notwithstanding any provision of this Agreement to the contrary, nothing in this Section 9.9 shall limit, or preclude Pfizer from seeking, any other remedy
Pfizer may have for CytomX’s breach of this Agreement; provided that Pfizer may not seek remedy under both this Section 9.9 and Section 9.3 with respect to the same performance failure by CytomX or its successor.

  
 68 

***Certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has
been requested with respect to the omitted portions. 

 9.10. Effects of CytomX Change of Control. In the event of a CytomX Change of
Control during the Term, the following provisions of this Section 9.10 shall apply:  
 9.10.1. Certain Terms
Regarding Intellectual Property.  
 (a) CytomX Intellectual Property. [***]  

(b) Existing Acquirer Intellectual Property. [***]  

(c) Independent Intellectual Property. [***] 

9.10.2. Effect on Certain Agreement Provisions. [***] 

 

	10.	LIMITATION ON LIABILITY, INDEMNIFICATION AND INSURANCE. 

 10.1. No
Consequential Damages. Except with respect to liability arising from a breach of Article 7, from any willful misconduct or intentionally wrongful act, or to the extent such Party may be required to provide indemnification under this
Article 10, in no event will either Party, its Affiliates, its Sublicensees or any of its, its Affiliates’ or its Sublicensees’ respective Representatives be liable under this Agreement for any special, indirect, incidental,
consequential or punitive damages, whether in contract, warranty, tort, negligence, strict liability or otherwise, including loss of profits or revenue suffered by either Party or any of its respective Affiliates or Representatives. Without limiting
the generality of the foregoing, “consequential damages” will be deemed to include, and neither Party will be liable to the other Party or any of such other Party’s Affiliates, Representatives or stockholders for, any damages based on
or measured by loss of projected or speculative future sales of the Licensed Products, any Milestone Payment due upon any unachieved event under Section 5.4, any unearned royalties under Section 5.5 or any other unearned, speculative
or otherwise contingent payments provided for in this Agreement. 
 10.2. Indemnification by Pfizer. Pfizer will
indemnify, defend and hold harmless CytomX, its Affiliates and each of its and their respective employees, officers, directors and agents (each, a “CytomX Indemnified Party”) from and against any and all liability, loss, damage,
expense (including reasonable attorneys’ fees and expenses) and cost (collectively, a “Liability”) that the CytomX Indemnified Party may be required to pay to one or more Third Parties resulting from or arising out of:

 10.2.1. Development, Manufacture, Commercialization or use of any Licensed Product by, on behalf of, or under the authority of, Pfizer
(other than by any CytomX Indemnified Party), other than claims for which CytomX is required to indemnify Pfizer pursuant to Section 10.3; or 

  
 69 

***Certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has
been requested with respect to the omitted portions. 

 10.2.2. the material breach by Pfizer of any of its representations, warranties or covenants set
forth in this Agreement; 
 except, in each case, to the extent caused by the negligence, recklessness or intentional acts of CytomX or any
CytomX Indemnified Party. 
 10.3. Indemnification by CytomX. CytomX will indemnify, defend and hold harmless Pfizer, its
Affiliates, Sublicensees, contractors, distributors and each of its and their respective employees, officers, directors and agents (each, a “Pfizer Indemnified Party”) from and against any and all Liabilities that the Pfizer
Indemnified Party may be required to pay to one or more Third Parties resulting from or arising out of: 
 10.3.1. any claim that the
exercise of rights under the Licensed Intellectual Property by, on behalf of, or under the authority of Pfizer (other than by any CytomX Indemnified Party) to Develop, Manufacture, Commercialize or use any Licensed Product infringes any Third Party
Patent Rights listed on the CytomX Letter; provided that all amounts due any Third Party under this Section 10.3.1, including damages awarded, and any royalties payable under any license or settlement entered into by Pfizer related to any such
Liability (together with litigation expenses of Pfizer in undertaking the defense of any such claim) shall be deemed payments under an Additional Third Party License and fifty percent (50%) of such amounts shall be offset against royalties due
CytomX under this Agreement as set forth in Section 5.5.2(b) (subject to the three percent (3%) minimum specified therein). Notwithstanding Section 10.4.2, such right of offset under Section 5.5.2(b) shall be the sole and
exclusive remedy with respect to the indemnity under this Section 10.3.1; 
 10.3.2. other than for claims described in
Section 10.3.1 or claims arising from or directed to the Development, Manufacture, Commercialization or use of any Licensed Product by a Pfizer Indemnitee (whether or not the Licensed Product was developed by CytomX in the performance of
Research Plan Activities), the use of any Licensed Intellectual Property for the Development, Manufacture, Commercialization or use of any products by, on behalf of, or under the authority of, CytomX (other than by any Pfizer Indemnified Party); or

 10.3.3. the material breach by CytomX of any of its representations, warranties or covenants set forth in this Agreement; 

except to the extent caused by the negligence, recklessness or intentional acts of Pfizer or any Pfizer Indemnified Party. 

  
 70 

***Certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has
been requested with respect to the omitted portions. 

 10.4. Procedure. 

10.4.1. Notice. Each Party will notify the other Party in writing in the event it becomes aware of a claim for which indemnification may
be sought hereunder. In the event that any Third Party asserts a claim or other proceeding (including any governmental investigation) with respect to any matter for which a Party (the “Indemnified Party”) is entitled to
indemnification hereunder (a “Third Party Claim”), then the Indemnified Party shall promptly notify the Party obligated to indemnify the Indemnified Party (the “Indemnifying Party”) thereof; provided, however, that
no delay on the part of the Indemnified Party in notifying the Indemnifying Party shall relieve the Indemnifying Party from any obligation hereunder unless (and then only to the extent that) the Indemnifying Party is prejudiced thereby. 

10.4.2. Control. Subject to Pfizer’s right to control any actions described in Section 6.2 (even where CytomX is the
Indemnifying Party), the Indemnifying Party shall have the right, exercisable by notice to the Indemnified Party within [***] after receipt of notice from the Indemnified Party of the commencement of or assertion of any Third Party Claim, to assume
direction and control of the defense, litigation, settlement, appeal or other disposition of the Third Party Claim (including the right to settle the claim solely for monetary consideration) with counsel selected by the Indemnifying Party and
reasonably acceptable to the Indemnified Party; provided that (a) the Indemnifying Party has sufficient financial resources, in the reasonable judgment of the Indemnified Party, to satisfy the amount of any adverse monetary judgment that is
sought, (b) the Third Party Claim seeks solely monetary damages and (c) the Indemnifying Party expressly agrees in writing that as between the Indemnifying Party and the Indemnified Party, the Indemnifying Party shall be solely obligated
to satisfy and discharge the Third Party Claim in full (the conditions set forth in clauses (a), (b) and (c) above are collectively referred to as the “Litigation Conditions”). Within [***] after the Indemnifying Party has
given notice to the Indemnified Party of its exercise of its right to defend a Third Party Claim, the Indemnified Party shall give notice to the Indemnifying Party of any objection thereto based upon the Litigation Conditions. If the Indemnified
Party reasonably so objects, the Indemnified Party shall continue to defend the Third Party Claim, at the expense of the Indemnifying Party, until such time as such objection is withdrawn. If no such notice is given, or if any such objection is
withdrawn, the Indemnifying Party shall be entitled, at its sole cost and expense, to assume direction and control of such defense, with counsel selected by the Indemnifying Party and reasonably acceptable to the Indemnified Party. During such time
as the Indemnifying Party is controlling the defense of such Third Party Claim, the Indemnified Party shall cooperate, and shall cause its Affiliates and agents to cooperate upon request of the Indemnifying Party, in the defense or prosecution of
the Third Party Claim, including by furnishing such records, information and testimony and attending such conferences, discovery proceedings, hearings, trials or appeals as may reasonably be requested by the Indemnifying Party. In the event that the
Indemnifying Party does not satisfy the Litigation Conditions or does not 

  
 71 

***Certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has
been requested with respect to the omitted portions. 

 
notify the Indemnified Party of the Indemnifying Party’s intent to defend any Third Party Claim within [***] after notice thereof, the Indemnified Party may (without further notice to the
Indemnifying Party) undertake the defense thereof with counsel of its choice and at the Indemnifying Party’s expense (including reasonable, out-of-pocket attorneys’ fees and costs and expenses of enforcement or defense). The Indemnifying
Party or the Indemnified Party, as the case may be, shall have the right to join in (including the right to conduct discovery, interview and examine witnesses and participate in all settlement conferences), but not control, at its own expense, the
defense of any Third Party Claim that the other Party is defending as provided in this Agreement. 
 10.4.3. Settlement. The
Indemnifying Party shall not, without the prior written consent of the Indemnified Party, enter into any compromise or settlement that commits the Indemnified Party to take, or to forbear to take, any action. The Indemnified Party shall have the
sole and exclusive right to settle any Third Party Claim, on such terms and conditions as it deems reasonably appropriate, to the extent such Third Party Claim involves equitable or other non-monetary relief, but shall not have the right to settle
such Third Party Claim to the extent such Third Party Claim involves monetary damages without the prior written consent of the Indemnifying Party. Each of the Indemnifying Party and the Indemnified Party shall not make any admission of liability in
respect of any Third Party Claim without the prior written consent of the other Party, and the Indemnified Party shall use reasonable efforts to mitigate Liabilities arising from such Third Party Claim. 

10.5. Insurance. Each Party shall obtain and maintain, during the Term, commercial general liability insurance, including
products liability insurance, with reputable and financially secure insurance carriers (or pursuant to a program of self-insurance reasonably satisfactory to the other Party) to cover its indemnification obligations under Section 10.2 or
Section 10.3, as applicable, in each case with limits of not less than $3,000,000 per occurrence and in the aggregate. Insurance (other than permitted self-insurance) shall be procured with carriers having an A.M. Best Rating of A-VII or
better. 
  

	11.	MISCELLANEOUS. 

 11.1. Assignment. CytomX may not assign this Agreement without
the prior written consent of Pfizer, which consent will not be unreasonably withheld or delayed; provided, however, that CytomX may, without the written consent of Pfizer, assign this Agreement in connection with the transfer or sale of all or
substantially all of its business, through merger, sale of assets or sale of stock or ownership interest. Pfizer may not assign this Agreement or any interest hereunder without the prior written consent of CytomX, which consent will not be
unreasonably withheld or delayed, except that this Agreement may be assigned as follows: (a) Pfizer may assign its rights and obligations under this Agreement by way of sale of itself or the sale of the portion of its business to which this
Agreement relates, through merger, sale of assets or sale of stock or ownership interest and (b) Pfizer 

  
 72 

***Certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has
been requested with respect to the omitted portions. 

 
may assign its rights and obligations under this Agreement to any of its Affiliates; provided that if such assignment would result in withholding or other similar taxes becoming due on payments
to CytomX under this Agreement, then any such assignment will require CytomX’s prior written consent absent an express agreement by Pfizer or the assignee to pay or reimburse CytomX for any such taxes resulting from such assignment, such
consent not to be unreasonably withheld or delayed. This Agreement shall be binding upon the successors and permitted assigns of the Parties and the name of a Party appearing herein shall be deemed to include the names of such Party’s
successors and permitted assigns to the extent necessary to carry out the intent of this Agreement. Any assignment not in accordance with this Section 11.1 shall be void. 

11.2. Further Actions. Each Party agrees to execute, acknowledge and deliver such further instruments, and to do all such other acts, as
may be necessary or appropriate in order to carry out the purposes and intent of the Agreement. 
 11.3. Force Majeure. Each Party
shall be excused from the performance of its obligations under this Agreement to the extent that such performance is prevented by force majeure (defined below) and the nonperforming Party promptly provides notice of the prevention to the other
Party. Such excuse shall be continued so long as the condition constituting force majeure continues and the nonperforming Party takes Commercially Reasonable Efforts to resume performance. For purposes of this Agreement, “force majeure”
shall include conditions beyond the control of the Parties, including an act of God, voluntary or involuntary compliance with any Applicable Law or order of any government, war, act of terror, civil commotion, labor strike or lock-out, epidemic,
failure or default of public utilities or common carriers, or destruction of production facilities or materials by fire, earthquake, storm or like catastrophe. 

11.4. Notices. Any notice or notification required or permitted to be provided pursuant to the terms and conditions of this Agreement
(including any notice of force majeure, breach, termination, change of address, etc.) shall be in writing and shall be deemed given upon receipt if delivered personally or by facsimile transmission (receipt verified), five days after deposited
in the mail if mailed by registered or certified mail (return receipt requested) postage prepaid, or on the next Business Day if sent by overnight delivery using a nationally recognized express courier service and specifying next Business Day
delivery (receipt verified), to the Parties at the following addresses or facsimile numbers (or at such other address or facsimile number for a Party as shall be specified by like notice, provided, however, that notices of a change of address shall
be effective only upon receipt thereof): 
 All correspondence to Pfizer shall be addressed as follows: 

Pfizer Inc. 
 Notices: R&D
Business Development 
 235 East 42nd Street 

New York, NY 10017 
 Attn.:
R&DBD Contract Notice 

  
 73 

***Certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has
been requested with respect to the omitted portions. 

 with a copy to: 

Pfizer Inc. 
 Notices: Pfizer
Legal Division 
 235 East 42nd Street 

New York, NY 10017 
 Attn.:
Chief Counsel, R&D 
 [***] 

To help expedite Pfizer’s awareness and response, copies of notices may be provided to Pfizer by email but must be supplemented by one of
the following methods: (a) personal delivery, (b) first class certified mail with return receipt requested, or (c) next-day delivery by major international courier, with confirmation of delivery. Electronic copies may be sent via
email to [***]. 
 All correspondence to CytomX shall be addressed as follows: 

CytomX Therapeutics, Inc. 
 650
Gateway Blvd., Suite 125 
 South San Francisco, CA 94080-7014 

Attn: CEO 
 Fax: 1-650-351-0353

 with a copy to: 
 [***] 

11.5. Amendment. No amendment, modification or supplement of any provision of this Agreement shall be valid or effective unless made in
writing and signed by a duly authorized officer of each Party. 
 11.6. Waiver. No provision of this Agreement shall be waived by any
act, omission or knowledge of a Party or its agents or employees except by an instrument in writing expressly waiving such provision and signed by a duly authorized officer of the waiving Party. The waiver by either of the Parties of any breach of
any provision hereof by the other Party shall not be construed to be a waiver of any succeeding breach of such provision or a waiver of the provision itself. 

11.7. Severability. If any clause or portion thereof in this Agreement is for any reason held to be invalid, illegal or unenforceable,
the same shall not affect any other portion of this Agreement, as it is the intent of the Parties that this Agreement shall be construed in such fashion as to maintain its existence, validity and enforceability to the greatest extent

  
 74 

***Certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has
been requested with respect to the omitted portions. 

 
possible. In any such event, this Agreement shall be construed as if such clause or portion thereof had never been contained in this Agreement, and there shall be deemed substituted therefor such
provision as will most nearly carry out the intent of the Parties as expressed in this Agreement to the fullest extent permitted by Applicable Law. 

11.8. Descriptive Headings. The descriptive headings of this Agreement are for convenience only and shall be of no force or effect in
construing or interpreting any of the provisions of this Agreement. 
 11.9. Dispute Resolution. If any dispute or disagreement arises
between Pfizer and CytomX in respect of this Agreement, they shall follow the following procedures in an attempt to resolve the dispute or disagreement: 

11.9.1. The Party claiming that such a dispute exists shall give notice in writing (a “Notice of Dispute”) to the other Party
of the nature of the dispute. 
 11.9.2. Within fourteen (14) days of receipt of a Notice of Dispute, the Pfizer Alliance Manager and
the CytomX Alliance Manager shall meet in person or by teleconference and exchange written summaries reflecting, in reasonable detail, the nature and extent of the dispute, and at this meeting they shall use their reasonable endeavors to resolve the
dispute. 
 11.9.3. If the Alliance Managers are unable to resolve the dispute during the meeting described in Section 11.9.2 or if
for any reason such meeting does not take place within the period specified in Section 11.9.2, then the dispute will be referred to the JRC which shall meet no later than forty-five (45) days following the initial receipt of the Notice
of Dispute and use reasonable endeavors to resolve the dispute. 
 11.9.4. If the JRC is unable to resolve the dispute during the meeting
described in Section 11.9.3 or if for any reason such meeting does not take place within the period specified in Section 11.9.3, then the Senior Vice President and Chief Scientific Officer, Oncology Research Unit, of Pfizer and the
Chief Executive Officer of CytomX shall meet at a mutually agreed-upon time and location for the purpose of resolving such dispute. 

11.9.5. If, within a further period of thirty (30) days, or if in any event within ninety (90) days of initial receipt of the Notice
of Dispute, the dispute has not been resolved, or if, for any reason, the meeting described in Section 11.9.4 has not been held within ninety (90) days of initial receipt of the Notice of Dispute, then the Parties agree that either Party
may initiate litigation to resolve the dispute. 
 11.9.6. Notwithstanding any provision of this Agreement to the contrary, either Party may
immediately initiate litigation in any court of competent jurisdiction seeking any remedy at law or in equity, including the issuance of a preliminary, 

  
 75 

***Certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has
been requested with respect to the omitted portions. 

 
temporary or permanent injunction, to preserve or enforce its rights under this Agreement. The provisions of this Section 11.9 will survive for five (5) years from the date of
termination or expiration of this Agreement. 
 11.10. Governing Law. This Agreement, and all claims arising under or in connection
therewith, shall be governed by and interpreted in accordance with the substantive laws of the State of Delaware, without regard to conflict of law principles thereof. 

11.11. Consent to Jurisdiction. Each Party to this Agreement, by its execution hereof, (a) hereby irrevocably submits to the exclusive
jurisdiction of the state courts of the State of Delaware or the United States District Court for the District of Delaware for the purpose of any and all actions, suits or proceedings arising in whole or in part out of, related to, based upon or in
connection with this Agreement or the subject matter hereof, (b) hereby waives to the extent not prohibited by Applicable Law, and agrees not to assert, by way of motion, as a defense or otherwise, in any such action, any claim that it is not
subject personally to the jurisdiction of the above-named courts, that its property is exempt or immune from attachment or execution, that any such action brought in one of the above-named courts should be dismissed on grounds of forum non
conveniens, should be transferred to any court other than one of the above-named courts, or should be stayed by reason of the pendency of some other proceeding in any other court other than one of the above-named courts, or that this Agreement or
the subject matter hereof may not be enforced in or by such court, and (c) hereby agrees not to commence any such action other than before one of the above-named courts nor to make any motion or take any other action seeking or intending to
cause the transfer or removal of any such action to any court other than one of the above-named courts whether on the grounds of inconvenient forum or otherwise. 

11.12. Entire Agreement. This Agreement, including its Exhibits and Schedules, constitutes and contains the complete, final and
exclusive understanding and agreement of the Parties and cancels and supersedes any and all prior negotiations, correspondence, understandings and agreements, whether oral or written, between the Parties respecting the subject matter hereof and
thereof, including the Confidentiality Agreement which is hereby terminated effective as of the Effective Date, provided that such Confidentiality Agreement will continue to govern the treatment of Confidential Information disclosed by the Parties
prior to the Effective Date in accordance with its terms. 
 11.13. Independent Contractors. Both Parties are independent contractors
under this Agreement. Nothing herein contained shall be deemed to create an employment, agency, joint venture or partnership relationship between the Parties hereto or any of their agents or employees, or any other legal arrangement that would
impose liability upon one Party for the act or failure to act of the other Party. Neither Party shall have any express or implied power to enter into any contracts or commitments or to incur any liabilities in the name of, or on behalf of, the other
Party, or to bind the other Party in any respect whatsoever. 

  
 76 

***Certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has
been requested with respect to the omitted portions. 

 11.14. Counterparts. This Agreement may be executed in two counterparts, each of which
shall be an original and both of which shall constitute together the same document. Counterparts may be signed and delivered by facsimile or PDF file, each of which shall be binding when received by the applicable Party. 

11.15. No Third Party Rights or Obligations. No provision of this Agreement shall be deemed or construed in any way to result in the
creation of any rights or obligation in any Person not a Party to this Agreement. However, Pfizer may decide, in its sole discretion, to use one or more of its Affiliates to perform its obligations and duties hereunder, provided that Pfizer shall
remain liable hereunder for the performance by any such Affiliates of any such obligations. 
 [The remainder of this page has been
intentionally left blank. The signature page follows.] 

  
 77 

***Certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has
been requested with respect to the omitted portions. 

 IN WITNESS WHEREOF, duly authorized representatives of the Parties have duly executed this
Agreement to be effective as of the Effective Date. 
  

									
	PFIZER INC.	 		 	CYTOMX THERAPEUTICS, INC.
					
	By:	 	 /s/ Mikael Dolsten
	 		 	By:	 	 /s/ Sean McCarthy

	Name:	 	Mikael Dolsten	 		 	Name:	 	Sean McCarthy
	Title:	 	Worldwide Research and Development	 		 	Title:	 	CEO

  
 ***Certain information contained
herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 Exhibit 2.3.1 

EGFR Research Plan 

[***]† 

†Eight pages of text have
been omitted. 

  
 ***Certain information contained
herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 Schedule 1.51 

EGFR 
 [***]† 
 †Three pages of text have been omitted. 

  
 ***Certain information contained
herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 Schedule 1.54 

EGFR Probody 
 [***]† 
 †One page of text has been omitted. 

  
 ***Certain information contained
herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 Schedule 1.159 

Tool Patent Rights 
  

																			
	Title	  	CYTX Ref No.	  	CY	  	Serial No. /
Issue No.	  	Filing /
Issue Dates	  	Priority
Dates	  	Status	  	Assignee	  	Pub No.	  	Pub Date
	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 
	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 
	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 

 [***]† 
 †One page of text has been omitted. 

  
 ***Certain information contained
herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 Schedule 6.2.1(d) 

Countries for Filing National Phase Applications (Part A and Part B) 

[***]† 

†One page of text has been
omitted 

  
 ***Certain information contained
herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 Schedule 7.3.1 

Press Release 

CytomX Announces Global Strategic Collaboration with Pfizer to Develop and Commercialize Multiple ProbodyTM-Drug Conjugates in Oncology

 CytomX Eligible to Receive Approximately $25 Million in Upfront and Pre-Clinical Milestone Payments, $610 Million in Regulatory and
Sales Milestones, Plus Tiered Royalties on Sales 
 SOUTH SAN FRANCISCO – DATE XX, 2013 – CytomX Therapeutics, Inc., a biotechnology
company developing a new generation of targeted antibody therapeutics, today announced that it has entered into a global strategic collaboration with Pfizer Inc. to develop and commercialize multiple ProbodyTM-Drug Conjugates (PDCs).
CytomX’s novel Probody Platform brings to the collaboration a proprietary, highly differentiated approach to developing safer and more effective antibody-drug conjugates (ADCs). PDCs are engineered to combine cytotoxic agents with masked
Probodies that remain inert in healthy tissue but are activated specifically in the tumor microenvironment, opening up new target space for this emerging therapeutic class. 

“Combining our novel Probody Platform with Pfizer’s broad capabilities in ADCs marks an important milestone for CytomX and underscores the potential
of our Probody Platform to enable new generations of empowered antibodies,” said Sean McCarthy, D.Phil., chief executive officer of CytomX. “Our innovative science is driving the development of groundbreaking Probodies and PDCs that have
already demonstrated preclinical activity when selectively activated within the tumor microenvironment. We look forward to collaborating with Pfizer with the aim of researching and developing highly differentiated PDC products that have the
potential to change the way cancer is treated.” 
 Under the terms of the agreement, Pfizer has exclusive rights to pursue development and
commercialization of select PDCs. The companies will work together on preclinical research and Pfizer will be responsible for development and potential commercialization of any selected PDCs. CytomX will be eligible to receive up-front and
pre-clinical milestone payments totaling approximately $25 million and approximately $610 million in regulatory and sales milestone payments, as well as tiered royalties reaching double digits on potential future sales. 

“This partnership is a great example of how Pfizer is seeking to innovate new capabilities in cutting-edge science and technology platforms with the aim
of delivering safer, more effective cancer medicines to patients,” said Robert T. Abraham, senior vice president and chief scientific officer, Pfizer’s Oncology Research Unit. “Pfizer’s investment in CytomX’s emerging
Probody Platform is an important component of our overall strategic focus to advancing the next generation of ADCs and reflects the disruptive potential of this approach.” 

  
 ***Certain information contained
herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 About The CytomX ProbodyTM Platform 

CytomX’s novel ProbodyTM Platform is enabling the development of a diversified pipeline of next-generation empowered antibodies, including Probodies,
Probody-Drug Conjugates (PDCs), bispecifics, and other formats, to address previously undruggable targets in cancer, inflammation, and other significant unmet medical needs. Probodies have the potential to expand the therapeutic window for targets
where therapeutic intervention is expected to have a significant impact on the disease, but also where normal tissue expression patterns are too widespread to allow for adequate safety margins using conventional antibody approaches. CytomX’s
Probodies are fully recombinant masked antibodies that remain inert in healthy tissue but are activated specifically in the disease microenvironment. Probodies leverage dysregulated protease activity, a hallmark of many diseased states, to locally
activate in the disease tissue thereby achieving unprecedented levels of tissue-specific targeting. 
 About CytomX 

CytomX Therapeutics is a biotechnology company developing a new generation of highly targeted antibody therapeutics with the potential to transform lives with
safer, more effective therapies. CytomX’s ProbodyTM Platform offers a highly differentiated approach to discovering and developing empowered antibodies and is enabling the development of a diversified pipeline addressing previously
undruggable targets in major unmet medical needs including cancer and inflammation. Probodies are masked antibodies that remain inert in healthy tissue but are activated specifically in the disease microenvironment. This improved selectivity allows
CytomX to open a therapeutic window for high potential, but previously inaccessible targets, and to expand the therapeutic index of existing, validated targets, thereby redefining the landscape for therapeutic antibodies. CytomX is led by a seasoned
and proven management team and is financed by leading life science investors including Third Rock Ventures, Canaan Partners and the Roche Venture Fund. For more information, please visit www.cytomx.com. 

# # # 

  
 ***Certain information contained
herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 Schedule 8.2.1 

CytomX Third Party Agreements 

Amended and Restated License Agreement between Regents of the University of California through its Santa Barbara Campus and CytomX Therapeutics, entered into
on August 19, 2010 

  
 ***Certain information contained
herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 Schedule 8.2.3 

CytomX Patent Rights 
 Schedule
1.159 is incorporated herein as are the following patent rights: 
  

																			
	Title	  	CYTX Ref No.	  	CY	  	Serial No. / Issue
No.	  	Filing /
Issue
Dates	  	Priority
Dates	  	Status	  	Assignee	  	Pub No.	  	Pub Date
	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 
	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 
	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 

 [***]† 
 †Two pages of text have been omitted. 

  
 ***Certain information contained
herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 Schedule 8.2.8 

Government Funding Agreements 

Federal Grant Nos. 1 U54 CA119335-01 and R43CA132498-01A1, awarded by the National Institutes of Health to University of California Santa Barbara 

SBIR Grant No. 1R43C139790-01, awarded by the National Institutes of Health to CytomX Therapeutics 

  
 ***Certain information contained
herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 Schedule 8.2.9 

Agreements Limiting IP Rights 
 None

  
 ***Certain information contained
herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 Schedule 8.2.10 

Disclosed Third Party Agreements 

Amended and Restated License Agreement between Regents of the University of California through its Santa Barbara Campus and CytomX Therapeutics, entered into
on August 19, 2010 

  
 ***Certain information contained
herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.EX-10.1

 Exhibit 10.1 

INCREMENTAL AMENDMENT 
 INCREMENTAL AMENDMENT,
dated as of September 25, 2015 (this “Incremental Amendment”), to the Credit Agreement referred to below among ENDO LUXEMBOURG FINANCE COMPANY I S.A R.L., a private limited liability company (société à
responsabilité limitée) incorporated under the laws of Luxembourg, having its registered office at 2a, rue Nicolas Bové, L-1253 Luxembourg, with a share capital of USD 123,695,800 and registered with the Register of Commerce
and Companies (Registre de Commerce et des Sociétés) of Luxembourg (the “RCS”) under number B 182.645 (the “Lux Borrower”), ENDO LLC, a limited liability company organized under the laws of
Delaware as a wholly-owned direct subsidiary of the Lux Borrower (the “Co-Borrower” and together with the Lux Borrower, the “Borrowers”), ENDO DESIGNATED ACTIVITY COMPANY
(formerly known as Endo Limited), a company duly incorporated under the laws of the Republic of Ireland (“Irish Holdco”), ENDO MANAGEMENT LIMITED, a company duly incorporated under the laws of the Republic of Ireland (“Irish
Sub Holdco”), ENDO LUXEMBOURG HOLDING COMPANY S.A R.L., a private limited liability company (société à responsabilité limitée) incorporated under the laws of Luxembourg, having its registered office
at 2a, rue Nicolas Bové, L-1253 Luxembourg, with a share capital of USD 123,695,800 and registered with the RCS under number B 182.517 (“Lux Holdco”), ENDO US HOLDINGS LUXEMBOURG I S.à r.l., a private limited liability
company (société à responsabilité limitée) incorporated under the laws of Luxembourg, having its registered office at 2a, rue Nicolas Bové, L-1253 Luxembourg, with a share capital of USD 17,000 and
registered with the RCS under number B 197.803 (“New Luxco 1”), ENDO US HOLDINGS LUXEMBOURG II S.à r.l., a private limited liability company (société à responsabilité limitée)
incorporated under the laws of Luxembourg, having its registered office at 2a, rue Nicolas Bové, L-1253 Luxembourg, with a share capital of USD 17,000 and registered with the RCS under number B 197.970 (“New Luxco 2”), ENDO
LUXEMBOURG FINANCE COMPANY II S.à r.l., a private limited liability company (société à responsabilité limitée) incorporated under the laws of Luxembourg, having its registered office at 2a, rue
Nicolas Bové, L-1253 Luxembourg, with a share capital of USD 17,000 and registered with the RCS under number B182.794 (“Lux Sub Finco”), the other Guarantors party hereto, the several banks and financial institutions
parties hereto that constitute the 2015 Incremental Term B Lenders and the 2015 Incremental Revolving Lenders (each as further defined in Section 2(b)(i) hereof) and the Administrative Agent (as defined below). 

RECITALS 
 WHEREAS, the Borrowers
have entered into that certain Credit Agreement, dated as of February 28, 2014 (as amended as of June 12, 2015, and as further amended, amended and restated, supplemented or otherwise modified from time to time, the “Credit
Agreement”), among the Lux Borrower, the Co-Borrower, Irish Holdco, Irish Sub Holdco, Lux Holdco, Deutsche Bank AG New York Branch, as administrative agent (in such capacity, the “Administrative Agent”), collateral agent
(in such capacity, the “Collateral Agent”), issuing bank and swingline lender, and the several lenders party thereto from time to time; and 

WHEREAS, pursuant to and in accordance with Section 2.20 of the Credit Agreement, (a) the Borrowers have requested that
(i) Incremental Term B Loan Commitments (as defined 

 
below) in an aggregate principal amount of $2,800,000,000 be made available to the Lux Borrower; and (ii) Incremental Revolving Commitments in an aggregate principal amount of $250,000,000
(the “2015 Incremental Revolving Commitment”) be made available to the Lux Borrower; and (b)(i) the 2015 Incremental Term B Lenders and the Administrative Agent have agreed, upon the terms and subject to the conditions set forth
herein, that the 2015 Incremental Term B Lenders will make Incremental Term B Loans in the form of the 2015 Incremental Term B Loans (as defined below); and (ii) the 2015 Incremental Revolving Lenders and the Administrative Agent have
agreed, upon the terms and subject to the conditions set forth herein, that each 2015 Incremental Revolving Lender will provide its portion of the 2015 Incremental Revolving Commitment to the Borrowers as of the First Incremental Amendment
Closing Date in the amount set forth opposite its name on Schedule 2.01 and will make Revolving Loans to the Borrowers in respect thereof from time to time during the Availability Period subject to the terms and conditions set forth herein and in
the Credit Agreement; and (c) the 2015 Incremental Term B Lenders, the 2015 Incremental Revolving Lenders, and the Administrative Agent have agreed, upon the terms and subject to the conditions set forth herein, that the proceeds of the
2015 Incremental Term B Loans will be used (i) to repay and refinance in full the 2014 Term B Loans, (ii) to finance, in part, the Par Transactions and/or (iii) to the extent any portion of the 2015 Incremental Term B Loans remains
available following application of proceeds pursuant to preceding clauses (i) and (ii), for general corporate purposes, including without limitation permitted acquisitions and debt repayments. 

NOW, THEREFORE, in consideration of the covenants and agreements contained herein, as well as other good and valuable consideration, the
receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows: 
 Section 1. Defined Terms.
Capitalized terms used but not defined herein shall have the meanings assigned to such terms in the Credit Agreement. Unless otherwise indicated, section references herein refer to sections in the Credit Agreement. 

Section 2. Amendment of the Credit Agreement. 

(a) For the avoidance of doubt, (i) the 2015 Incremental Term B Loans shall be deemed to be “Loans”,
“Incremental Term B Loans” and “Other Term B Loans”; (ii) each 2015 Incremental Term B Lender shall be deemed to be a “Lender” and an “Incremental Term B Lender”; (iii) each 2015 Incremental
Revolving Lender shall be deemed to be a “Lender” and an “Incremental Revolving Lender”; (iv) the 2015 Incremental Term B Loan Commitments shall be deemed to be “Incremental Term B Loan Commitments”; (v) the
2015 Incremental Revolving Commitment shall be deemed to be “Incremental Revolving Commitments” and “Multicurrency Tranche Commitments”; (vi) each Loan made pursuant to the 2015 Incremental Revolving Commitments shall be
deemed to be “Multicurrency Tranche Revolving Loans”, “Incremental Revolving Loans” and “Revolving Loans”; and (vii) this Incremental Amendment shall be deemed to be an “Incremental Amendment” and a
“Loan Document”, in each case, for all purposes of the Credit Agreement and the other Loan Documents. 

  
 - 2 - 

 (b) Section 1.01 of the Credit Agreement is hereby amended as follows: 

(i) by adding the following new definitions, to appear in proper alphabetical order: 

“Applicable Excess Cash Flow Percentage” means 50%, with a step down to 25% upon the achievement and
maintenance of a Leverage Ratio of less than or equal to 4.50:1.00 and a further step down to 0% upon the achievement and maintenance of a Leverage Ratio of less than or equal to 4.00:1.00. 

“Asset Sale Step Down” has the meaning set forth in Section 2.11(c). 

“Consolidated Current Assets” means, with respect to the Irish Holdco and its Restricted Subsidiaries on a
consolidated basis at any date of determination, all assets (other than cash and Permitted Investments) that would, in accordance with GAAP, be classified on a consolidated balance sheet of the Irish Holdco and its Restricted Subsidiaries as current
assets at such date of determination, other than amounts related to current or deferred Taxes based on income or profits (but excluding (i) assets held for sale, (ii) permitted loans to third parties, (iii) Plan assets,
(iv) deferred bank fees, and (v) derivative financial instruments). 
 “Consolidated Current
Liabilities” means, with respect to the Irish Holdco and its Restricted Subsidiaries on a consolidated basis at any date of determination, all liabilities that would, in accordance with GAAP, be classified on a consolidated balance sheet of
the Irish Holdco and its Restricted Subsidiaries as current liabilities at such date of determination, other than (i) the current portion of any Indebtedness, (ii) the current portion of interest, (iii) accruals for current or
deferred Taxes based on income or profits, (iv) accruals of any costs or expenses related to restructuring reserves, (v) the aggregate amount of outstanding Revolving Loans and Swingline Loans and LC Exposure and (vi) the current
portion of pension liabilities. 
 “Consolidated Working Capital” means, at any time, Consolidated Current
Assets (but excluding therefrom all cash and Permitted Investments) less Consolidated Current Liabilities at such time; provided that increases or decreases in Adjusted Consolidated Working Capital shall be calculated without regard to any
changes in Consolidated Current Assets or Consolidated Current Liabilities as a result of (x) any reclassification in accordance with GAAP of assets or liabilities, as applicable, between current and noncurrent, (y) the effects of purchase
accounting or (z) the effect of fluctuations in the amount of accrued or contingent obligations, assets or liabilities under Swap Agreements. 

“Excess Cash Flow” means, for any period, the remainder (if positive) of (a) the sum of, without
duplication, (i) Consolidated Net Income for such period, (ii) the decrease, if any, in Consolidated Working Capital from the first day to the last day of such period (other than any such decreases arising from Permitted Acquisitions or
Dispositions of any person by Irish Holdco or any of its Restricted Subsidiaries), (iii) the amount of expenses for Taxes paid or accrued to the extent 

  
 - 3 - 

 
same reduced Consolidated Net Income for such period, (iv) any expense related to Swap Agreements which decreased Consolidated Net Income for such period, (v) non-cash charges, losses
or expenses deducted in calculating Consolidated Net Income such period, (vi) cash charges or expenses reducing Consolidated Net Income during such period in respect of expenditures for which a deduction from Excess Cash Flow was made in a
prior period and (vii) items not included in Excess Cash Flow in a previous period as items that were committed to be spent in a future period which are not actually spent during the subsequent period, minus (b) the sum of, without
duplication, (i) the aggregate amount of all Capital Expenditures in cash made (or committed to be made in the next succeeding period) by Irish Holdco and its Restricted Subsidiaries not expensed during such period (other than to the extent
made with proceeds of long-term Indebtedness), (ii) the aggregate amount of permanent principal repayments of Indebtedness of Irish Holdco and its Restricted Subsidiaries (including (x) the principal component of payments made on Capital
Lease Obligations of Irish Holdco and its Restricted Subsidiaries during such period and (y) the aggregate principal amount of any mandatory prepayment of Term Loans pursuant to Section 2.11(c)(1), to the extent required due to the
circumstances described in clauses (a) or (b) of the definition of “Prepayment Event” that resulted in an increase to Consolidated Net Income and not in excess of such increase), but excluding (A) all repayments and
prepayments of Term Loans (other than payments required pursuant to Section 2.10 and mandatory prepayments described in clause (y) of the foregoing parenthetical), (B) all repayments and prepayments of Revolving Loans, Swingline Loans
or loans under any Incremental Revolving Commitment or other revolving credit or similar facility unless such prepayments are accompanied by a corresponding permanent reduction of the related revolving or similar commitments and (C) any such
repayments and prepayments to the extent made with proceeds of long-term Indebtedness, (iii) the increase, if any, in Consolidated Working Capital from the first day to the last day of such period (other than any such increase in Consolidated
Working Capital arising from a Permitted Acquisition or Disposition of any person by Irish Holdco and/or any of its Restricted Subsidiaries), (iv) to the extent included or not deducted in calculating Consolidated Net Income, the aggregate
amount of all cash payments made in respect of all Permitted Acquisitions and other Investments (including earn-out obligations, working capital or similar adjustments paid in connection therewith and in connection with acquisitions or Investments
consummated prior to the First Incremental Amendment Closing Date) permitted by Section 6.04 consummated (or committed or budgeted to be consummated in the next succeeding period) by Irish Holdco and its Restricted Subsidiaries (other than
intercompany Investments among Irish Holdco and its Restricted Subsidiaries or Investments in cash or Permitted Investments) during such period or prior to the applicable Excess Cash Payment Date, except to the extent financed with long-term
Indebtedness, (v) to the extent not expensed or not deducted in calculating Consolidated Net Income, the aggregate amount of any premium, make-whole or penalty payments actually paid, except to the extent financed with long-term

  
 - 4 - 

 
Indebtedness during such period that are required to be made in connection with any prepayment of Indebtedness, (vi) cash payments by Irish Holdco and its Restricted Subsidiaries during such
period in respect of long-term liabilities of Irish Holdco and its Restricted Subsidiaries other than Indebtedness, except to the extent financed with long-term Indebtedness, (vii) cash expenditures for costs and expenses in connection with
acquisitions or Dispositions and the issuance of Equity Interests or Indebtedness or amendments or modifications to any Indebtedness to the extent not deducted in arriving at such Consolidated Net Income (in each case, including any such
transactions undertaken but not completed), except to the extent financed with long-term Indebtedness, (viii) the aggregate amount of expenditures actually made by Irish Holdco and its Restricted Subsidiaries in cash during such period
(including expenditures for the payment of financing fees) to the extent that such expenditures are not expensed during such period, (ix) any payment of cash to be amortized or expensed over a future period and recorded as a long-term asset (so
long as any related amortization or expense in a future period shall be added back in the calculation of Excess Cash Flow in such future period), (x) reimbursable or insured expenses incurred during such fiscal year to the extent that
reimbursement has not yet been received (in which case the respective reimbursement shall increase Excess Cash Flow in the period in which it is received), (xi) the aggregate amount of Taxes actually paid or payable by Irish Holdco and its
Restricted Subsidiaries in cash during such period, (xii) to the extent not expensed or not deducted in calculating Consolidated Net Income, the aggregate amount of any permitted Restricted Payments actually made in cash during such period by
Irish Holdco and by any Restricted Subsidiary to any Person other than Irish Holdco or the Restricted Subsidiaries, in each case, pursuant to Section 6.07, except to the extent financed with long term Indebtedness and (xiii) cash
expenditures made in respect of Swap Agreements during such period. Notwithstanding anything in the definition of any term used in the definition of Excess Cash Flow to the contrary, all components of Excess Cash Flow shall be computed for Irish
Holdco and its Restricted Subsidiaries on a consolidated basis. 
 “Excess Cash Payment Date” means the
date occurring five (5) Business Days after the date on which the Parent’s annual audited financial statements are required to be delivered pursuant to Section 5.01(a) (commencing with the fiscal year of the Parent ended
December 31, 2016). 
 “First Incremental Amendment” means the Incremental Amendment, dated as of
September 25, 2015, by and among the Borrowers, the Guarantors, the 2015 Incremental Term B Lenders, the 2015 Incremental Revolving Lenders and the Administrative Agent. 

“First Incremental Amendment Closing Date” means the date on which all the conditions precedent set forth in
Section 4 of the First Incremental Amendment shall have been satisfied or waived. 

  
 - 5 - 

 “Original Arrangers” means the Lead Arrangers (as defined in
this Agreement prior to effectiveness of the First Incremental Amendment). 
 “2015 Incremental Revolving
Commitment” means, with respect to each 2015 Incremental Revolving Lender, the commitment, if any, of such 2015 Incremental Revolving Lender to make Incremental Revolving Loans hereunder, as such commitment may be (a) reduced or
terminated from time to time pursuant to Section 2.09 and (b) reduced or increased from time to time pursuant to assignments by or to such Lender pursuant to Section 9.04. The amount of each 2015 Incremental Revolving Lender’s
2015 Incremental Revolving Commitment is set forth on Schedule 2.01, or in the Assignment and Assumption (or other documentation contemplated by this Agreement) pursuant to which such 2015 Incremental Revolving Lender shall have assumed its 2015
Incremental Revolving Commitment, as applicable. The aggregate principal amount of the 2015 Incremental Revolving Commitments on the First Incremental Amendment Closing Date is $250,000,000. 

“2015 Incremental Revolving Lender” means any Lender having a 2015 Incremental Revolving Commitment
outstanding hereunder. 
 “2015 Incremental Term B Lender” means any Lender having a 2015 Incremental Term
B Loan Commitment and/or a 2015 Incremental Term B Loan outstanding hereunder. 
 “2015 Incremental Term B Loan
Commitments” means, with respect to each 2015 Incremental Term B Lender, the commitment, if any, of such 2015 Incremental Term B Lender to make 2015 Incremental Term B Loans hereunder, as such commitment may be (a) reduced or
terminated from time to time pursuant to Section 2.09 and (b) reduced or increased from time to time pursuant to assignments by or to such Lender pursuant to Section 9.04. The amount of each 2015 Incremental Term B Lender’s 2015
Incremental Term B Loan Commitment is set forth on Schedule 2.01, or in the Assignment and Assumption (or other documentation contemplated by this Agreement) pursuant to which such 2015 Incremental Term B Lender shall have assumed its 2015
Incremental Term B Loan Commitment, as applicable. The aggregate principal amount of the 2015 Incremental Term B Loan Commitments on the First Incremental Amendment Closing Date is $2,800,000,000. 

“2015 Incremental Term B Loans” means the incremental term loans made by the 2015 Incremental Term B Lenders
to the Lux Borrower on the First Incremental Amendment Closing Date pursuant to Section 2.01(a)(iii). Each 2015 Incremental Term B Loan shall be a Eurocurrency Loan denominated in Dollars or an ABR Loan denominated in Dollars. 

  
 - 6 - 

 “2015 Lead Arrangers” means Barclays Bank PLC, Deutsche Bank
Securities Inc., Merrill Lynch, Pierce, Fenner & Smith Incorporated and Morgan Stanley Senior Funding, Inc. 
 (ii)
by amending and restating the definition of “Alternate Base Rate” in Section 1.01 of the Credit Agreement as follows: 

““Alternate Base Rate” means, for any day, a rate per annum equal to the greatest of (a)(i) solely in
the case of 2014 Term B Loans, 1.75% and (ii) solely in the case of 2015 Incremental Term B Loans, 1.75%, (b) the Prime Rate in effect on such day, (c) the Federal Funds Effective Rate in effect on such day plus 1/2 of 1% and
(d) the Adjusted LIBO Rate for a one month Interest Period on such day (or if such day is not a Business Day, the immediately preceding Business Day) plus 1%; provided that, for the avoidance of doubt, the Adjusted LIBO Rate for any day
shall be based on the rate appearing on Reuters Screen LIBOR01 Page (or on any successor or substitute page of such page) at approximately 11:00 a.m. London time on such day. Any change in the Alternate Base Rate due to a change in the Prime Rate,
the Federal Funds Effective Rate or the Adjusted LIBO Rate shall be effective from and including the effective date of such change in the Prime Rate, the Federal Funds Effective Rate or the Adjusted LIBO Rate, respectively.” 

(iii) by replacing clause (b) of the definition of “Applicable Rate” in Section 1.01 of the Credit
Agreement with the following: 
 “(b)(i) with respect to (x) any Eurocurrency 2014 Term B Loan, 2.50% per
annum, (y) any ABR 2014 Term B Loan, 1.50% per annum and (ii) with respect to (x) any Eurocurrency 2015 Incremental Term B Loan, 3.00% per annum and (y) any ABR 2015 Incremental Term B Loan, 2.00% per annum.”

 (iv) by amending and restating the definition of “Lead Arrangers” in Section 1.01 of the Credit Agreement
as follows: 
 ““Lead Arrangers” means, collectively, the Original Arrangers and the 2015 Lead
Arrangers; provided, that all references to “Lead Arrangers” in Section 4.01 herein shall be deemed to include only the Original Arrangers.” 

(v) by amending and restating the definition of “LIBO Rate” in Section 1.01 of the Credit Agreement as follows:

 ““LIBO Rate” means, for any Interest Period (a) with respect to any Term B Loan that is a
Eurocurrency Borrowing, the greater of (i)(x) solely in the case of 2014 Term B Loans, 0.75% and (y) solely in the case of 2015 Incremental Term B Loans, 0.75% and (ii) the rate appearing on Reuters Screen LIBOR01 Page (or on any successor
or substitute page on such screen) at approximately 11:00 a.m., London time, on the Quotation Day for such Interest Period, as the rate for 

  
 - 7 - 

 
deposits in the relevant Agreed Currency in the London interbank market with a maturity comparable to such Interest Period (the “Eurocurrency Base Rate”) and (b) with
respect to any other Eurocurrency Borrowing, the Eurocurrency Base Rate. In the event that the Eurocurrency Base Rate is not available at such time for any reason, then the “Eurocurrency Base Rate” shall be determined by reference to such
other publicly available service displaying interest rates applicable to deposits in such Agreed Currency in the London interbank market as may be selected by the Administrative Agent or, in the absence of such availability, by reference to the rate
at which deposits in such Agreed Currency in reasonable market size and for a maturity comparable to such Interest Period are offered by the principal London office of the Administrative Agent in immediately available funds in the London interbank
market at approximately 11:00 a.m., London time, on the Quotation Day for such Interest Period.” 
 (vi) by amending
and restating the definition of “Maturity Date” in Section 1.01 of the Credit Agreement as follows: 

““Maturity Date” means (i) with respect to the Term A Loans that have not been extended pursuant to
Section 2.23, the date occurring five years after the Closing Date, (ii) with respect to the 2014 Term B Loans that have not been extended pursuant to Section 2.23, the date occurring seven years after the Closing Date,
(iii) with respect to the 2015 Incremental Term B Loans that have not been extended pursuant to Section 2.23, the date occurring seven years after the First Incremental Amendment Closing Date, (iv) with respect to the Revolving
Commitments of the Revolving Lenders that have not been extended pursuant to Section 2.23, the date occurring five years after the Closing Date, and (v) with respect to any other tranche of Term Loans or Revolving Commitments (including
any Extended Term Loans, Other Term Loans, Other Refinancing Term Commitments, Extended Revolving Commitments, Incremental Revolving Commitments and Other Refinancing Revolving Commitments), the maturity dates specified therefor in the applicable
Incremental Amendment, Extension Amendment or Refinancing Amendment; provided that if any such day is not a Business Day, the Maturity Date shall be the Business Day immediately succeeding such day.” 

(vii) by amending and restating the definition of “Repricing Event” in Section 1.01 of the Credit Agreement as
follows: 
 ““Repricing Event” means (a) the prepayment or refinancing of any of the Term B Loans
with the incurrence by any Loan Party of any Indebtedness incurred for the primary purpose (as reasonably determined by the Borrowers) of lowering the Effective Yield of the applicable Term B Loans or (b) any effective reduction in the
Effective Yield of any Term B Loans (e.g., by way of amendment or waiver); provided that in no event shall any prepayment or repayment of Term B Loans in connection with a Change in Control or an acquisition not permitted by Section 6.04
constitute a Repricing Event.”” 

  
 - 8 - 

 (c) Section 2.01 of the Credit Agreement is hereby amended as follows: 

(i) by amending and restating clause (a) thereof as follows: 

“(a) each (i) 2014 Term A Lender agrees, severally and not jointly, to make a 2014 Term A Loan to the Lux Borrower
on the Closing Date in a principal amount not to exceed its 2014 Term A Loan Commitment, (ii) 2014 Term B Lender agrees, severally and not jointly, to make a 2014 Term B Loan to the Lux Borrower on the Closing Date in a principal amount not to
exceed its 2014 Term B Loan Commitment and (iii) 2015 Incremental Term B Lender agrees, severally and not jointly, to make a 2015 Incremental Term B Loan to the Lux Borrower on the First Incremental Amendment Closing Date in a principal amount
not to exceed its 2015 Incremental Term B Loan Commitment.” 
 (ii) by amending and restating the last sentence of the
penultimate paragraph of Section 2.01 as follows: 
 “The full amount of each Class of Term Loan Commitments must
be drawn in a single drawing on the Closing Date (or, with respect to the 2015 Incremental Term B Loan Commitments, on the First Incremental Amendment Closing Date) and amounts repaid or prepaid in respect of Term Loans may not be reborrowed.”

 (d) Section 2.03(a) is hereby amended by inserting the words “or the First Incremental Amendment Closing
Date” after the words “(or, with respect to Borrowings to be made on the Closing Date.” 
 (e)
Section 2.09(a) of the Credit Agreement is hereby amended and restated as follows: 
 “(a) Unless previously
terminated, (i) the Revolving Commitment of each Revolving Lender shall automatically and permanently terminate on the relevant Maturity Date, (ii) the 2014 Term A Loan Commitment and 2014 Term B Loan Commitment of each Term A Lender or
Term B Lender, as applicable, shall automatically and permanently terminate on the Closing Date (after giving effect to the incurrence of such Term Loans on such date) and (iii) the 2015 Incremental Term B Loan Commitment of each applicable
2015 Incremental Term B Lender shall automatically and permanently terminate on the First Incremental Amendment Closing Date (after giving effect to the incurrence of such 2015 Incremental Term B Loans on such date).” 

(f) Section 2.10(c) of the Credit Agreement is hereby amended and restated as follows: 

“(c)(i) Beginning June 30, 2014, the Lux Borrower shall repay principal of outstanding 2014 Term B Loans on each
Scheduled Principal Repayment Date described below in the aggregate principal amount described opposite such Scheduled Principal Repayment Date (as adjusted from time to time pursuant to Sections 2.11(a) and 2.11(d)(i)): 

 

			
	 Scheduled Principal Repayment Dates
	  	 Amount

	Each Scheduled Principal Repayment Date	  	0.25% of the aggregate principal amount of 2014 Term B Loans incurred on the Closing Date
		
	Maturity Date	  	All remaining outstanding principal of 2014 Term B Loans

  
 - 9 - 

 (ii) Beginning on the last day of the first full fiscal quarter after the First
Incremental Amendment Closing Date; provided that such day shall be no earlier than March 31, 2016 to the extent the First Incremental Amendment Closing Date occurs on or after September 1, 2015, the Lux Borrower shall repay
principal of outstanding 2015 Incremental Term B Loans on each Scheduled Principal Repayment Date described below in the aggregate principal amount described opposite such Scheduled Principal Repayment Date (as adjusted from time to time
pursuant to Sections 2.11(a), 2.11(d)(i) and 2.11(e)): 
  

			
	 Scheduled Principal Repayment Dates
	  	 Amount

	Each Scheduled Principal Repayment Date	  	0.25% of the aggregate principal amount of 2015 Incremental Term B Loans incurred on the First Incremental Amendment Closing Date
		
	Maturity Date	  	All remaining outstanding principal of 2015 Incremental Term B Loans

 To the extent not previously repaid, all unpaid 2014 Term B Loans and 2015 Incremental Term B Loans shall be
paid in full in Dollars by the Lux Borrower on the applicable Maturity Date; provided that, to the extent specified in the applicable Extension Offer, amortization payments with respect to Extended Term B Loans for periods prior to the then
current Maturity Date for such Term B Loans may be reduced (but not increased) and amortization payments required with respect to Extended Term B Loans for periods after such applicable Maturity Date shall be as specified in the applicable
Extension Offer.” 
 (g) Section 2.11(a) of the Credit Agreement is hereby amended by inserting the words
“applicable Tranche,” after the words “and shall specify the” in the third sentence thereof. 
 (h)
Section 2.11(c) of the Credit Agreement is hereby amended as follows: 
 (a) by moving “(1)” to the beginning
of Section 2.11(c); 

  
 - 10 - 

 (b) by inserting the words “(in the case of prepayments of 2015 Incremental
Term B Loans only, with a step down to 50% (such step down, the “Asset Sale Step Down”) based upon the achievement and maintenance of a Leverage Ratio of less than or equal to 4.00:1.00)” after the words “equal to
100%” in clause (1) thereof; 
 (c) by inserting “in the event and on each occasion that” after
“(2)”; 
 (d) by replacing “ and” before clause (2) thereof with “,”; and 

(e) by inserting the following at the end of clause (2) thereof: 

“and (3) on each Excess Cash Payment Date the Borrowers shall prepay the Obligations as set forth in Section 2.11(d)(iii) below
in an amount equal to the Applicable Excess Cash Flow Percentage of the Excess Cash Flow for the related Excess Cash Payment Period; provided that repayments of principal of Loans made as a voluntary prepayment pursuant to
Section 2.11(a) (other than with the proceeds of long-term Indebtedness) (but in the case of a voluntary prepayment of Revolving Loans or Swingline Loans, only to the extent accompanied by a voluntary reduction to the Revolving Commitments in
an amount equal to such prepayment) during the applicable Excess Cash Payment Period shall reduce on a dollar-for-dollar basis the amount of such mandatory repayment otherwise required on the applicable Excess Cash Payment Date pursuant to this
clause (3).” 
 (i) Section 2.11(d) of the Credit Agreement is hereby amended and restated as follows: 

“Subject to Sections 2.11(e) and 2.11(f) below, (i) all such amounts pursuant to Section 2.11(c)(1) shall be applied to prepay
(A) if the Asset Sale Step Down does not apply, the outstanding Term A Loans and Term B Loans in the direct order of maturity on pro rata basis and (B) if the Asset Sale Step Down applies (x) with respect to all such amounts equal to
50% of the Net Proceeds, the outstanding Term A Loans and Term B Loans in the direct order of maturity on a pro rata basis and (y) with respect to the remaining Net Proceeds required to be prepaid in accordance with Section 2.11(c)(1), the
outstanding Term A Loans in the direct order of maturity, (ii) all such amounts pursuant to Section 2.11(c)(2) shall be applied to prepay an aggregate principal amount of the applicable Refinanced Debt equal to the Net Proceeds of the
applicable Credit Agreement Refinancing Indebtedness (and to the extent the applicable Refinanced Debt is not repaid in full, such Net Proceeds shall reduce the remaining scheduled principal repayments of such Refinanced Debt on a pro rata basis)
and (iii) all such amounts pursuant to Section 2.11(c)(3) shall be applied to prepay any remaining scheduled principal payments in respect of the Term B Loans on a pro rata basis.” 

  
 - 11 - 

 (j) Section 2.11(f) of the Credit Agreement is hereby amended and restated
as follows: 
 “The Lux Borrower shall notify the Administrative Agent in writing of any mandatory prepayment of Term
Loans required to be made pursuant to Section 2.11(c)(1) or 2.11(c)(3) at least five (5) Business Days prior to the date of such prepayment. Each such notice shall specify the date of such prepayment and provide a reasonably detailed
calculation of the amount of such prepayment. The Administrative Agent will promptly notify each Term Lender of the contents of any such prepayment notice and of such Term Lender’s ratable portion of such prepayment (based on such Lender’s
Applicable Percentage of each relevant Tranche of the Term Loans). Any Term B Lender (a “Declining Term B Lender,” and any Term B Lender which is not a Declining Term B Lender, an “Accepting Term B
Lender”) may elect, by delivering written notice to the Administrative Agent and the Lux Borrower no later than 5:00 p.m. one (1) Business Day after the date of such Term B Lender’s receipt of notice from the Administrative
Agent regarding such prepayment, that the full amount of any mandatory prepayment otherwise required to be made with respect to the Term B Loans held by such Term B Lender pursuant to Section 2.11(c)(1) or 2.11(c)(3) not be made (the
aggregate amount of such prepayments declined by the Declining Term B Lenders, the “Declined Prepayment Amount”). If a Term B Lender fails to deliver notice setting forth such rejection of a prepayment to the Administrative
Agent within the time frame specified above or such notice fails to specify the principal amount of the Term B Loans to be rejected, any such failure will be deemed an acceptance of the total amount of such mandatory prepayment of Term B Loans. In
the event that the Declined Prepayment Amount related to a prepayment under Section 2.11(c)(1) is greater than $0, the Administrative Agent will promptly notify each Term A Lender (unless no Term A Loans remain outstanding) and
Accepting Term B Lender of the amount of such Declined Prepayment Amount and of any such Term A Lender’s and Accepting Term B Lender’s ratable portion of such Declined Prepayment Amount (based on such Lender’s Applicable Percentage in
respect of the Term A Loans and Term B Loans (excluding the Applicable Percentage of Declining Term B Lenders), as applicable). In the event that the Declined Prepayment Amount related to a prepayment under Section 2.11(c)(3) is greater
than $0, the Administrative Agent will promptly notify each Accepting Term B Lender of the amount of such Declined Prepayment Amount and of any such Accepting Term B Lender’s ratable portion of such Declined Prepayment Amount (based on
such Lender’s Applicable Percentage in respect of the Term B Loans (excluding the Applicable Percentage of Declining Term B Lenders), as applicable). Any such Accepting Term B Lender may elect, by delivering, no later than 5:00 p.m. one
(1) Business Day after the date of such Accepting Term B Lender’s receipt of notice from the Administrative Agent regarding such additional prepayment, a written notice, that such Accepting Term B Lender’s ratable portion of such
Declined Prepayment Amount not be applied to repay such Accepting Term B Lender’s Term Loans, in which case the portion of such Declined Prepayment Amount which would otherwise have been applied to such Term Loans of the Declining
Term B Lenders shall instead 

  
 - 12 - 

 
be retained by the Lux Borrower. Each Term A Lender’s ratable portion of such Declined Prepayment Amount related to a prepayment under Section 2.11(c)(1) (if any) and each Term B
Lender’s ratable portion of such Declined Prepayment Amount related to a prepayment under Section 2.11(c)(1) or Section 2.11(c)(3) (unless declined by the respective Term B Lender as described in the preceding sentence) shall be
applied to the respective Term Loans of such Lenders. For the avoidance of doubt, the Borrowers may, at their option, apply any amounts retained in accordance with the immediately preceding sentence to prepay loans in accordance with
Section 2.11(a) above.” 
 (k) Section 2.12 of the Credit Agreement is hereby amended by adding a new clause
(f) as follows: 
 “If any Repricing Event occurs prior to the date occurring six months after the First
Incremental Amendment Closing Date, the Borrowers agree to pay to the Administrative Agent, for the ratable account of each 2015 Incremental Term B Lender with 2015 Incremental Term B Loans that are subject to such Repricing Event (including any
Lender which is replaced pursuant to Section 9.02(e) as a result of its refusal to consent to an amendment giving rise to such Repricing Event), a fee in an amount equal to 1.00% of the aggregate principal amount of the 2015 Incremental Term B
Loans subject to such Repricing Event. Such fees shall be earned, due and payable upon the date of the occurrence of the respective Repricing Event.” 

(l) Section 2.20(c)(vi) of the Credit Agreement is hereby amended and restated as follows: 

“the Effective Yield of any Other Term B Loans may exceed the Effective Yield then applicable to the 2015 Incremental Term
B Loans; provided that the Effective Yield for the 2015 Incremental Term B Loans is increased (to the extent necessary) such that the Effective Yield thereof is not less than the Effective Yield of such Other Term B Loans minus 0.50%.”

 (m) Section 5.09 of the Credit Agreement is hereby amended by adding a new clause (h) as follows: 

“The Irish Holdco will, and will cause each other Loan Party to, take each of the actions set forth on
Schedule 5.09(h) within the time period prescribed therefor on such schedule (as such time period may be extended by the Administrative Agent in its sole discretion exercised reasonably).” 

(n) Schedule 2.01 to the Credit Agreement is hereby amended by inserting thereto the Schedule I attached hereto. 

(o) Schedule 3.01 to the Credit Agreement is hereby amended by inserting thereto the Schedule II attached hereto. 

(p) Schedule 5.09(h) to the Credit Agreement is hereby amended by inserting thereto the Schedule III attached hereto. 

  
 - 13 - 

 Section 3. Existing Term B Loans. Upon effectiveness of this Incremental Amendment,
all 2014 Term B Loans outstanding as of such date are deemed to be repaid and refinanced by the 2015 Incremental Term B Loans. 

Section 4. Conditions to Effectiveness of Amendment. The effectiveness of this Incremental Amendment and the obligations of each
2015 Incremental Term B Lender to make a 2015 Incremental Term B Loan and each 2015 Incremental Revolving Lender to provide its portion of the 2015 Incremental Revolving Commitment is subject to the satisfaction or waiver of the following
conditions: 
 (a) Incremental Amendment. The Administrative Agent shall have received this Incremental Amendment
executed and delivered by a duly authorized officer of each Borrower, each 2015 Incremental Term B Lender and each 2015 Incremental Revolving Lender. 

(b) Collateral Documents. The Collateral Agent shall have received a supplement to the U.S. Security Agreement in
substantially the form of Annex I thereto (other than as required to comply with local laws in accordance with the Agreed Security Principles, if applicable), a Luxembourg law governed master security confirmation made between, inter alios,
the Pledgors (as defined therein), the Administrative Agent as collateral agent and in the presence of the Companies (as defined therein), in respect of the Luxembourg law governed Collateral Documents, and a supplement to the Subsidiary Guaranty in
substantially the form of Annex I thereto (other than as required to comply with local laws in accordance with the Agreed Security Principles, if applicable). 

(c) Legal Opinions. The Administrative Agent shall have received the following executed legal opinions: 

(i) a customary legal opinion of Skadden, Arps, Slate, Meagher & Flom LLP, special New York counsel to each of the
Borrowers and the other Loan Parties; 
 (ii) customary legal opinions of (A) Elvinger, Hoss and Prussen, special
Luxembourg counsel to the Lux Borrower and the Loan Parties and (B) Nauta Dutilh Avocats Luxembourg, Luxembourg counsel to the Administrative Agent, the 2015 Lead Arrangers, the 2015 Incremental Term B Lenders and the 2015 Incremental Revolving
Lenders; 
 (iii) a customary legal opinion of A&L Goodbody, special Irish counsel to the Loan Parties; 

  
 - 14 - 

 (iv) customary legal opinions of (A) Torys LLP, special Canadian Ontario
counsel to the Loan Parties and (B) Lavery de Billy LLP, Quebec counsel to the Loan Parties; and 
 (v) such other
customary legal opinions of special counsel as agreed between the Loan Parties and the Administrative Agent. 
 (d)
Acquisition. Concurrently with the initial funding of the 2015 Incremental Term B Loans, the Par Acquisition shall have been consummated in accordance, in all material respects, with the terms and conditions of the Par Acquisition
Agreement. The Par Acquisition Agreement shall not have been altered, amended or otherwise changed or supplemented or any provision or condition therein waived by Parent, and neither the Parent nor any affiliate thereof shall have consented to
any action which would require the consent of the Parent or such affiliate under the Acquisition Agreement, if such alteration, amendment, change, supplement, waiver or consent would be adverse to the interests of the 2015 Lead Arrangers or the
Lenders party to this Incremental Amendment in any material respect, in any such case without the prior written consent of the 2015 Lead Arrangers (such consent not to be unreasonably withheld) (it being understood and agreed that any alteration,
supplement, amendment, modification, waiver or consent that (a) decreases the purchase price in respect of the Par Acquisition by 10% or more other than purchase price adjustments pursuant to the express terms of the Par Acquisition Agreement
shall be deemed to be adverse to the interests of the Lenders party hereto in a material respect, (b) increases the purchase price in respect of the Par Acquisition shall not be deemed to be adverse to the interests of the Lenders party hereto
so long as such increase is funded solely by the issuance of common equity of the Parent or cash on hand of the Parent and its subsidiaries and (c) modifies the so-called “Xerox” provisions of the Par Acquisition Agreement providing
protection with respect to exclusive jurisdiction, waiver of jury trial, liability caps, restrictions on certain amendments, and third party beneficiary status for the benefit of the Administrative Agent, the 2015 Lead Arrangers, the Lenders party
hereto and their respective affiliates shall be deemed to be adverse to the interests of the Lenders party hereto in a material respect). 

(e) No Target Material Adverse Effect. (i) since December 31, 2014 to May 18, 2015, except as set forth
in the disclosure schedule to the Par Acquisition Agreement delivered by Par to the Parent and dated as of the date of the Par Acquisition Agreement, there has not been any event or occurrence of any condition that, individually or in the aggregate,
has had a Target Material Adverse Effect and (ii) on the First Incremental Amendment Closing Date there is no Target Material Adverse Effect. 

For purposes hereof, “Target Material Adverse Effect” means (with capitalized terms used in this definition and not otherwise
defined herein having the meanings assigned thereto in the Par Acquisition Agreement) any change, effect, event, occurrence, state of facts, circumstance or development that, individually or in the aggregate with all other changes, effects, events,
occurrences, state of facts, circumstances or developments, (i) is or would reasonably be expected to be materially adverse to the business, properties, assets, liabilities (contingent or otherwise), condition (financial or otherwise) or
results of operations of the Par and its Subsidiaries, taken as a whole, or (ii) would reasonably be expected to prevent the 

  
 - 15 - 

 
consummation by the Par of the Transactions (as defined in the Par Acquisition Agreement); provided, however, that none of the following shall constitute, or be taken into account in
determining whether there has been or would reasonably be expected to be, a Target Material Adverse Effect: (A) any change relating to the economy or securities markets in general, (B) any adverse change, effect, event, occurrence, state
of facts, condition, circumstance or development affecting the generic pharmaceutical industry; (C) acts of war (whether or not declared), armed hostilities, sabotage, military actions or the escalation thereof (whether underway on the date
hereof or hereafter commenced), and terrorism; (D) changes in or the conditions of financial or banking markets (including any disruption thereof and any decline in the price of any security or any market index); (E) changes in GAAP (or
any underlying accounting principles or the interpretation of any of the foregoing) after the date hereof; (F) a flood, hurricane or other natural disaster; (G) any failure by Par to meet any internal or published projections, forecasts or
revenue or earnings predictions for any period ending on or after the date of this Agreement (provided, however, that the underlying causes of any such failure may be considered in determining whether there is a Target Material Adverse Effect);
(H) changes in any Laws; (I) any action taken or omitted to be taken by, or at the written request of, Parent or any of its Affiliates after the date hereof and on or prior to the Closing Date; and (J) any action taken by Par or any
of its Subsidiaries as required by this Agreement (other than any action required to be taken by Par or any of its Subsidiaries to comply with Section 6.1 of the Par Acquisition Agreement); except, in the case of clauses (A)-(F) and
(H) above, to the extent that such change, effect, event, occurrence, state of facts, circumstance or development disproportionately affects the business, properties or assets of Par as compared to other participants operating in the generic
pharmaceutical industry, in which case, such change, effect, event, occurrence, state of facts, circumstance or development may constitute a Target Material Adverse Effect to such extent, and may be taken into account to such extent, in determining
whether a Target Material Adverse Effect has occurred or would reasonably be expected to occur. 
 (f) Closing
Certificate. The 2015 Lead Arrangers shall have received a certificate from the Lux Borrower, dated the First Incremental Amendment Closing Date, substantially in the form of Exhibit A hereto, with appropriate insertions and attachments.

 (g) Existing Indebtedness. The Par Refinancing shall have been consummated substantially concurrently with the Par
Acquisition and the 2014 Term B Loans outstanding as of the First Incremental Amendment Closing Date shall have been repaid and refinanced in full substantially concurrently with the funding of the 2015 Incremental Term B Loans. 

(h) Corporate Proceedings, Governing Documents and Incumbency of the Loan Parties. The 2015 Lead Arrangers shall have
received (i) a copy of the certificate or articles of incorporation or other formation documents, including all amendments thereto, of each Loan Party as of the First Incremental Amendment Closing Date, certified (to the extent available in any
non-U.S. jurisdiction, provided that no such certification shall be required to the extent the applicable Loan Party is formed or incorporated in Canada) as of a recent date by the Secretary of State of the state of its organization (or similar
Governmental Authority in any foreign jurisdiction with respect to any such Loan Party organized outside the United States of America) or, in the case of any such Loan Party incorporated in Luxembourg, pursuant to the

  
 - 16 - 

 
terms set forth in clause (E) below, and (to the extent available in a non-U.S. jurisdiction) a certificate as to the good standing of each such Loan Party as of a recent date, from such
Secretary of State (or similar Governmental Authority in any foreign jurisdiction (to the extent available in that foreign jurisdiction) with respect to any Loan Party organized outside the United States of America (including, in the case of any
Loan Party organized in the Republic of Ireland, a certificate of status from the Irish Companies Registration Office)); (ii) a certificate of the secretary or assistant secretary of each Loan Party as of the First Incremental Amendment Closing
Date (or of a manager or director, in the case of any such Loan Party incorporated in Luxembourg or the Republic of Ireland) dated the First Incremental Amendment Closing Date and certifying (A) that attached thereto is a true and complete copy
of the by-laws (or similar governing documentation) of such Loan Party as in effect on the First Incremental Amendment Closing Date and at all times since a date prior to the date of the resolutions described in clause (B) below, (B) that
attached thereto is a true and complete copy of resolutions duly adopted by the board of directors or similar governing body of such Loan Party authorizing the transactions contemplated by this Incremental Amendment, (in the case of each Borrower)
the borrowings hereunder, (in the case of each such Loan Party) the granting of the Liens contemplated to be granted by it under the Collateral Documents and (in the case of each Guarantor) the guaranteeing of the Secured Obligations as contemplated
by the Loan Documents, and that such resolutions have not been modified, rescinded or amended and are in full force and effect, (C) if applicable, that the certificate or articles of incorporation or other formation documents of such Loan Party
have not been amended since the date of the last amendment thereto shown on the certificate of good standing furnished pursuant to clause (i) above or where a certificate of good standing is not applicable in its jurisdiction of incorporation
that attach a true, up to date and correct copy of the certificate or articles of incorporation or other formation documents of each Loan Party duly certified as being true, up to date and correct, (D) as to the incumbency and specimen
signature of each officer executing any Loan Document or any other document delivered in connection herewith on behalf of such Loan Party; and (iii) a certificate of another officer as to the incumbency and specimen signature of the secretary
or assistant secretary (or manager or director, if applicable) executing the certificate pursuant to (ii) above and (E) for the Lux Borrower, Lux Holdco, New Luxco 1, New Luxco 2 and Lux Sub Finco, (i) an electronic certified excerpt
of the RCS dated on the First Incremental Amendment Closing Date or at the earliest one Business Day before the First Incremental Amendment Closing Date and (ii) a certified true certificate of non-registration of judgments (certificat de
non-inscription de décision judiciaire) dated on the First Incremental Amendment Closing Date or at the earliest one Business Day before the First Incremental Amendment Closing Date, issued by the RCS. 

(i) Financial Statements. The 2015 Lead Arrangers shall have received (1) audited consolidated balance sheets and
related statements of income and cash flows of each of the Parent and Par for the most recent three fiscal years ended at least 90 days prior to the First Incremental Amendment Closing Date (other than the Par’s balance sheet for the 2012
fiscal year), (2) unaudited consolidated balance sheets and related statements of income and cash flows of each of the Parent and Par for each fiscal quarter ended after the close of its most recent fiscal year and at least 45 days prior to the
Closing Date and (3) pro forma consolidated financial statements (including a consolidated balance sheet and related statements of income 

  
 - 17 - 

 
and cash flow) of the Parent and its subsidiaries (including the Parent and Par) meeting the requirements of Regulation S-X for registration statements (as if such a registration statement for a
debt issuance of the Parent became effective on the First Incremental Amendment Closing Date) on Form S-1 (subject to exceptions customary for a Rule 144A offering involving high yield debt securities) and a pro forma consolidated
statement of income of the Parent (subject to exceptions customary for a Rule 144A offering involving high yield debt securities) for the twelve-month period ending on the last day of the most recently completed four fiscal quarter period ended at
least 45 days before the First Incremental Amendment Closing Date, prepared after giving effect to the Par Transactions as if the Par Transactions had occurred at the beginning of such period. The 2015 Lead Arrangers hereby acknowledge receipt of
(x) the audited financial statements referred to in clause (1) above of each of the Parent and Par as of, and for the years ended, December 31, 2012, 2013 and 2014 and (y) the unaudited consolidated balance sheets and related
statements of income and cash flows referred to in clause (2) above of each of the Parent and Par as of March 31, 2015. For the avoidance of doubt, references to “Par” in this clause (i) includes its predecessors. 

(j) Specified Representations. The Specified Representations shall be true and correct in all material respects other
than where such representation is already qualified by materiality, in which case they shall be true and correct in all respects (except in the case of any Specified Representation which expressly relates to a given date or period, such
representation and warranty shall be true and correct in all material respects (or true and correct in all respects) as of the respective date or for the respective period, as the case may be); provided, that to the extent that any Specified
Representation is qualified by or subject to a “material adverse effect”, “material adverse change” or similar term or qualification, (a) the definition thereof for purposes of Par and its subsidiaries shall be the
definition of Target Material Adverse Effect for purposes of the making or deemed making of such Specified Representation on, or as of, the Closing Date (or any date prior thereto). 

For purposes hereof, “Specified Representations” means the representations and warranties of the Borrowers and
Guarantors set forth in Sections 5(a)(i), (b), (c), (d), (e), (f), (g), (h) and (i) of this Incremental Amendment. 
 (k)
Par Acquisition Agreement Representations. The Par Acquisition Agreement Representations shall be true and correct. 
 For purposes
hereof, “Par Acquisition Agreement Representations” means the representations made by Par and its subsidiaries in the Acquisition Agreement as are material to the interests of the Lenders party to this Incremental Amendment, but
only to the extent that the Irish Holdco (or the Irish Holdco’s affiliate) has the right to terminate its (or its affiliate’s) obligations (or to refuse to consummate the Par Acquisition) under the Par Acquisition Agreement as a result of
a breach of such representations. 
 (l) Borrowing Notice. The Administrative Agent shall have received a customary Notice of
Borrowing as required by Section 2.03 of the Credit Agreement (or such notice shall have been deemed given in accordance with such Section 2.03). 

  
 - 18 - 

 (m) Fees. To the extent invoiced with reasonable detail at least two business days prior
to the First Incremental Amendment Closing Date, the Administrative Agent, the 2015 Lead Arrangers and the Lenders party hereto shall have received all costs, fees and expenses (including, without limitation, legal fees and expenses) and other
compensation as otherwise agreed, in each case, payable to them on or prior to the First Incremental Amendment Closing Date. 
 (n)
Solvency. The 2015 Lead Arrangers shall have received a certificate of the chief financial officer (or manager or director) of the Lux Borrower certifying the solvency, as of the First Incremental Amendment Closing Date after giving pro forma
effect to the Par Transactions on such date, of the Lux Borrower and its Subsidiaries on a consolidated basis, substantially in the form of Exhibit B hereto. 

(o) PATRIOT Act and Anti-Money Laundering. The Lenders party hereto shall have received at least 3 business days prior to the First
Incremental Amendment Closing Date all documentation and other information required by regulatory authorities with respect to the Loan Parties and the parent companies of the Loan Parties under applicable “know your customer” and
anti-money laundering rules and regulations, including without limitation the PATRIOT Act to the extent requested in writing at least 10 days prior to the First Incremental Amendment Closing Date. 

For the avoidance of doubt, each 2015 Incremental Term B Lender acknowledges and agrees that the making of a 2015 Incremental Term B Loan
shall not be subject to the conditions set forth in Section 4.02 of the Credit Agreement. Pursuant to Section 2.20(e) of the Credit Agreement, the Administrative Agent shall give prompt notice in writing to the Lenders of the occurrence of
the First Incremental Amendment Closing Date. Each Lender party hereto hereby authorizes the Administrative Agent to provide such notice and agrees that such notice shall be irrevocably conclusive and binding upon such Lender. 

Notwithstanding the foregoing, (a) to the extent a security interest in any Collateral that is being acquired as part of the Par
Acquisition (including the creation or perfection of any security interest that is being acquired as part of the Par Acquisition) may not be perfected by (A) the filing of a UCC or PPSA (or equivalent statute in the applicable Canadian
provinces) financing statement, or (B) taking delivery and possession of a stock certificate of Par and its material wholly-owned domestic (or Canadian) restricted subsidiaries which will be required to be delivered on the First Incremental
Amendment Closing Date only to the extent received from Par after Irish Holdco’s use of commercially reasonable efforts to do so), then the perfection of the security interest in such Collateral shall not constitute a condition precedent to the
availability of the 2015 Incremental Revolving Commitments and the 2015 Incremental Term B Loans on the First Incremental Amendment Closing Date but, instead, may be accomplished within the time set forth in Schedule III or such longer period as may
be approved by the Administrative Agent acting reasonably and (b) nothing in the preceding clause (a) shall be construed to limit the applicability of the individual conditions expressly set forth in Section 4 herein. 

Section 5. Representations and Warranties. To induce the other parties hereto to enter into this Incremental Amendment and each
2015 Incremental Term B Lender to make a 

  
 - 19 - 

 
2015 Incremental Term B Loan and each 2015 Incremental Revolving Lender to provide its portion of the 2015 Incremental Revolving Commitment, each Loan Party hereby represents and warrants, on the
First Incremental Amendment Closing Date, to the Administrative Agent and each 2015 Incremental Term B Lender that: 
 (a)
Each Loan Party (i) is duly organized, incorporated (in the case of the Parent, Irish Holdco, Irish Sub Holdco and Irish Sub Finco) and validly existing, (ii) is (to the extent the concept is applicable in such jurisdiction) in good
standing under the laws of the jurisdiction of its organization, (iii) has all requisite power and authority to carry on its business as now conducted and (iv) except where the failure to do so, individually or in the aggregate, could not
reasonably be expected to result in a Material Adverse Effect, is qualified to do business in, and (to the extent the concept is applicable in such jurisdiction) is in good standing in, every jurisdiction where such qualification is required; 

(b) The performance by the Loan Parties of their obligations under this Incremental Amendment, the Credit Agreement as amended
hereby, any other Loan Documents delivered pursuant to the Incremental Amendment on the date hereof (including any additional guarantee and collateral documents) (collectively, with the Incremental Amendment, the “2015 Incremental
Documents”), and each other Loan Document as amended or supplemented by such 2015 Incremental Documents to the extent applicable, are within each Loan Party’s corporate or other organizational powers and have been duly authorized by
all necessary corporate or other organizational actions and, if required, actions by shareholders, members or equity holders. The 2015 Incremental Documents to which each Loan Party is a party have been duly executed and delivered by such Loan Party
and constitute a legal, valid and binding obligation of such Loan Party, enforceable in accordance with its terms, subject to applicable bankruptcy, insolvency, reorganization, moratorium or other laws affecting creditors’ rights generally and
subject to general principles of equity, regardless of whether considered in a proceeding in equity or at law; 
 (c) The
performance by the Loan Parties of their obligations under this Incremental Amendment, the Credit Agreement as amended hereby, the 2015 Incremental Documents and each other Loan Document as amended or supplemented by such 2015 Incremental Document
to the extent applicable will not violate the charter, by-laws or other organizational documents of any Loan Party; 
 (d) No
Loan Party is an “investment company” as defined in, or subject to regulation under, the Investment Company Act of 1940; 

(e) No part of the proceeds of any Loan made pursuant to the 2015 Incremental Revolving Commitments or the 2015 Incremental
Term B Loans have been used or will be used, whether directly or indirectly, for any purpose that entails a violation of any of the Regulations of the Board, including Regulations T, U and X; 

  
 - 20 - 

 (f) Subject to the last paragraph of Section 4 hereto, the Loan Documents
create in favor of the Collateral Agent, for the benefit of the Secured Parties, a valid and enforceable security interest in the Collateral covered thereby and (i) when the Collateral constituting certificated securities (as defined in the UCC
or the PPSA, as applicable) is delivered to the Collateral Agent, together with instruments of transfer duly endorsed in blank, the Liens under such Loan Document will constitute a fully perfected security interest in all right, title and interest
of the pledgors thereunder in such Collateral, prior and superior in right to any other Person, and (ii) when financing statements in appropriate form are filed in the applicable filing offices, the security interest created under such Loan
Document will constitute a fully perfected security interest in all right, title and interest of the Loan Parties in the remaining Collateral to the extent perfection can be obtained by filing UCC or PPSA, as applicable, financing statements, prior
and superior to the rights of any other Person, except for (x) Liens permitted by Section 6.02 of the Credit Agreement and (y) any requirement under Luxembourg law, including the foreign lex rei sitae, referred to under
Luxembourg international private law, with respect to any Collateral which (1) under Luxembourg law, would be located or deemed located in Luxembourg or (2) would be granted by the Lux Borrower; 

(g) Immediately after the consummation of the Par Transactions (a) the fair value of the assets of the Irish Holdco and
its Restricted Subsidiaries on a consolidated basis will exceed their consolidated debts and liabilities, subordinated, contingent or otherwise; (b) the present fair saleable value of the property of the Irish Holdco and its Restricted
Subsidiaries on a consolidated basis will be greater than the amount that will be required to pay the probable liability on their debts and other liabilities, subordinated, contingent or otherwise, as such debts and other liabilities become absolute
and matured; (c) the Irish Holdco and its Restricted Subsidiaries on a consolidated basis will not have incurred any debts and liabilities, subordinated, contingent or otherwise, that they do not believe that they will be able to pay as such
debts and liabilities become absolute and matured; and (d) the Irish Holdco and its Restricted Subsidiaries on a consolidated basis will not have unreasonably small capital with which to conduct the business in which they are engaged as such
business is now conducted and is proposed to be conducted following the First Incremental Amendment Closing Date; 
 (h) No
Borrower will directly or indirectly use the proceeds of the Loans made pursuant to the 2015 Incremental Revolving Commitments or the 2015 Incremental Term B Loans or otherwise make available such proceeds to any Person who is a Prohibited Person, a
Sanctioned Person or an Embargoed Person; 
 (i) No part of the proceeds of any of the Loans made pursuant to the 2015
Incremental Revolving Commitments or the 2015 Incremental Term B Loans will be used, directly or indirectly, for any payments to any governmental official or employee, political party, official of a political party, candidate for political office,
or anyone else acting in an official capacity, in order to obtain, retain or direct business or obtain any improper advantage, in violation of the U.S. Foreign Corrupt Practices Act of 1977; and 

(j) For the period of time from June 12, 2015 until the First Incremental Amendment Closing Date, the terms of the Credit
Agreement have not been amended or changed in a manner materially adverse to the 2015 Incremental Revolving Lenders or the 2015 Incremental Term B Lenders without the prior written consent of the Lead Arrangers. 

  
 - 21 - 

 Section 6. Effects on Loan Documents; Acknowledgement. 

(a) Except as expressly set forth herein, (i) this Incremental Amendment shall not by implication or otherwise limit,
impair, constitute a waiver of or otherwise affect the rights and remedies of the Lenders, the Administrative Agent, the Collateral Agent or the Loan Parties under the Credit Agreement or any other Loan Document, and (ii) shall not alter,
modify, amend or in any way affect any of the terms, conditions, obligations, covenants or agreements contained in the Credit Agreement or any other provision of the Credit Agreement or any other Loan Document. Each and every term, condition,
obligation, covenant and agreement contained in the Credit Agreement or any other Loan Document is hereby ratified and re-affirmed in all respects and shall continue in full force and effect and nothing herein can or may be construed as a novation
thereof. Each Loan Party reaffirms its obligations under the Loan Documents to which it is party and the validity, enforceability and perfection of the Liens granted by it pursuant to the Collateral Documents on the First Incremental Amendment
Closing Date. This Incremental Amendment shall constitute a Loan Document for purposes of the Credit Agreement and from and after the First Incremental Amendment Closing Date, all references to the Credit Agreement in any Loan Document and all
references in the Credit Agreement to “this Agreement”, “hereunder”, “hereof” or words of like import referring to the Credit Agreement, shall, unless expressly provided otherwise, refer to the Credit Agreement as
amended by this Incremental Amendment. Each of the Loan Parties hereby consents to this Incremental Amendment and confirms that all obligations of such Loan Party under the Loan Documents to which such Loan Party is a party shall continue to apply
to the Credit Agreement, as amended hereby. 
 (b) Without limiting the foregoing, each of the Loan Parties hereby
(i) acknowledges and agrees that the 2015 Incremental Term B Loans are Loans and the 2015 Incremental Term B Lenders are Lenders and Incremental Revolving Lenders, (ii) acknowledges and agrees that (A) the Loans made pursuant to the
2015 Incremental Revolving Commitments are Revolving Loans, (B) the 2015 Incremental Revolving Lenders are Lenders and (C) the 2015 Incremental Revolving Commitments are Revolving Commitments, (iii) acknowledges and agrees that all of
its obligations under the Credit Agreement, the U.S. Security Agreement, the Subsidiary Guaranty and the other Collateral Documents to which it is a party are reaffirmed and remain in full force and effect on a continuous basis, (iv) reaffirms
each Lien granted by each Loan Party to the Collateral Agent for the benefit of the Secured Parties (including the 2015 Incremental Term B Lenders and the 2015 Incremental Revolving Lenders) and reaffirms the guaranties made pursuant to the Credit
Agreement and the Subsidiary Guaranty, as applicable, (v) acknowledges and agrees that the grants of security interests by and the guaranties of the Loan Parties contained in the U.S. Security Agreement and the other Collateral Documents are,
and shall remain, in full force and effect after giving effect to this 

  
 - 22 - 

 
Incremental Amendment, and (vi) agrees that the Secured Obligations include, among other things and without limitation, the prompt and complete payment and performance by the Borrowers when
due and payable (whether at the stated maturity, by acceleration or otherwise) of principal and interest on each of the 2015 Incremental Term B Loans and the 2015 Incremental Revolving Commitment. 

(c) Each 2015 Incremental Term B Lender and 2015 Incremental Revolving Lender, by delivering its signature page to this
Incremental Amendment on or prior to the First Incremental Amendment Closing Date, shall be deemed to have acknowledged receipt of, and consented to and approved, each Loan Document and each other document required to be delivered to, or be approved
by or satisfactory to, the Administrative Agent or any Lender on or prior to the First Incremental Amendment Closing Date. 

Section 7. Expenses. The Borrowers and the other Loan Parties agree to pay or reimburse the 2015 Lead Arrangers for all reasonable
and documented out-of-pocket costs and expenses incurred in connection with this Incremental Amendment, any other documents prepared in connection herewith and the transactions contemplated hereby, including the reasonable fees, charges and
disbursements of Latham & Watkins LLP, as counsel to the 2015 Lead Arrangers. 
 Section 8. Counterparts. This
Incremental Amendment may be executed in any number of counterparts and by different parties hereto on separate counterparts, each of which when so executed and delivered shall be deemed to be an original, but all of which when taken together shall
constitute a single instrument. Delivery of an executed counterpart of a signature page of this Incremental Amendment by facsimile or any other electronic transmission shall be effective as delivery of a manually executed counterpart hereof. 

Section 9. Applicable Law. THIS INCREMENTAL AMENDMENT AND THE RIGHTS AND OBLIGATIONS OF THE PARTIES HEREUNDER SHALL BE GOVERNED
BY, AND CONSTRUED IN ACCORDANCE WITH, THE LAW OF THE STATE OF NEW YORK; provided, however, that (a) the interpretation of the definition of Target Material Adverse Effect and whether there shall have occurred a Target
Material Adverse Effect, including for purposes of Section 4 hereof, (b) whether the Acquisition has been consummated as contemplated by the Par Acquisition Agreement and (c) the determination of whether the Par Acquisition Agreement
Representations are accurate and whether as a result of any inaccuracy of any such representations Irish Holdco (or its affiliates) has the right to terminate its (or their) obligations, or has the right not to consummate the Par Acquisition, under
the Par Acquisition Agreement, shall be governed by, and construed in accordance with, the domestic laws of the State of Delaware without regard to the principles of conflicts of law. 

Section 10. Headings. The headings of this Incremental Amendment are for purposes of reference only and shall not limit or
otherwise affect the meaning hereof. 
 [Remainder of page intentionally left blank.] 

  
 - 23 - 

 IN WITNESS WHEREOF, the parties hereto have caused this Incremental Amendment to be executed and
delivered by their respective duly authorized officers as of the date first above written. 
  

					
	ENDO LUXEMBOURG FINANCE COMPANY I S.À R.L.
		
	By:	 	 /s/ Orla Dunlea

		 	Name:	 	Orla Dunlea
		 	Title:	 	Manager A
	
	ENDO LLC
		
	By:	 	 /s/ Deanna Voss

		 	Name:	 	Deanna Voss
		 	Title:	 	Assistant Secretary

 
					
	Acknowledged and Agreed:
	
	ENDO DESIGNATED ACTIVITY COMPANY
		
	By:	 	 /s/ Orla Dunlea

		 	Name:	 	Orla Dunlea
		 	Title:	 	Director
	
	ENDO VENTURES LIMITED
		
	By:	 	 /s/ John Boyle

		 	Name:	 	John Boyle
		 	Title:	 	Director
	
	ENDO MANAGEMENT LIMITED
		
	By:	 	 /s/ John Boyle

		 	Name:	 	John Boyle
		 	Title:	 	Director
	
	ENDO FINANCE LIMITED
		
	By:	 	 /s/ Orla Dunlea

		 	Name:	 	Orla Dunlea
		 	Title:	 	Director

 
					
	ENDO FINANCE II LIMITED
		
	By:	 	 /s/ Orla Dunlea

		 	Name:	 	Orla Dunlea
		 	Title:	 	Director
	
	HAWK ACQUISITION IRELAND LIMITED
		
	By:	 	 /s/ Orla Dunlea

		 	Name:	 	Orla Dunlea
		 	Title:	 	Director
	
	ENDO TOPFIN LIMITED
		
	By:	 	 /s/ Orla Dunlea

		 	Name:	 	Orla Dunlea
		 	Title:	 	Director
	
	ENDO IRELAND FINANCE LIMITED
		
	By:	 	 /s/ John Boyle

		 	Name:	 	John Boyle
		 	Title:	 	Director
	
	ENDO FINANCE III LIMITED
		
	By:	 	 /s/ John Boyle

		 	Name:	 	John Boyle
		 	Title:	 	Director

 
					
	ENDO LUXEMBOURG HOLDING COMPANY S.À R.L
		
	By:	 	 /s/ Orla Dunlea

		 	Name:	 	Orla Dunlea
		 	Title:	 	Manager A
	
	ENDO LUXEMBOURG FINANCE COMPANY II S.À R.L.
		
	By:	 	 /s/ Orla Dunlea

		 	Name:	 	Orla Dunlea
		 	Title:	 	Manager A
	
	ENDO US HOLDINGS LUXEMBOURG I S.À R.L.

		
	By:	 	 /s/ Orla Dunlea

		 	Name:	 	Orla Dunlea
		 	Title:	 	Manager A
	
	ENDO US HOLDINGS LUXEMBOURG II S.À R.L.

		
	By:	 	 /s/ Orla Dunlea

		 	Name:	 	Orla Dunlea
		 	Title:	 	Manager A

 
							
	ENDO FINCO INC.
			
		 	By:	 	 /s/ Deanna Voss

		 		 	Name:	 	Deanna Voss
		 		 	Title:	 	Secretary
	
	ENDO U.S. INC.
			
		 	By:	 	 /s/ Deanna Voss

		 		 	Name:	 	Deanna Voss
		 		 	Title:	 	Secretary
	
	ENDO HEALTH SOLUTIONS INC.
			
		 	By:	 	 /s/ Deanna Voss

		 		 	Name:	 	Deanna Voss
		 		 	Title:	 	Assistant Secretary
	
	ENDO PHARMACEUTICALS INC.
			
		 	By:	 	 /s/ Deanna Voss

		 		 	Name:	 	Deanna Voss
		 		 	Title:	 	Assistant Secretary
	
	ENDO PHARMACEUTICALS SOLUTIONS INC.
			
		 	By:	 	 /s/ Deanna Voss

		 		 	Name:	 	Deanna Voss
		 		 	Title:	 	Assistant Secretary

 
							
	ENDO PHARMACEUTICALS VALERA INC.
			
		 	By:	 	 /s/ Deanna Voss

		 		 	Name:	 	Deanna Voss
		 		 	Title:	 	Assistant Secretary
	
	LEDGEMONT ROYALTY SUB LLC
		
		 	By: ENDO PHARMACEUTICALS SOLUTIONS INC., its manager
		 	
		 	By:	 	 /s/ Deanna Voss

		 		 	Name:	 	Deanna Voss
		 		 	Title:	 	Assistant Secretary
	
	GENERICS INTERNATIONAL (US PARENT), INC.
			
		 	By:	 	 /s/ Deanna Voss

		 		 	Name:	 	Deanna Voss
		 		 	Title:	 	Assistant Secretary
	
	GENERICS INTERNATIONAL (US MIDCO), INC.
			
		 	By:	 	 /s/ Deanna Voss

		 		 	Name:	 	Deanna Voss
		 		 	Title:	 	Assistant Secretary
	
	GENERICS INTERNATIONAL (US HOLDCO), INC.
			
		 	By:	 	 /s/ Deanna Voss

		 		 	Name:	 	Deanna Voss
		 		 	Title:	 	Assistant Secretary

 
							
	GENERICS INTERNATIONAL (US), INC.
			
		 	By:	 	 /s/ Deanna Voss

		 		 	Name:	 	Deanna Voss
		 		 	Title:	 	Assistant Secretary
	
	GENERICS BIDCO I, LLC
			
		 	By: 	 	GENERICS INTERNATIONAL (US), INC., its manager
			
		 	By:	 	 /s/ Deanna Voss

		 		 	Name:	 	Deanna Voss
		 		 	Title:	 	Assistant Secretary
	
	VINTAGE PHARMACEUTICALS, LLC
			
		 	By:	 	GENERICS INTERNATIONAL (US), INC., its manager
			
		 	By:	 	 /s/ Deanna Voss

		 		 	Name:	 	Deanna Voss
		 		 	Title:	 	Assistant Secretary
	
	GENERICS BIDCO II, LLC
			
		 	By:	 	GENERICS INTERNATIONAL (US), INC., its manager
			
		 	By:	 	 /s/ Deanna Voss

		 		 	Name:	 	Deanna Voss
		 		 	Title:	 	Assistant Secretary

 
							
	MOORES MILL PROPERTIES L.L.C.
			
		 	By:	 	GENERICS INTERNATIONAL (US), INC., its manager
			
		 	By:	 	 /s/ Deanna Voss

		 		 	Name:	 	Deanna Voss
		 		 	Title:	 	Assistant Secretary
	
	WOOD PARK PROPERTIES LLC
			
		 	By:	 	GENERICS INTERNATIONAL (US), INC., its manager
			
		 	By:	 	 /s/ Deanna Voss

		 		 	Name:	 	Deanna Voss
		 		 	Title:	 	Assistant Secretary
	
	QUARTZ SPECIALTY PHARMACEUTICALS, LLC
			
		 	By:	 	GENERICS INTERNATIONAL (US), INC., its manager
			
		 	By:	 	 /s/ Deanna Voss

		 		 	Name:	 	Deanna Voss
		 		 	Title:	 	Assistant Secretary

 
							
	AMERICAN MEDICAL SYSTEMS HOLDINGS, INC.
			
		 	By:	 	 /s/ Deanna Voss

		 		 	Name:	 	Deanna Voss
		 		 	Title:	 	Assistant Secretary
	
	APHRODITE WOMEN’S HEALTH, LLC
			
		 	By:	 	AMERICAN MEDICAL SYSTEMS HOLDINGS, INC., its manager
			
		 	By:	 	 /s/ Deanna Voss

		 		 	Name:	 	Deanna Voss
		 		 	Title:	 	Assistant Secretary
	
	DAVA PHARMACEUTICALS, INC.
			
		 	By:	 	 /s/ Deanna Voss

		 		 	Name:	 	Deanna Voss
		 		 	Title:	 	Assistant Secretary
	
	DAVA INTERNATIONAL, LLC
			
		 	By:	 	DAVA PHARMACEUTICALS, INC., its manager
			
		 	By:	 	 /s/ Deanna Voss

		 		 	Name:	 	Deanna Voss
		 		 	Title:	 	Assistant Secretary

 
							
	DAVA CAPITAL MANAGEMENT, INC.
			
		 	By:	 	 /s/ Deanna Voss

		 		 	Name:	 	Deanna Voss
		 		 	Title:	 	Assistant Secretary
	
	AUXILIUM PHARMACEUTICALS, INC.
			
		 	By:	 	 /s/ Deanna Voss

		 		 	Name:	 	Deanna Voss
		 		 	Title:	 	Assistant Secretary
	
	SLATE PHARMACEUTICALS, INC.
			
		 	By:	 	 /s/ Deanna Voss

		 		 	Name:	 	Deanna Voss
		 		 	Title:	 	Assistant Secretary
	
	AUXILIUM INTERNATIONAL HOLDINGS, INC.
			
		 	By:	 	 /s/ Deanna Voss

		 		 	Name:	 	Deanna Voss
		 		 	Title:	 	Assistant Secretary
	
	TIMM MEDICAL TECHNOLOGIES, INC.
			
		 	By:	 	 /s/ Deanna Voss

		 		 	Name:	 	Deanna Voss
		 		 	Title:	 	Assistant Secretary

 
							
	ACTIENT PHARMACEUTICALS LLC
			
		 	By:	 	AUXILIUM PHARMACEUTICALS, INC., its manager
			
		 	By:	 	 /s/ Deanna Voss

		 		 	Name:	 	Deanna Voss
		 		 	Title:	 	Assistant Secretary
	
	ACTIENT THERAPEUTICS LLC
			
		 	By:	 	 /s/ Deanna Voss

		 		 	Name:	 	Deanna Voss
		 		 	Title:	 	Assistant Secretary

  

									
	
	TIMM MEDICAL HOLDINGS, LLC
			
		 	By:	 	ACTIENT PHARMACEUTICALS LLC, its manager
				
		 		 	    By:	 	AUXILIUM PHARMACEUTICALS, INC., its manager
				
		 		 	    By:	 	 /s/ Deanna Voss

		 		 		 	Name:	 	Deanna Voss
		 		 		 	Title:	 	Assistant Secretary

 
									
	70 MAPLE AVENUE, LLC
			
		 	By:	 	ACTIENT PHARMACEUTICALS LLC, its manager
				
		 		 	    By:	 	AUXILIUM PHARMACEUTICALS, INC., its manager
				
		 		 	    By:	 	 /s/ Deanna Voss

		 		 		 	Name:	 	Deanna Voss
		 		 		 	Title:	 	Assistant Secretary

  

							
	AUXILIUM US HOLDINGS, LLC
			
		 	By:	 	AUXILIUM PHARMACEUTICALS, INC., its manager
			
		 	By:	 	 /s/ Deanna Voss

		 		 	Name:	 	Deanna Voss
		 		 	Title:	 	Assistant Secretary

  

					
	ENDO FINANCE LLC
		
	By:	 	 /s/ Deanna Voss

		 	Name:	 	Deanna Voss
		 	Title:	 	Secretary

 
					
	HAWK ACQUISITION ULC
		
	By:	 	 /s/ Laurence S. Smith

		 	Name:	 	 Laurence S. Smith

		 	Title:	 	Director
	
	ENDO GLOBAL VENTURES
		
	By:	 	 /s/ Sue Hall

		 	Name:	 	 Sue Hall

		 	Title:	 	Director
	
	ENDO VENTURES BERMUDA LIMITED
		
	By:	 	 /s/ Sue Hall

		 	Name:	 	Sue Hall
		 	Title:	 	Director
	
	ENDO BERMUDA FINANCE LIMITED
		
	By:	 	 /s/ Sue Hall

		 	Name:	 	 Sue Hall

		 	Title:	 	Director

 
					
	ENDO NETHERLANDS B.V.
		
	By:	 	 /s/ Robert J. Corbuzzi Jr.

		 	Name:	 	Robert J. Corbuzzi Jr.
		 	Title:	 	Director

 
					
	PALADIN LABS CANADIAN HOLDING INC.
		
	By:	 	 /s/ Deanna Voss

		 	Name:	 	Deanna Voss
		 	Title:	 	Secretary
	
	PALADIN LABS INC.
		
	By:	 	 /s/ Deanna Voss

		 	Name:	 	Deanna Voss
		 	Title:	 	Secretary

 
					
	ENDO VENTURES CYPRUS LIMITED
		
	By:	 	 /s/ Orla Dunlea

		 	Name:	 	Orla Dunlea
		 	Title:	 	Director

 
					
	AUXILIUM UK LTD
		
	By:	 	 /s/ Orla Dunlea

		 	Name:	 	Orlea Dunlea
		 	Title:	 	Director

 
					
	ENDO FINANCE IV LIMITED
		
	By:	 	 /s/ John Boyle

		 	Name:	 	John Boyle
		 	Title:	 	Director

 
					
	 DEUTSCHE BANK AG NEW YORK BRANCH,

as Administrative Agent and Collateral Agent

		
	By:	 	 /s/ Michael Winters

		 	Name:	 	Michael Winters
		 	Title:	 	Vice President
		
	By:	 	 /s/ Peter Cucchiara

		 	Name:	 	Peter Cucchiara
		 	Title:	 	Vice President

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00249-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00249-of-00352.parquet"}]]